日本臨牀　66/増刊3　新時代の糖尿病学1

出版社： 日本臨牀社
発行日： 2008-05-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 新時代の糖尿病学1−病因・診断・治療研究の進歩−
電子書籍版： 2008-05-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,180 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,180 円(税込)

購入する

目次

  • 日本臨牀　66/増刊3　新時代の糖尿病学1

    ―目次―

    特集　新時代の糖尿病学1−病因・診断・治療研究の進歩−

    A． 序　論 　 　
    I． 糖尿病疾患概念の変遷
    II． 糖尿病病型分類のあゆみ
    III． 糖尿病診断のあゆみと今後の課題
    IV． 糖尿病の疫学−糖尿病患者の推移と将来−
    V． 糖尿病治療法の歴史
    VI． 糖尿病死因の歴史的変遷
    VII． 糖尿病学の今後の課題
    VIII． メタボリックシンドローム発症の分子メカニズム
    IX． メタボリックシンドロームにおける糖尿病の位置づけ

    B． 糖尿病基礎研究の進歩 　 　
    　I． 糖代謝とその調節機序 　 　
    　　1 糖代謝概論 　 　
    　　2 膵の発生と膵β細胞の機能 　 　
    　　3 糖代謝関連ホルモンの作用と代謝調節 　 　
    　　4 臓器における糖代謝とその調節 　 　
    　II． 糖尿病と耐糖能低下の成因分類と発症機序 　 　
    　　1 耐糖能異常 　 　
    　　2 1型糖尿病 　 　
    　　3 2型糖尿病 　 　
    　　4 単一遺伝子異常による糖尿病 　 　
    　　5 他の疾患や病態に起因する糖尿病 　 　
    　　6 妊娠糖尿病 本田　正志 594
    　　7 ソフトドリンクケトーシス 安孫子亜津子 599
    　III． 糖尿病モデル動物 　 　
    　　1 自然発症糖尿病モデル動物 　 　
    　　2 実験的糖尿病モデル動物 　 　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.5 掲載の参考文献
1) Wild S, et al:Global prevalence of diabetes:estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004.
PubMed
2) Lipscombe LL, Hux JE:Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005:a population-based study. Lancet 369:750-756, 2007.
PubMed
3) Booth GL, et al:Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people:a population-based retrospective cohort study. Lancet 368:29-36, 2006.
PubMed
4) 堀田饒ほか:アンケート調査による日本人糖尿病の死因-1991～2000年の10年間, 18,385名での検討-. 糖尿病 50:47, 2007.
 

A. 序論

P.14 掲載の参考文献
1) 垂井清一郎:糖尿病物語 (Papyrus Ebers). 最新医学 49:1188-1190, 1994.
Medical*Online
2) Barnett DM, Krall LP:The history of diabetes. In:Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p 1-17, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
3) Banting FG, Best CH:The internal secretion of the pancreas. J Lab Clin Med 7:251-266, 1922.
 
4) Yallow R, Berson S:Immunoassay of exogeneous plasma insulin in man. J Clin Invest 39:1157-1175, 1960.
 
5) Simpson NE, et al:Multifactorial inheritance:A possible hypothesis for diabetes. Diabetes 13:462-471, 1964.
PubMed
6) 葛谷信貞ほか:糖負荷試験における糖尿病診断基準委員会報告 (糖尿病の診断に用いるための糖負荷試験の判定基準についての勧告). 糖尿病 13:1-7, 1970.
 
7) World Health Organization Expert Committee on Diabetes Mellitus:Second Report on Diabetes Mellitus (Tech. Rep. Ser, no 646), World Health Organization, Geneva, 1980.
 
8) 小坂樹徳ほか:糖尿病の診断に関する委員会報告. 糖尿病 25:859-866, 1982.
 
9) The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997.
PubMed
10) Kuzuya T, Matsuda A:Classification of diabetes on the basis of etiologies versus degree of insulin deficiency. Diabetes Care 20:219-220, 1997.
PubMed
11) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999.
 
12) 小坂樹徳, 門脇孝:糖尿病の疾患概念の史的変遷. 糖尿病診療のあゆみと展望, p79, 文光堂, 2007.
 
P.20 掲載の参考文献
1) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999.
 
2) 上野宏行ほか:糖尿病病型分類のあゆみと展望. 日本臨牀 60 (増刊7):28-35, 2002.
 
3) 小坂樹徳, 門脇孝:糖尿病診療のあゆみと展望, 文光堂, 2007.
 
4) National Diabetes Data Group:Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979.
 
5) WHO Expert Committee on Diabetes Mellitus:Second Report. Technical Report Series 646, World Health Organization, Geneva, 1980.
 
6) WHO Expert Committee on Diabetes Mellitus:Technical Report Series 727, World Health Organization, Geneva, 1985.
 
7) The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Report of the Expert Committee on the Diagnosis and Classhication of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997.
PubMed
8) Alberti KGMN, Zimmet PZ for the WHO Consultation:Definition, diagnosis and classhication of diabetes mellitus and its complications. Part 1:Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med 15:539-553, 1998.
 
P.28 掲載の参考文献
1) Wrenshall GA, et al:The Story of Insulin, Max Reinhardt, Toronto, 1962. (二宮陸雄 (訳):インシュリン物語, 岩波書店, 1965.)
 
2) 葛谷信貞, 小坂樹徳:糖尿病の定義・概念. 糖尿病のすべて第2版 (葛谷信貞, 小坂樹徳), p9, 南江堂, 1980.
 
3) Joslin EP:The Treatment of Diabetes Mellitus, 4th ed, Lea & Febiger, Philadelphia, 1928.
 
4) Poulsen JE:Features of the History of Diabetology, Munkusgaard, Copenhagen, 1982.
 
5) 葛谷信貞:糖尿病研究班の思い出-飽食試験のいきさつ-. Diabetes Journal 2:199-205, 1974.
 
6) Diabetes Mellitus. Report of a WHO Expert Committee, World Health Organization, Geneva, WHO Technical Report Series 310, 1965.
 
7) 葛谷信貞ほか:GTTにおける糖尿病診断基準委員会報告 (糖尿病の診断に用いるためのGTTの判定基準についての報告). 糖尿病 13:1-7, 1970.
 
8) National Diabetes Data Group:Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979.
 
9) WHO Expert Committee on Diabetes Mellitus:Second Report, World Health Organization, Geneva, WHO Technical Report Series 646, 1980.
 
10) WHO Study Group:Diabetes Mellitus, World Health Organization, Geneva, WHO Technical Report Series 727, 1985.
 
11) 小坂樹徳ほか:糖尿病の診断に関する委員会報告. 糖尿病 25:859-866, 1982.
 
12) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14):977-986, 1993.
 
13) UK Prospective Diabetes Study Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998.
PubMed
14) UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317:703-713, 1998.
Medical*Online
15) Heart Outcomes Prevention Evaluation (HOPE) Study lnvestigators:Effects of ramipri1 on cardiovascular and microvascular outcomes in people with diabetes mellitus:results from the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000.
PubMed
16) Pyorala K, et al:the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997.
 
17) King H, et al:Global burden of diabetes, 1995-2025:prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998.
PubMed
18) The Expert Committee on the Diagnosis and Classhication of Diabetes Mellitus:Report of the Expert Committee on the Diagnosis and Classhication of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997.
PubMed
19) World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1:Diagnosis and Classification of diabetes mellitus. Report of a WHO Consultation, World Health Organization, Geneva, 1999.
 
20) Kuzuya T, et al;Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus:Report of the Committee on the classhfication and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 55:65-85, 2002.
 
21) DECODE Study Group:Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317:371-375, 1998.
 
22) Qiao Q, et al;DECODA Study Group:Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 43:1470-1475, 2000.
 
23) Knowler WC, et al;Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002.
PubMed
24) Genuth S, et al;Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Follow-up report of the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003.
 
25) Forouhi N, et al;EDEG:The threshold for diagnosing impaired fasting glucose:a position statement by the European Diabetes Epidemiology Group. Diabetologia 49:822-827, 2006.
PubMed
P.35 掲載の参考文献
1) 厚生労働省健康局:平成14年度糖尿病実態調査報告. http://wwwmhlw.go.jp/shingi/2004/03/s03
 
2) 財団法人健康・体力づくり事業財団:健康日本21 (糖尿病). http://www1.mhlw.go.jp/topics/ken11/b7f.html
 
3) 佐々木陽ほか:疫学調査による糖尿病およびIGT有病率の国際比較. 糖尿病 41:355-362, 1998.
 
4) Islam MM, et al:Current trend in prevalence of diabetes mellitus in Japan, 1964-1992. J Epidemiol 9:155-162, 1999.
PubMed
5) International Diabetes Federation:Diabetes Atlas, 3rd ed, 2006.
 
6) WHO:Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/index.html
 
7) Narayan KM, et al:Lifetime risk fbr diabetes melhtus in the United States. JAMA 290:1884-1890, 2003.
 
8) Ohmura T, et al:Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population:the Hisayama Study. Diabetologia 36:1198-1203, 1993.
PubMed
9) Sekikawa A, et al:Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata diabetes study. J Diabetes Complications 14:78-83, 2000.
 
10) Beran D, Yudkin JS:Diabetes care in sub-Saharan Africa. Lancet 368:1689-1695, 2006.
PubMed
P.42 掲載の参考文献
1) Sanders U:From Thebes to Toronto and the 21st Century:An Incredible Journey. Diabetes Spectrum 15:56-60, 2002.
 
2) Bamett DM, Krall LP:The history of diabetes. In:Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p 1-17, Lippincott Williams & Wilkins, Philadelphia, 2005.
 
3) Rosner F:The hfe of Moses Maimonides, a Prominent Medieval Physician. Einstein Quart J Biol Med 19:125-128, 2002.
 
4) Bliss M:The Discovery of Insulin. The University of Chicago Press, Chicago, 1982.
 
5) 武田仁, 門脇孝:インスリン分泌促進薬の歴史と現状. インスリン分泌促進薬 SU薬とグリニド (清野裕編), p9-12, フジメディカル出版, 2006.
 
6) Patlak M:New weapons to combat an ancient disease:treating diabetes. FASEB J 16:1853, 2002.
PubMed
7) Witters LA:The blooming of the French Lilac. J Clin Invest 108:1105-1107, 2001.
PubMed
8) 黒瀬健:α-グルコシダーゼ阻害薬. 内分泌・糖尿病科 12:12-19, 2001.
 
9) 葛谷健:チアゾリジン誘導体の治療薬としての開発経緯と現状. 日本臨牀 58 (2):364-369, 2000.
Medical*Online
10) Gabbay KH:The sorbitol pathway and the complications of diabetes. N Engl J Med 288:831-836, 1973.
PubMed
P.48 掲載の参考文献
1) Entmacher PS, et al:Diabetes mortality from vital statistics. In:Joslin's Diabetes Mellitus, 12th edition (ed by Marble A, et al), p 278-297, Lea & Febiger, Philadelphia, 1985.
 
2) 人口動態統計課:死亡原因の年次推移. 昭和57年人口動態統計上巻 (厚生省大臣官房統計情報部編), p82-109, 厚生統計協会, 1984.
 
3) 坂本信夫, 宇野智子:糖尿病死因の歴史的変遷. 日本臨牀 60 (増刊号7):72-82, 2002.
Medical*Online
4) 後藤由夫, 福原則夫:糖尿病患者の死因-剖検例933例についての統計的観察-. 糖尿病 11:197-205, 1968.
 
5) 三原俊彦, 平田幸正:重症度別にみた糖尿病死亡患者1,843名の死因統計-アンケート調査による-. 糖尿病 17:232-239, 1974.
 
6) 小坂樹徳, 坂本信夫:糖尿病とMacroangiopathy 1) わが国の現状-最近のアンケート調査から-. 糖尿病 24:1146-1147, 1981.
 
7) 坂本信夫ほか:アンケート調査による日本人糖尿病の死因-1981-1990年10年間, 11,648名での検討-. 糖尿病 39:221-236, 1996.
 
8) 堀田饒ほか:アンケート調査による日本人糖尿病の死因-1991-2000年10年間, 18,385名での検討-. 糖尿病 50:47-61, 2007.
 
9) Gu K, et al:Mortality in adults with and Without diabetes in a national cohort of the US population. Diabetes Care 21:1138-1145, 1998.
 
10) Narayan KM, et al:Lifetime risk for diabetes mellitus in the United States. JAMA 290:1884-1890, 2003.
PubMed
11) Franco OH, et al:Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 167:1145-1151, 2007.
PubMed
12) 曽根博仁, 山田信博, JDSグループ:糖尿病における動脈硬化症予防のためのトータルケア-Japan Diabetes Complication Study (JDCS) 中間結果より-. 最新医学 59:99-105, 2004.
 
P.56 掲載の参考文献
1) Kirchhoff K, et al:Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsuhn conversion. Diabetologia 51:597-601, 2008.
PubMed
2) Omori S, et al:Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes 57 (3):791-795, 2008.
 
3) Kang ES, et al:A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 57:1043-1047, 2008.
PubMed
4) Florez JC, et al:TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355 (3):241-250, 2006.
 
5) Boullu-Ciocca S, et al:Postnatal programming of glucocorticoid metabohsm in rats modulates high-fat diet-induced regulation of visceral adipose tissue glucocorticoid exposure and sensitivity and adiponectin and proinflammatory adipokines gene expression in adulthood. Diabetes 57:669-677, 2008.
PubMed
6) Shoelson SE, et al:Inflammation and insulin resistance. J Clin Invest 116 (7):1793-1801, 2006.
PubMed
7) Sugiyama E, et al:Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 22 (11):2020-2026, 1995.
PubMed
8) Temaru R, et al:High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells:possible role of interleukin-8 in diabetic macroangiopathy. Diabetologia 40 (5):610-613, 1997.
 
9) Kobashi C, et al:Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97 (12):1245-1252, 2005.
PubMed
10) Kibayashi E, et al:Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond) 108 (6):515-521, 2005,
 
11) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (9131):837-853, 1998.
 
12) Li Y, et al:Glucagon-like-peptide-1receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478, 2003.
 
13) Bonora E:Protection of pancreatic beta-cells:is it feasible? Nutr Metab Cardiovasc Dis 18 (1):74-83, 2008.
PubMed
14) Kaneto H, et al:Possible novel therapy for diabetes with cell-permeable JNK inhibitory peptide. Nat Med 10:1128-1132, 2004.
PubMed
15) Knowler WC, et al;Diabetes Prevention Program Research Group:Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54 (4):1150-1156, 2005.
 
16) 小坂樹徳:糖尿病基礎研究の進歩-糖尿病の病因・発症機序-臨床疫学からみた2型糖尿病の成因. 日本臨牀 60 (増刊号7):423-467, 2002.
 
17) 岩田実ほか:富山-大山Study;短期間の生活習慣介入による糖尿病一次予防の試み. 糖尿病 50 (Suppl I):S-266, 2007.
 
P.68 掲載の参考文献
1) 門脇孝:2型糖尿病の分子機構に関する研究. 日医会誌 136 (10):64-70, 2008.
 
2) 門脇孝:アディポサイトカイン. 日医会誌 136 (特別号1):S71-S75, 2007.
 
3) Kadowaki T, et al:The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 582:74-80, 2008.
PubMed
4) Kadowaki T, et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes and metabolic syndrome-Adiponectin hypothesis-. J Clin lnvest 116:1784-1792, 2006.
 
5) Matsuzawa Y:Therapy insight:adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Prac Cardiovasc Med 3:35-42, 2006.
 
6) Lazar MA:The humoral side of insulin resistance. Nat Med 12:43-44, 2006.
PubMed
7) Tamemoto H, et al:Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186, 1994.
PubMed
8) Yamauchi T, et al:Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 16 (6):3074-3084, 1996.
PubMed
9) Abe H, et al:Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784-1788, 1998.
PubMed
10) Kubota T, et al:Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation 107:3073-3080, 2003.
PubMed
11) Tobe K, et al:Increased expression of the sterol regulatory element-binding protein-1gene in insulin receptor substrate-2-/ mouse liver. J Biol Chem 276 (42):38337-38340, 2001.
 
12) Suzuki R, et al:Both insulin signaling defects in the liver and obesity contribute to insulin resistance and cause diabetes in Irs2-/- mice. J Biol Chem 279 (24):25039-25049, 2004.
PubMed
13) Kubota N, et al:Insulin receptor substrate 2 plays a crucial role inβcells and the hypothalamus. J Clin Invest 114 (7):917-927, 2004.
 
14) Zheng Y, et al:Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. J Am Soc Nephrol 16 (8):2288-2295, 2005.
PubMed
15) Despres JP, Lemieux I:Abdominal obesity and metabolic syndrome. Nature 444:881-887, 2006.
PubMed
16) Hotamisligil GS, et al:Adipose expression of tumor necrosis factor-α:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993.
 
17) Steppan CM, et al:The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001.
PubMed
18) Kamei N, et al:Overexpression of MCP-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602-26614, 2006.
PubMed
19) Kanda H, et al:MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116 (6):1494-1505, 2006.
 
20) Yamauchi T, et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001.
PubMed
21) Yamauchi T, et al:Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 30 (2):221-226, 2002.
PubMed
22) Hara K, et al:Genetic variation in the gene encoding adiponectin is associated with increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002.
PubMed
23) Kubota N, et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002.
PubMed
24) Maeda N, et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002.
PubMed
25) Yamauchi T, et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003.
PubMed
26) Kubota N, et al:Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007.
PubMed
27) Yamauchi T, et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002.
PubMed
28) Yamauchi T, et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003.
PubMed
29) Yamauchi T, et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007.
PubMed
30) Tsuchida A, et al:Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004.
 
31) Civitarese AE, et al:Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 4:75-87, 2006.
PubMed
32) Tsuchida A, et al:Peroxisome proliferator-activated receptor (PPARα) activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPARα, PPARγ, and their combination. Diabetes 54:3358-3370, 2005.
 
P.77 掲載の参考文献
1) World Health Organization:Definition, Diagnosis and Classification of diabetes mellitus and its complications. Part 1:Diagnosis and classification of diabetes mellitus, World Health Organization, Geneva, 1999.
PubMed
2) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults:Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
 
3) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日内会誌 94:188-203, 2005.
 
4) Matsuzawa Y:Pathophysiology and molecular mechanisms of visceral fat syndrome:the Japanese experience. Diabetes Metab Rev 13:3-13, 1997.
PubMed
5) Shoelson S, et al:Infiammation and insulin resistance. J Clin Invest 116:1793-1801, 2006.
 
6) Adams JM, et al:Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25-31, 2004.
PubMed
7) Ugi S, et al:Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24:8778-8789, 2004.
PubMed
8) Boden G, et al:Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes 54:3458-3465, 2005.
 
9) Arita Y, et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999.
PubMed
10) Hasty AH, et al:Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level. J Biol Chem 275:31069-31077, 2000.
 
11) Nagai Y, et al:Amelioration of high fructose-induced metabolic derangements by activation of PPAR-α. Am J Physiol 282:E1180-E1190, 2002.
 
12) Shimizu S, et al:Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J Biol Chem 278:43095-43101, 2003.
PubMed
13) Pan DA, et al:Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983-988, 1997.
PubMed
14) Sattar N, et al:Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419, 2003.
PubMed
15) Bogardus C, et al:Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238, 1984.
PubMed
16) DeFronzo RA:Lilly Lecture 1987:The triumvirate:βcell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1988.
 
17) Weyer C, et al:The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999.
PubMed
18) Hara K, et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002.
PubMed
19) Zacharova J, et al:STOP-NIDDM Study Group:The common polymorphisms (single nucleotide polymorphism [SNP] + 45 and SNP+ 276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes:the STOP-NIDDM trial. Diabetes 54:893-899, 2005.
 
20) Zacharova J, et al:The G-250A substitution in the promoter region of the hepatic lipase gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes:the STOPNIDDM trial. J Intern Med 257:185-193, 2005.
 
21) AndrulionytさL, et al:Common polymorphisms of the PPAR-gamma 2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176-2184, 2004.
 
22) Nagata R, et al:Single nucleotide polymorphism (-468 Gly to A) at the promoter region of SREBP-1c associates with genetic defect of fructose-induced hepatic lipogenesis [corrected]. J Biol Chem 279:29031-29042, 2004.
 
23) Takemoto T, et al:RBMX is a novel hepatic transcriptional regulator of SREBP-1c gene response to high-fructose diet. FEBS Lett 581 (2):218-222, 2007.
PubMed
24) Butterner R, et al:Defining high fat diet rat models:metabolic and molecular effects of different fat types. J Mol Endocrinol 36:485-501, 2006.
 
25) Ren B, et al:Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require PPARα. J Biol Chem 272:26827-26832, 1997.
 

B. 糖尿病基礎研究の進歩

P.84 掲載の参考文献
1) Vittal H, et al:Mechanisms of disease:the pathological basis of gastroparesis-a review of experimental and clinical studies. Nat Clin Pract Gastroenterol Hepatol 4:336-346, 2007.
PubMed
2) Drozdowski LA, Thomson AB:Intestinal sugar transport. World J Gastroenterol 12:1657-1670, 2006.
PubMed
3) Osswald C, et al:Mice without the regulator gene Rsc1AI exhibit increased Na+ -D-glucose cotransport in small intestine and develop obesity. Mol Cell Biol 25:78-87, 2005.
 
4) Wright EM, et al:Active sugar transport in health and disease. J Intern Med 261:32-43, 2007.
 
5) Wright EM, et al:Intestinal absorption in health and disease-sugars. Best Pract Res Clin Gastroenterol 17:943-956, 2003.
PubMed
6) Leturque A, et al:The role of GLUT2 in dietary sugar handling. J Physiol Biochem 61:529-537, 2005.
PubMed
7) Dyer J, et al:Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 282:G241-G248, 2002.
PubMed
8) Li Q, et al:Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol 287:G236-G242, 2004.
PubMed
9) Tazawa S, et al:SLC5A9/SGLT4, a new Na+ -dependent glucose transporter, is an essential transporter for mannose, 1, 5-anhydro-D-glucitol, and fructose. Life Sci 76:1039-1050, 2005.
 
10) Wood IS, Trayhurn P:Glucose transporters (GLUT and SGLT):expanded families of sugar transport proteins. Br J Nutr 89:3-9, 2003.
PubMed
P.89 掲載の参考文献
1) Koo SH, et al:The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437:1109-1111, 2005.
PubMed
2) Dentin R, et al:Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449 (7160):366-369, 2007.
PubMed
3) Yoon JC, et al:Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 (6852):131-138, 2001.
PubMed
4) Puigserver P, et al:Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction. Nature 423 (6939):550-555, 2003.
 
5) Yamashita H, et al:A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci USA 98 (16):9116-9121, 2001.
PubMed
6) Ishii S, et al:Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA 101 (44):15597-15602, 2004.
PubMed
7) Iizuka K, et al:Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 101 (19):7281-7286, 2004.
 
8) Iizuka K, et al:Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am J physiol Endocrinol Metab 291 (2):E358-364, 2006.
PubMed
9) Kawaguchi T, et al:Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci USA 98 (24):13710-13715, 2001.
 
10) Shimano H:SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling. J Mol Med 85 (5):437-444, 2007.
PubMed
P.96 掲載の参考文献
1) Patel MS, et al:Gene regulation and genetic defects in the pyruvate dehydrogenase complex. J Nutr 125 (Suppl 6):1753S-1757S, 1995.
 
2) 山崎知行, 河野典夫:TCA回路によるエネルギー産生:TCA回路, 酸化的リン酸化と脱共役蛋白. 日本臨牀 60 (増刊7):129-134, 2002.
 
3) Patel MS, Korotchkina LG:Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans 34 (Pt 2):217-222, 2006.
 
4) Patel MS, Harris RA:Mammalian α-keto acid dehydrogenase complex:gene regulation and genetic defects. EASEB J 9 (12):1164-1172, 1995.
 
5) Sugden MC, Holness MJ:Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase ldnases. Arch Physiol Biochem 112 (3):139-149, 2006.
PubMed
6) Bowker-Kinley MM, et al:Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 329 (Pt 1):191-196, 1998.
 
7) Churchill EN, et al:Reperfusion-induced translocation of δPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Circ Res 97 (1):78-85, 2005.
 
8) Semenza GL:Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 405:1-9, 2007.
PubMed
9) Huang B, et al:Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-α ligands, glucocorticoids, and insulin. Diabetes 51 (2):276-283, 2002.
 
10) Wu P, et al:Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor? Biochem Biophys Res Commun 287 (2):391-396, 2001.
PubMed
11) 荒木信ほか:エネルギー代謝調節鍵酵素PDK4の正常時及び病態時における発現調節. 薬学雑誌 127 (1):153-162, 2007.
 
12) Furuyama T, et al:Forkhead transcription factor FOXO 1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J 375 (Pt 2):365-371, 2003.
 
13) Kwon HS, Harris RA:Mechanisms responsible for regulation of pyruvate dehydrogenase kinase 4 gene expression. Adv Enzyme Regul 44:109-121, 2004.
PubMed
14) Kwon HS, et al:Protein kinase B-α inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. Diabetes 53 (4):899-910, 2004.
 
15) Denton RM, et al:The hormonal regulation of pyruvate dehydrogenase complex. Adv Enzyme Regul 36:183-189, 1996.
PubMed
16) Denton RM, et al:Studies into the mechanism whereby insulin activates pyruvate dehydrogenase complex in adipose tissue. Ann N Y Acad Sci 573:285-296, 1989.
PubMed
17) Serdikoff C, Adibi SA:Protein expressions of branched-chain keto acid dehydrogenase subunits are selectively and posttranscriptionally altered in liver and skeletal muscle of starved rats. J Nutr 131:1682-1686, 2001.
PubMed
18) Shimomura Y, et al:Regulation of branched-chain amino acid catabolism:nutritional and hormonal reguladon of activity and expression of the branched-chain alpha-keto acid dehydrogenase kinase. Curr Opin Clin Nutr Metab Care 4 (5):419-423, 2001.
PubMed
19) Costeas PA, Chinsky JM:Glucocorticoid regulation of branched-chain α-ketoacid dehydrogenase E2 subunit gene expression. Biochem J 347:449-457, 2000.
 
20) Costeas PA, Chinsky JM:Effects of insulin on the regulation of branched-chain α-keto acid dehydrogenase E1α subunit gene expression. Biochem J 318 (Pt 1):85-92, 1996.
 
21) Henriksen EJ, Halseth AE:Adaptive responses of GLUT4 and citrate synthase in fast-twitch muscle of voluntary running rats. Am J Physiol 268 (1 Pt 2):R130-R134, 1995.
 
22) Mishra G, et al:Alloxan diabetes in Swiss mice:activity of Na (+ )-K (+ )-ATPase and succinic dehydrogenase. Indian J Physiol Pharmacol 39 (3):271-274, 1995.
PubMed
23) Rustin P, et al:Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 228 (1):35-51, 1994.
PubMed
24) Dummler K, et al:Regulation of adenine nucleotide translocase and glycerol 3-phosphate dehydrogenase expression by thyroid hormones in different rat tissues. Biochem J 317 (Pt 3):913-918, 1996.
 
P.101 掲載の参考文献
1) Mueckler M, et al:Sequence and structure of a human glucose transporter. Science 229 (4717):941-945, 1985.
PubMed
2) Joost HG, et al:Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282 (4):E974-976, 2002.
PubMed
3) Guillam M, et al:Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet 17 (3):327-330, 1997.
PubMed
4) Baumann C, et al:CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407 (6801):202-207, 2000.
PubMed
5) Chiang S, et al:Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410 (6831):944-948, 2001.
PubMed
6) Katz E, et al:Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377 (6545):151-155, 1995.
PubMed
7) Stenbit A, et al:GLUT4 heterozygous knockout mice develop muscle insuln resistance and diabetes. Nat Med 3 (10):1096-1101, 1997.
 
8) Yang Q, et al:Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (7049):356-362, 2005.
PubMed
9) Stuart C, et al:Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone. Diabetes Care 30 (4):925-931, 2007.
PubMed
10) Lisinski I, et al:Targeting of GLUT 6 (formerly GLUT9) and GLUT8 in rat adipose cells. Biochem J 358 (Pt 2):517-522, 2001.
 
11) Li Q, et al:Cloning and functional characterization of the human GLUT7 isoform SLC2A7 from the small intestine. Am J Physiol Gastrointest Liver Physiol 287 (1):G236-242, 2004.
PubMed
12) Coucke PJ, et al:Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet 38 (4):452-457, 2006.
PubMed
13) Turk E, et al:Glucose/galactose malabsorption caused by a defect in the Na+ /glucose cotransporter. Nature 350 (6316):354-356, 1991.
PubMed
14) Oku A, et al:T-1095, an inhibitor of renal Na+ -glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48 (9):1794-1800, 1999.
PubMed
15) Ueta K, et al:Long-term treatment with the Na+ -glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 76 (23):2655-2668, 2005.
PubMed
P.109 掲載の参考文献
1) Kawaguchi Y, et al:The role of the transcriptional regulator Ptfl a in converting intestinal to pancre atic progenitors. Nat Genet 32:128-134, 2002.
 
2) Deutsch G, et al:A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 128:871-881, 2001.
 
3) Kim SK, et al:Notochord to endoderm signaling is required for pancreas development. Development 124:4243-4252, 1997.
PubMed
4) Lammert E, et al:Induction of pancreatic differentiation by signals from blood vessels. Science 294:564-567, 2001.
PubMed
5) Yoshitomi H, et al:Endothelial cell interactions initiate dorsal pancreas development by selectively inducin the transcription factor Ptf1a. Development 131:807-817, 2004.
 
6) Ahlgren U, et al:Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature 385:257-260, 1997.
PubMed
7) Gu G, et al:Direct evidence for the pancreatic lineage:NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129:2447-2457, 2002.
PubMed
8) Gradwohl G, et al:neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci USA 97:1607-1611, 2000.
PubMed
9) Schwitzgebel W, et al:Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. Development 127:3533-3542, 2000.
 
10) Jensen J, et al:Control of endodermal endocrine development by Hes-1. Nat Genet 24:36-44, 2000.
PubMed
11) Sumazaki R, et al:Conversion of biliary system to pancreatic tissue in Hes1-deficient mice. Nat Genet 36:83-87, 2004.
PubMed
12) Jacquemin P, et al:Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene ngn3. Mol Cell Biol 20:4445-4454, 2000.
PubMed
13) Heremans Y, et al:Recapitulation of embryonic neuroendocrine differentiation in adult human pancreatic duct cells expressing neurogenin 3. J Cell Biol 159:303-312, 2002.
PubMed
14) Fujitani Y, et al:Identification of a portable repression domain and an E1A-responsive activation domain in Pax4:a possible role of Pax4 as a transcriptional repressor in the pancreas. Mol Cell Biol 19:8281-8291, 1999.
 
15) Prado CL, et al:Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci USA 101:2924-2929, 2004.
PubMed
16) Sander M, et al:Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. Development 127:5533-5540, 2000.
PubMed
17) Matsuoka T, et al:Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. Mol Cell Biol 23:6049-6062, 2003.
PubMed
18) Watada H, et al:Involvement of the homeodomain-containing transcription factor PDX-1 in islet amyloid polypeptide gene transcription. Biochem Biophys Res Commun 229:746-751, 1996.
PubMed
19) Fujitani Y, et al:Targeted deletion of a cis-regulatory region reveals differential gene dosage requirements for Pdx1 in foregut organ differentiation and pancreas formation. Genes Dev 20:253-266, 2006.
PubMed
20) Bell GI, et al:Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 414:788-791, 2001.
PubMed
21) Shimajiri Y, et al:A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese. Diabetes 50:2864-2869, 2001.
PubMed
22) Yasuda T, et al:PAX6 mutation as a genetic factor common to aniridia and glucose intolerance. Diabetes 51:224-230, 2002.
PubMed
23) Sladek R, et al:A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885, 2007.
PubMed
24) Miyatsuka T, et al:Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev 20:1435-1440, 2006.
PubMed
25) Minami K, et al:Lineage tracing and characterization of insulin-secreting cells generated from adult pancreatic acinar cells. Proc Natl Acad Sci USA 102:15116-15121, 2005.
PubMed
26) Desai BM, et al:Preexisting pancreatic acinar cells contribute to acinar cell, but not islet beta cell, regenera60n. J Clin Invest 117:971-977, 2007.
 
27) Moritoh Y, et al:Analysis of insulin-producing cells during in vitro differentiation from feeder-free embryonic stem cells. Diabetes 52:1163-1168, 2003.
PubMed
28) D'Amour KA, et al:Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 24:1392-1401, 2006.
PubMed
P.114 掲載の参考文献
1) Patel YC, et al:Production, action, and degradation of somatostatin. In:Handbook of Physiology, Sec. 7, Vol.II, The endocrine pancreas and regulation of metabolism (ed by Jefferson LS, et al), p 267-302, Oxford University Press, New York, 2001.
 
2) Fujita T:Insulo-acinar portal system in the horse pancreas. Arch Histol Jap 35:161-171, 1973.
PubMed
3) Cirulli V, et al:Expression of neural cell adhesion molecule (N-CAM) in rat islets and its role in islet cell type segregation. J Cell Sci 107:1429-1436, 1994.
PubMed
4) Cirulli V, et al:Expression and function of αvβ3 and αvβ5 integrins in the developing pancreas:roles in the adhesion and migration of putative endocrine progenitor cells. J Cell Biol 150:1445-1460, 2000.
 
P.118 掲載の参考文献
1) Brunicardi FC, et al:Microcirculation of the islets of Langerhans. Long Beach Veterans Administration Regional Medical Education Center Symposium. Diabetes 45:385-392, 1996.
 
2) Jansson L:The regulation of pancreatic islet blood flow. Diabetes Metab Rev 10:407-416, 1994.
PubMed
3) Iwase M, et al:Pancreatic islet blood flow in conscious rats during hyperglycemia and hypoglycemia. Am J Physiol Regul Integr Comp Physiol 280:R1601-1605, 2001.
PubMed
4) Carlsson PO, et al:Stimulation of intestinal glucoreceptors in rats increases pancreatic islet blood flow through vagal mechanisms. Am J Physiol 276:R233-R236, 1999.
PubMed
5) Carlsson PO, et al:Intraportal glucose infusion and pancreatic islet blood flow in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 279:R1224-R1229, 2000.
PubMed
6) Carlsson PO, et al:Glucose-induced islet blood flow increase in rats:interaction between nervous and metabolic mediators. Am J Physiol Endocrinol Metab 283:E457-E464, 2002.
PubMed
7) Svensson AM, et al:Inhibition of nitric oxide synthase by NG-nitro-L-arginine causes a preferential decrease in pancreatic islet blood flow in normal rats and spontaneously diabetic GK rats. Endocrinology 135:849-853, 1994.
PubMed
8) Iwase M, et al:Effect of exogenous cholecystokinin on islet blood flow in anesthetized rats. Regul Pept 116:87-93, 2003.
PubMed
9) Iwase M, et al:Nateglinide, a non-sulfonylurea rapid insuhn secretagogue, increases pancreatic islet blood flow in rats. Eur J Pharmacol 518:243-250, 2005.
PubMed
10) Iwase M, et al:Islet hyperperfusion during prediabetic phase in OLETF rats, a model of type 2 diabetes. Diabetes 51:2530-2535, 2002.
 
11) Carlsson PO, et al:Islet capillary blood pressure increase mediated by hyperglycemia in NIDDM GK rats. Diabetes 46:947-952, 1997.
PubMed
12) Iwase M, et al:The pancreatic islets in spontaneously hypertensive rats:islet blood fiow and insulin production. Eur J Endocrinol 144:169-178, 2001.
 
13) Iwashita N, et al:Impaired insulin secretion in vivo but enhanced insulm secretion from isolated islets in pancreatic beta cell-spechic vascular endothelial growth factor-A knock-out mice. Diabetologia 50:380-389, 2007.
PubMed
14) Lammert E, et al:Induction of pancreatic differentiation by signals from blood vessels. Science 294:564-567, 2001.
PubMed
15) Johansson M, et al:Islet endothelial cells and pancreatic beta-cell proliferation:studies in vitro and during pregnancy in adult rats. Endocrinology 147:2315-2324, 2006.
PubMed
P.122 掲載の参考文献
1) Butler AE, et al:β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003.
 
2) Kulkarni RN, et al:Tissue-spechic knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339, 1999.
PubMed
3) Ueki K, et al:Total insulin and IGF-1 resistance in pancreatic beta cells causes overt diabetes. Nat Genet 38:583-588, 2006.
PubMed
4) Kido Y, et al:Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 277:36740-36747, 2002.
PubMed
5) Hashimoto N, et al:Ablation of PDKI in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 38:589-593, 2006.
 
6) Kitamura T, et al:The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110:1839-1847, 2002.
PubMed
7) Uchida T, et al:Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med 11:175-182, 2005.
PubMed
8) Inoki K, et al:TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 4:648-657, 2002.
PubMed
9) Briaud I, et al:Insulin receptor substrate-2 proteosomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells. J Biol Chem 280:2282-2293, 2005.
 
10) Ozcan U, et al:Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461, 2004.
PubMed
11) Kathryn E, et al:Inflammation, stress, and diabetes. J Clin Invest 115:111-119, 2005.
 
12) Strinivasan S, et al:Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes 54:968-975, 2005.
 
13) Ohoka N, et al:TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J 24:1243-1255, 2005.
PubMed
P.128 掲載の参考文献
1) Dor Y, et al:Adult pancreatic β cells are fomled by self-duplication rather than stem-cell dfferentiation. Nature 429:41-46, 2004.
 
2) Gershengorn MC, et al:Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306:2261-2264, 2004.
PubMed
3) Uchida T, et al:Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med 11:175-182, 2005.
PubMed
4) Joglekar MV, et al:MicroRNA profiling of developing and regenerating pancreas reveal post-tran-scriptional regulation of neurogenin3. Dev Biol 311:603-612, 2007.
 
5) Rhodes CJ:Type 2 diabetes-a matter of β-cell life and death. Science 307:380-384, 2005.
 
6) Ogata T, et al:Promotion of β-cell differentiation by conophyline in fetal and neonatal rat pancreas. Diabetes 53:2596-2602, 2004.
 
7) Ogata T, et al:Betacellulin-δ4, a novel differentiation factor for pancreatic β-cells, ameliorates glucose intolerance in streptozotocin-treated rats. Endocrinology 146:4673-4681, 2005.
 
P.134 掲載の参考文献
1) Bell GI, et al:Sequence of the human insulin gene. Nature 284:26-32, 1980.
PubMed
2) Walker MD, et al:Cell-specific expression controlled by the 5'-flanking region of the insulin and chymotrypsin genes. Nature 306:557-561, 1983.
PubMed
3) Hanahan D:Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-122, 1985.
 
4) Ohlsson H, et al:IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 12:4251-4259, 1993.
PubMed
5) German MS, et al:Synergistic activation of the insulin gene by a LIM-homeodomain protein and a basic heliX-loop-helix protein:building a fmctional insulin minienhancer complex. Genes Dev 6:2165-2176, 1992.
 
6) Karlsson O, et al:A mutational analysis of the insulin gene transcription control region:expression in β-cells is dependent on two related sequences within the enhancer. Proc Natl Acad Sci USA 84:8819-8823, 1987.
 
7) Crowe DT, Tsai MJ:Mutagenesis of the rat insulin II 5'-flanking region defines sequences important for expression in HIT cells. Mol Cel Biol 9:1784-1789, 1989.
 
8) Boam DS, et al:Positive and negative regulation of the human insulin gene by multiple trans-acting factors. J Biol Chem 265:8285-8296, 1990.
PubMed
9) Sander M, et al:A novel glucose-responsive element in the human insulin gene functions uniquely in primary cultured islets. Proc Natl Acad Sci USA 95:11572-11577, 1998.
 
10) Inagaki N, et al:c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements. Proc Natl Acad Sci USA 89:1045-1049, 1992.
PubMed
11) Kennedy GC, et al:The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcHption. Nat Genet 9:293-298, 1995.
PubMed
12) Mosley AL, Ozcan S:The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J Biol Chem 279:54241-54247, 2004.
PubMed
13) Francis J, et al:Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription. J Biol Chem 280:36244-36253, 2005.
PubMed
P.142 掲載の参考文献
1) Banting FG, Best CH:The internal secretion of the pancreas. J Lab Clin Med 7:251-266, 1922.
 
2) Ryle AP, et al:The disulphide bonds of insulin. Biochem J 60:541-556, 1955.
PubMed
3) Steiner DF, et al:Insulin biosynthesis:evidence for a precursor. Science 157:697-700, 1967.
PubMed
4) Yip CC, et al:Translation of messenger ribonucleic acid from isolated pancreatic islets and human insulinomas. Proc Natl Acad Sci USA 72:4777-4779, 1975.
PubMed
5) Patzelt C, et al:Detection and kinetic behavior of preproinsulin in pancreatic islets. Proc Natl Acad Sci USA 75:1260-1264, 1978.
PubMed
6) Howell SL:Role of ATP in the intracellular translocation of proinsulin and insulin in the rat pancreatic B-cell. Nat New Biol 235:85-86, 1972.
PubMed
7) Malaisse-Lagae F, et al:Role of microtUbules in the synthesis, conversion, and release of (pro) insulin. J Clin Invest 63:1284-1296, 1979.
PubMed
8) Beckers CJ, et al:Vesicular transport between the endoplasmic reticulum and the Golgi stack requires the NEM-sensitive fusion protein. Nature 339:397-398, 1989.
PubMed
9) Bourne HR:Do GTPases direct membrane traffic in secretion? Cell 53:669-671, 1988.
PubMed
10) Pelham HR:Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell 46:959-961, 1986.
PubMed
11) Serafini T, et al:A coat subunit of Golgi-derived non-clathrin-coated vesicles with homology to the clathrin-coated vesicle coat protein β-adaptin. Nature 349:215-220, 1991.
 
12) Moss J, et al:Structure and function of ARF proteins:Activators of cholera to) dn and critical components of intracellular vesicular transport processes. J Biol Chem 270:12327-12330, 1995.
 
13) Malhotra V, et al:Role of an N-ethylmaleimide-sensitive transport component in promoting fusion of transport vesicles with cisternae of the Golgi stack. Cell 54:221-227, 1988.
 
14) Melancon P, et al:Involvement of the GTP-binding 'G' proteins in transport through the Golgi stack. Cell 51:1053-1062, 1987.
PubMed
15) Clary DO, et al:SNAPs, a family of NSF attachment proteins involved in intracellular membrane fusion in animals and yeast. Cell 61:709-721, 1990.
PubMed
16) Pfanner N, et al:Fatty acyl-coenzyme A is required for budding of transport vesicles from Golgi cisternae. Cell 59:95-102, 1989.
PubMed
17) Rhodes CJ, Halban PA:Newly-synthesized proinsulin/insulin and stored insulin are released form pancreatic B-cells via a regulated, rather than a constitutive pathway. J Cell Biol 105:145-153, 1987.
 
18) Orci L, et al:The trans-most cisternae of the Golgi complex:A compartment for sorting of secretory and plasma membrane proteins. Cell 56:1039-1051, 1987.
 
19) Orci L, et al:(Pro) insulin associates with Golgi membranes of pancreatic B cells. Proc Natl Acad Sci USA 81:6743-6746, 1984.
PubMed
20) Cool DR, et al:Carboxypeptidase E is a regulated secretory pathway sorting receptor:genetic obliteration leads to endocrine disorders in Cpe (fat) mice. Cell 88:73-83, 1997.
PubMed
21) Cool DR, Loh YP:Carboxypeptidase E is a sorting receptor for prohormones:binding and kinetic studies. Mol Cell Endocrinol 139:7-13, 1998.
PubMed
22) Normant E, Loh YP:Depletion of carboxypeptidase E, a regulated secretory pathway sorting receptor, causes misrouting and constitutive secretion of proinsulin and proenkephalin, but chromogranin A. Endocrinology 139:2137-2145, 1998.
PubMed
23) Thiele C, et al:Protein secretion:puzzling receptors. Curr Biol 7:R496-R500, 1997.
PubMed
24) Naggert JK, et al:Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 10:135-142, 1995.
PubMed
25) Iminger JC, et al:Proinsulin targeting to the regulated pathway is not impaired in carboxypeptidase E-deficient Cpefat/Cpefat mice. J Biol Chem 272:27532-27534, 1997.
 
26) Halban PA, Irminger JC:Sorting and processing of secretory proteins. Biochem J 299:1-18, 1994.
PubMed
27) Bauerfeind R, Huttner WB:Biogenesis of constitutive secretory vesicles, secretory granules and synaptic vesicles. Curr Opin Cell Biol 5:628-635, 1993.
PubMed
28) Tooze SA:Biogenesis of secretory granules in the trans-Golgi netWork of neuroendocrine and endocrine cells. Biochim Biophys Acta 1404:231-244, 1998.
PubMed
29) Arvan P, Castle D:Sorting and storage during secretory granule biogenesis:looking backward and looking forward. Biochem J 332:593-610, 1998.
PubMed
30) Sopwith AM, et al:Pancreatic B-cells secrete a range of novel peptides besides insulin. Biochim Biophys Acta 803:342-345, 1984.
PubMed
31) Guest PC, et al:Insulin secretory granule biogenesis:co-ordinate regulaUon of the biosynthesis of the majority of constituent proteins. Biochem J 274:73-78, 1991.
PubMed
32) Alarcon C, et al:Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest 95:1032-1039, 1995.
 
33) Guest PC, et al:Co-secretion of carboxypeptidase H and insulm from isolated rat islets of Langerhans. Biochem J 264:503-508, 1989.
PubMed
34) Jackson AP, et al:Clathrin light chains contain brain-specific insertion sequences and a region of homology with intermediate filaments. Nature 326:154-159, 1987.
 
35) Hirst J, Robinson MS:Clathrin and adaptors. Biochim Biophys Acta 1404:173-193, 1998.
PubMed
36) Pearse BM, Robinson MS:Clathrin, adaptors, and sorting. Annu Rev Cell Biol 6:151-171, 1990.
PubMed
37) Brodsky FM:Living with clathrin:its role in intracellular membrane traffic. Science 242:1396-1402, 1988.
PubMed
38) Dittie AS, et al:The AP-1 adaptor complex binds to immature secretory granules from PC 12 cells, and is regulated by ADP-ribosylation factor. J Cell Biol 132:523-536, 1996.
 
39) Austin C, et al:Direct and GTP-dependent interaction of ADP-ribosylation factor l with clathrin adaptor protein, AP-1 on immature secretory granules. J Biol Chem 275:21862-21869, 2000.
 
40) Orci L, et al:Direct identification of prohormone conversion site in insulin-secreting cells. Cell 42:671-681, 1985.
PubMed
41) Orci L, et al:Conversion of proinsulin to insulin occurs coordinately with acidification of maturing secretory granules. J Cell Biol 103:2273-2281, 1986.
PubMed
42) Orci L, et al:Proteolytic maturation of insulin is a post-Golgi event which occurs in acidifying clathrin-coated secretory vesicles. Cell 49:865-868, 1987.
PubMed
43) Orci L, et al:pH-independent and-dependent cleavage of proinsulin in the same secretory vesicle. J Cell Biol 126:1149-1156, 1994.
PubMed
44) Smeekens SP, et al:Identiiication of a human insulinoma cDNA encoding a novel mammalian protein structurally related to the yeast dibasic processing protease Kex2. J Biol Chem 265:2997-3000, 1990.
 
45) Smeekens SP, et al:Identification of cDNA encoding a second putative prohormone convertase related to PC2 in AtT20 cells and islets of Langerhans. Proc Natl Acad Sci USA 88:340-344, 1991.
PubMed
46) Halban PA, et al:Sorting and processing of secretory proteins. Biochem J 299:1-18, 1994.
PubMed
47) Rhodes CJ, et al:What β-cell defect could lead to hyperproinsulinemia in NIDDM? Diabetes 43:511-517, 1994.
 
48) Neeman-Arbez M, et al:Levels of the conversion endoproteases PC1 (PC3) and PC2 distinguish between insulin-producing pancreatic islet beta cells and non-beta cells. Biochem J 300:57-61, 1994.
 
49) Fricker LD, et al:Purification and characterization of enkephahn convertase, an enkephalin-synthesizing carboxypeptidase. J Biol Chem 258:10950-10955, 1983.
PubMed
50) Davidson HW, et al:The insulin-secretory-granule carboxypeptidase H. Biochem J 245:575-582, 1987.
PubMed
51) Steiner DF, et al:Chemistry and biosynthesis of pancreatic protein hormones. In:Endocrinology, 2nd ed, Vol 2 (ed by DeGroot IJ, et al), p 1263-1289, WB Saunders, Philadelphia, 1989.
 
52) Rubenstein AH, et al:Evidence for proinsulin in human urine and serum. Lancet 291:1353-1355, 1968.
 
53) Sobey WJ, et al:Sensitive and specific two-site immunoradiometric assays for human insuhn, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 260:535-541, 1989.
PubMed
54) Horwitz DL, et al:Proinsulin, insuHn, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 55:1278-1283, 1975.
 
55) Duckworth WC, et al:Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 53:418-427, 1972.
PubMed
56) Heaton DA, et al:Increased proinsulin levels as an early indicator of B-sell dysfunction in non-diabetic twins of type 1 (insulin-dependent) patients. Diabetologia 31:182-184, 1988.
 
57) Hartlmg SG, et al:Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity. Diabetes 38:1271-1274, 1989.
 
58) Kahn SE, et al:Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44:173-179, 1995.
PubMed
59) Furukawa H, et al:Long-term elevation of free fatty acids leads to delayed processing of proinsulin and proinsulin convertases 2 and 3 in the pancreatic β-cell line MIN6. Diabetes 48:1395-1401, 1999.
 
60) Gorden P, et al:Circulating proinsulin-like component in man. Diabetologia 10:469-474, 1974.
PubMed
61) Melani F, et al:Proinsulin secretion by a pancreatic beta-cell adenoma:proinsulin and C-peptide secretion. N Engl J Med 283:713-719, 1970.
 
62) Gorden P, et al:Proinsulin-like component of circulating insulin in the basal state and in patients and hamsters with islet cell tumors. J Clin Invest 50:2113-2122, 1971.
PubMed
63) Cohen RM, et al:Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism 35:1137-1146, 1986.
PubMed
64) Halban PA:Proinsulin trafficking and processing in the pancreatic B cell. Trends Endocrinol Metab 1:261-265, 1990.
 
65) Neerman-Arbez M, et al:Slow cleavage at the proinsulin B-chain/connecting peptide junction associated with low levels of endoprotease PC1/3 in transformed β cells. J Biol Chem 268:16098-16100, 1993.
 
66) Pullen RA, et al:Receptor-binding region of insulin. Nature 259:369-373, 1976.
PubMed
67) Blundell TL, et al:Insulin-like growth factor:a model for tertiary structure accounting for immunoreactivity and receptor binding. Proc Natl Acad Sci USA 75:180-184, 1978.
 
68) Renscheidt H, et al:A solution equivalent of the 2Zn→4Zn transformation of insulin in the crystal. Eur J Biochem 142:7-14, 1984.
 
69) Ekberg K, et al:Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278:E759-E768, 2000.
PubMed
70) Wahren J, et al:C-peptide is a bioactive peptide. Diabetologia 50:503-509, 2007.
PubMed
71) Rhodes CJ:Insulin biosynthesis, processing, and chemistry. In:Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p 66-82, Lippincott Williams & Wilkins, Philadelphia, 2005.
 
72) Rhodes CJ:Processing of the insulin molecule. In:Diabetes Mellitus, 2nd ed (ed by LeRoith D, et al), p 20-38, Lippincott Williams & Wilkins, Philadelphia, 2000.
 
P.148 掲載の参考文献
1) Noma A:ATP-regulated K+ channels in cardiac muscle. Nature 305 (5930):147-148, 1983.
PubMed
2) Cook DL, Hales CN:Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 311 (5983):271-273, 1984.
PubMed
3) Sato Y, et al:Dual functional role of membrane depolarization/Ca2+ influx in rat pancreatic B-cell. Diabetes 41:438-443, 1992.
PubMed
4) Meats JE, et al:Lactate alters plasma membrane potential, increases the concentration of cytosolic Ca2+ and stimulates the secretion of insulin by the hamster beta-cell line HIT-T15. J Mol Endocrinol 3:121-128, 1989.
PubMed
5) Togashi K, et al:TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion. EMBO J 25:1804-1815, 2006.
PubMed
6) Corkey BE, et al:The role of long-chain fatty acyl-CoA esters in beta-cell signal transduction. J Nutr 130:299S-304S, 2000.
PubMed
7) MacDonald MJ, et al:Perspective:emerging eVidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. Am J Physiol Endocrinol Metab 288:E1-15, 2005.
PubMed
8) Maechler P, Wollheim CB:Mitochondrial signals in glucose-stimulated insulin secretion in the beta cell. J Physiol 529 (Pt 1):49-56, 2000.
 
9) Kasai K, et al:Rab27a mediates the tight docking of insulin granules onto the plasma membrane during glucose stimulation. J Clin Invest 115:388-396, 2005.
PubMed
10) Niki I, Senda T:Regulation of insulm release at pre-exocytotic stages of the secretory process. Curr Med Chem-Imun Endoc & Metab Agents 2:219-231, 2002.
 
11) Niki I, et al:Ca2+ -influx does not trigger glucose-induced traffic of the insulin granules and alteration of their distribution. Exp Biol Med 228:1218-1226, 2003.
 
12) Daniel S, et al:Identhication of the docked granule pool responsible for the first phase of glucosestimulated insulin secretion. Diabetes 48:1686-1690, 1999.
PubMed
13) Straub SG, et al:Stimulation of insulin release by glucose is associated with an increase in the number of docked granules in the beta-cells of rat pancreatic islets. Diabetes 53:3179-3183, 2004.
PubMed
14) Ohara-Imaizumi M, Nagamatsu S:Insulin exocytotic mechanism by imaging technique. J Biochem (Tokyo) 140:1-5, 2006.
PubMed
P.156 掲載の参考文献
1) Miki T, et al:The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. J Mol Endocrinol 22 (2):113-123, 1999.
PubMed
2) Inagaki N, et al:Reconstitution of IKATP:An inward rectifier subunit plus the sulfonylurea receptor. Science 270:1166-1170, 1995.
PubMed
3) Mukai E, et al:The antiarrhythmic agent cibenzoline inhibits KATp channels by binding to Kir6.2. Biochem Biophys Res Commun 251 (2):477-481, 1998.
PubMed
4) Saraya A, et al:Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 497 (1):111-117, 2004.
PubMed
5) Aguilar-Bryan L, et al:Cloning of the β cell high affinity sulfonylurea receptor:A regtilator of insulin secretion. Science 268:423-426, 1995.
 
6) Inagaki N, et al:cDNA sequence, gene structure, and chromosomal localization of the human ATP-sensitive potassium channel, uKATP-1, gene (KCNJ8). Genomics 30 (1):102-104, 1995.
PubMed
7) Inagaki N, et al:Subunit stoichiometry of the pancreatic beta-cell ATP-sensitive K+ channel. FEBS Lett 409 (2):232-236, 1997.
PubMed
8) Suzuki M, et al:Role of sarcolemmal K (ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 109 (4):509-516, 2002.
PubMed
9) Miki T, et al:ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 283 (6):E1178-1184, 2002.
PubMed
10) Gong B, et al:AK (ATP) channel deficiency affects resting tension, not contractile force, during fatigue in skeleta1 muscle. Am J Physiol Cell Physiol 279 (5):C1351-1358, 2000.
 
11) Yamada K, et al:Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 292 (5521):1543-1546, 2001.
PubMed
12) Miki T, et al:ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 4 (5):507-512, 2001.
PubMed
13) Detimary P, et al:Concentration dependence and time course of the effects of glucose on adenine and guanine nucleotides in mouse pancreatic islets. J Biol Chem 271 (34):20559-20565, 1996.
PubMed
14) Nagashima K, et al:Sulfonylurea and non-sulfonylurea hypoglycemic agents:pharmachological properties and tissue selectivity. Diabetes Res Clin Pract 66 (Suppl 1):S75-78, 2004.
 
15) Yamada C, et al:Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 553 (1-3):67-72, 2006.
 
16) Sharma N, et al:Familial hyperinsulinism and pancreatic β-cell ATP-sensitive potassium channels. Kidney Int 57:803-808, 2000.
 
17) McQuarrie I:Ideopathic spontaneously occurring hypoglycemia in infants:clinical significance of problem and treatment. AMA Am J Dis Child 87:399-428, 1954.
 
18) Shyng SL, et al:Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes 47 (7):1145-1151, 1998.
PubMed
19) Otonkoski T, et al:A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 48 (2):408-415, 1999.
PubMed
20) Gloyn AL, et al:Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kr6.2 and permanent neonatal diabetes. N Engl J Med 350 (18):1838-1849, 2004.
 
21) Yorifuji T, et al:The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus. J Clin Endocrinol Metab 90 (6):3174-3178, 2005.
PubMed
22) Proks P, et al:Aheterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 15 (11):1793-1800, 2006.
PubMed
23) Proks P, et al:Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome. Hum Mol Genet 16 (16):2011-2019, 2007.
PubMed
24) Ellard S, et al:Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations With opposite functional effects. Am J Hum Genet 81 (2):375-382, 2007.
 
P.162 掲載の参考文献
1) 加計正文ほか インスリン分泌のイオンチャネル機構と神経性調節. 内分泌・糖尿病科 17:526, 2003.
 
2) Larsson O, et al:Oscillations in KATp channel activity promote oscillations in cytoplasmic free Ca2+ concentration in the pancreatic β cells. Proc Natl Acad Sci USA 93:5161-5165, 1996.
 
3) Santos RM, et al:Widespread synchronous [Ca2+ ] ioscillations due to bursting electrical activity in single pancreadc islets. Pflugers Arch 418:417-422, 1991.
 
4) Holz GG IV, et al:Activation of a cAMP-regulated Ca2+ -signaling pathway in pancreatic β-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270:17749-17757, 1995.
 
5) Yada T, et al:Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet β-cells. J Biol Chem 269:1290-1293, 1994.
 
6) Fujiwara K, et al:Oleic acid interacts with GPR40 to induce Ca2+ signahng in rat islet β-cells:mediation by phospholipase C and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289:E670-677, 2005.
 
7) Yada T, et al:Two distinct modes of Ca2+ signalling by ACh in rat pancreatic β-cells:concentration, glucose dependence and Ca2+ origin. J Physiol (Lond) 488:13-24, 1995.
 
8) Ikeda Y, et al:Identification of N-arachidonylglycine, U18666A, and 4-androstene-3, 17-dione as novel insulin Secretagogues. Biochem Biophys Res Commun 333:778-786, 2005.
 
9) Dezaki K, et al:Ghrelin uses Gαi2 and activates voltage-dependent K+ channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet β-cells:novel signal transduction of ghrelin. Diabetes 56:2319-2327, 2007.
 
10) Splawski I, et al:CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhytlimia and autism. Cell 119:19-31, 2004.
 
11) Yamada Y, et al:Genomic variation in pancreatic ion channel genes in Japanese type 2 diabetic patients. Diabetes Metab Res Rev 17:213-216, 2001.
PubMed
12) Namkung Y, et al:Requirement for the L-type Ca2+ channel α1D subunit in postnatal pancreatic β cell generation. J Clin Invest 108:1015-1022, 2001.
 
13) Kawaguchi M, et al:Essential role of ubiquitin-proteasome system in normal regulation of insulin secretion. J Biol Chem 281:13015-13020, 2006.
PubMed
14) Jing X, et al:CaV2.3 calcium channels control second-phase insulin release. J Clin Invest 115:146-154, 2005.
PubMed
15) Rustenbeck I, et al:Energetic requirement of insulin secretion distal to calcium influx. Diabetes 46:1305-1311, 1997.
PubMed
16) Takiyama Y, et al:A Japanese family with spinocerebellar ataxia type 6 which includes three individuals homozygous for an expanded CAG repeat in the SCA6/CACNL1A4 gene. J Neurol Sci 158:141-147, 1998.
 
17) Sellick GS, et al:A novel gene for neonatal diabetes maps to chromosome 10p12.1-p13. Diabetes 52:2636-2638, 2003.
PubMed
18) Berggren PO, et al:Removal of Ca2+ channel beta3 subunit enhances Ca2+ oscillation frequency and insulin exocytosis. Cell 119:273-284, 2004.
PubMed
19) Beguin P, et al:Regulation of Ca2+ channel expression at the cell surface by the small G-protein kir/Gem. Nature 411:701-706, 2001.
PubMed
20) Soldatov NM:Ca2+ channel moving tail:link between Ca2+ -induced inactivation and Ca2+ signal transduction. Trends Pharmacol Sci 24:167-171, 2003.
PubMed
21) Juntti-Berggren L, et al:Apolipoprotein CIII promotes Ca2+ -dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci USA 101:10090-10094, 2004.
PubMed
22) Efanova IB, et al:Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 273:33501-33507, 1998.
PubMed
23) Liu YJ, Gylfe E:Store-operated Ca2+ entry in insulin-releasing pancreatic β-cells. Cell Calcium 22:277-286, 1997.
 
24) Leech CA, et al:Voltage-independent calcium channels mediate slow oscillations of cytosolic calcium that are glucose dependent in pancreatic β-cells. Endocrinology 135:365-372, 1994.
 
25) Roe MW, et al:Characterization of a Ca2+ release-activated nonselective cation current regulating membrane potential and [Ca2+] ioscillations in transgenically derived β-cells. J Biol Chem 273:10402-10410, 1998.
 
26) Sakura H, Ashcroft FM:Identification of four trp1 gene variants murine pancreatic β-cells. Diabetologia 40:528-532, 1997.
 
27) Togashi K, et al:TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion. EMBO J 25:1804-1815, 2006.
PubMed
28) Cheng H, et al:TRPM4 controls insulin secretion in pancreatic β-cells. Cell Calcium 41:51-61, 2007.
 
29) Prawitt D, et al:TRPM5 is a transient Ca2+ -activated cation channel responding to rapid changes in [Ca2+]i. Proc Natl Acad Sci USA 100:15166-15171, 2003.
PubMed
30) Akiba Y, et al:Transient receptor potential vanilloid subfamily l expressed in pancreatic islet β cells modulates insulin secretion in rats. Biochem Biophys Res Commun 321:219-225, 2004.
 
P.168 掲載の参考文献
1) Delmeire D, et al:Type VIII adenylyl cyclase in rat beta cells:coincidence signal detector/generator for glucose and GLP-1. Diabetologia 46:1383-1393, 2003.
PubMed
2) Harndahl L, et al:Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J Biol Chem 279:15214-15222, 2004.
PubMed
3) Dyachok O, et al:Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature 439:349-352, 2006.
PubMed
4) Wang X, et al:Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142:1820-1827, 2001.
 
5) Ozaki N, et al:cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2:805-811, 2000.
PubMed
6) Light PE, et al:Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A-and ADP-dependent mechanism. Mol Endocrinol 16:2135-2144, 2002.
 
7) MacDonald PE, et al:Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 278:52446-52453, 2003.
PubMed
8) Tsuboi T, et al:Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J 369:287-299, 2003.
PubMed
9) Nagy G, et al:Regulation of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25. Neuron 41:417-429, 2004.
PubMed
10) Takahashi N, et al:Post-priming actions of ATP on Ca2+ -dependent exocytosis in pancreatic beta cells. Proc Natl Acad Sci USA 96:760-765, 1999.
PubMed
11) Hatakeyama H, et al:Rapid glucose sensing by protein kinase A for insulin exocytosis in mouse pancreatic islets. J physiol 570:271-282, 2006.
PubMed
12) Hatakeyama H, et al:Two cAMP-dependent pathways differentially regulate exocytosis of large dense-core and small vesicles in mouse beta-cells. J Physiol 582:1087-1098, 2007.
 
13) Kashima Y, et al:Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046-46053, 2001.
PubMed
P.172 掲載の参考文献
1) 泉哲郎:調節性分泌制御の分子メカニズム. 実験医学 24:2093-2097, 2006.
Medical*Online
2) Burgoyne RD, Morgan A:Secretory granule exocytosis. Physiol Rev 83:581-632, 2003.
PubMed
3) Rorsman P, Renstr6m E:Insulin granule dynamics in pancreatic beta cells. Diabetologia 46:1029-1045, 2003.
 
4) Rizzoli SO, Betz WJ:Synaptic vesicle pools. Nat Rev Neurosci 6:57-69, 2005.
PubMed
5) Wang J, et al:Novel rabphilin-3-like protein associates with insulin-containing granules in pancreatic beta cells. J Biol Chem 274:28542-28548, 1999.
PubMed
6) Yi Z, et al:The Rab27a/granuphilin complex regulates the exocytosis of insulin-containing densecore granules. Mol Cell Biol 22:1858-1867, 2002.
PubMed
7) Torii S, et al:Granuphilin modulates the exocytosis of secretory granules through interaction with syntaxin la. Mol Cell Biol 22:5518-5526, 2002.
 
8) Torii S, et al:Rab27 effector granuphilin promotes the plasma membrane targeting of insulin granules via interaction with syntaxin la. J Biol Chem 279:22532-22538, 2004.
 
9) Gomi H, et al:Granuphilin molecularly docks insulin granules to the fusion machinery. J Cell Biol 171:99-109, 2005.
 
10) 泉哲郎:インスリン開口放出におけるGranuphilinの役割. 内分泌・糖尿病科 25:224-228, 2007.
 
11) Ohara-Imaizumi M, et al:Imaging exocytosis of single insulin secretory granules with evanescent wave microscopy:distinct behavior of granule motion in biphasic insulin release. J Biol Chem 277:3805-3808, 2002.
PubMed
12) Ohara-lmaizumi M, et al:TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic β-cells:different behaviour of granule motion between normal and Goto-Kaldzaki diabetic rat β-cells. Biochem J 381:13-18, 2004.
 
13) Izumi T, et al:Secretory vesicle docking to the plasma membrane:molecular mechanism and functional signhicance. Diabetes Obes Metab 9 (Suppl 2):109-117, 2007.
 
14) Jahn R, Scheller RH:SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol 7:631-643, 2006.
PubMed
15) Wojcik SM, Brose N:Regulation of membrane fusion in synaptic excitation-secretion coupling:speed and accuracy matter. Neuron 55:11-24, 2007.
PubMed
P.180 掲載の参考文献
1) Grodsky GM:Kinetics of insulin secretion;Underlying metabolic events. In:Diabetes Mellitus, A fundamental and clinical text, 2nd ed (ed by LeRoith D, et al), p 2-11, Lippincott Williams & Wilkins, Philadelphia, 2000.
 
2) Rorsman P, et al:Insulin granule dynamics in pancreatic beta cells. Diabetologia 46:1029-1045, 2003.
PubMed
3) Axelrod D:Cell-substrate contacts illuminated by total internal reflection fluorescence. J Cell Biol 89:141-145, 1981.
PubMed
4) Ohara-Imaizumi M, et al:Imaging exocytosis of single insulin secretory granules with evanescent wave microscopy:distinct behavior of granule motion in biphasic insulin release. J Biol Chem 277:3805-3808, 2002.
PubMed
5) Ohara-Imaizumi M, et al:TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic beta-cells:different behaViour of granule motion betWeen normal and Goto-Kakizaki diabetic rat beta-cells. Biochem J 381:13-18, 2004.
PubMed
6) Rizzoli SO, et al:The structural organization of the readily releasable pool of synaptic vesicles. Science 303:2037-2039, 2004.
PubMed
7) Zenisek D, et al:Transport, capture and exocytosis of single synaptic vesicles at active zones. Nature 406:849-854, 2000.
PubMed
8) Ohara-Imaizumi M, et al:Site of docking and fusion of insulin secretory granules in live MIN6 beta cells analyzed by TAT-conjugated anti-syntaxin l antibody and total intemal reflection fluorescence microscopy. J Biol Chem 279:8403-8408, 2004.
 
9) Ohara-Imaizumi M, et al:Imaging analysis reveals mechanistic differences between first- and second-phase insulin exocytosis. J Cell Biol 177:695-705, 2007.
PubMed
P.186 掲載の参考文献
1) Sato Y, et al:Dual functional role of membrane depolarization/Ca2+ influx in rat pancreatic B-cell. Diabetes 41:438-443, 1992.
PubMed
2) Komatsu M, et al:Glucose stimulation of insulin release in the absence of extracellular Ca2+ and in the absence of any increase in intracellular Ca2+ in rat pancreatic islets Proc Natl Acad Sci USA 92:10728-10732, 1995.
PubMed
3) Szollosi A, et al:Ovemight culture unmasks glucose-induced insulin secretion in mouse islets lacking ATP-sensitive K+ channels by improving the triggering Ca2+ signal. J Biol Chem 282:14768-14776, 2007.
 
4) Sato Y, Henquin JC:The K+ -ATP channel-independent pathway of regulation of insulin secretion by glucose:in search of the underlying mechanism. Diabetes 47:1713-1721, 1998.
 
5) Takahashi N, et al:Post-priming actions of ATP on Ca2+ -dependent exocytosis in pancreatic β cells. Proc Natl Acad Sci USA 96:760-765, 1999.
 
6) Kasai K, et al:Rab27a mediates the tight docking of insulin granules onto the plasma membrane during glucose stimulation. J Clin Invest 115:388-396, 2005.
PubMed
7) Komatsu M, et al:Augmentation of Ca2+ -stimulated insulin release by glucose and long-chain fatty acids in rat pancreatic islets. Free fatty acids mimic ATP-sensitive K+ channel-independent insulinotropic action of glucose. Diabetes 48:1543-1549, 1999.
PubMed
8) Yajima H, et al:Cerulenin, an inhibitor of protein acylation, selectively attenuates nutrient stimulation of insulin release. A study in rat pancreatic islets. Diabetes 49:712-717, 2000.
PubMed
9) Yamada S, et al:Nutrient modulation of palmitoylated 24-kilodalton protein in rat pancreatic islets. Endocrinology 144:5232-5241, 2003.
PubMed
10) Maechler P, Wollheim CB:Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis. Nature 402:685-689, 1999.
PubMed
11) Ronnebaum SM, et al:A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem 281:30593-30602, 2006.
PubMed
P.192 掲載の参考文献
1) Neve B, et al:Role of transcription factor KLF11 and its diabetes-associated gene variants in pancre atic beta cell function. Proc Natl Acad Sci USA 102 (13):4807-4812, 2005.
 
2) Kaczynski J, et al:Sp1- and Krufppel-like transcription factors. Genome Biol 4 (2):206, 2003,
PubMed
3) van Vliet J, et al:Human KLF17 is a new member of the Sp/KLF family of transcription factors. Genomics 87 (4):474-482, 2006.
PubMed
4) Baneriee SS, et al:The Krtippel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem 278 (4):2581-2584, 2003.
 
5) Shindo T, et al:Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 8 (8):856-863, 2002.
 
6) Ellenrieder V, et al:KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology 127 (2):607-620, 2004.
PubMed
7) Niu X, et al:Human Kruppel-like factor 11 inhibits human proinsulin promoter activity in pancreatic beta cells. Diabetologia 50 (7):1433-1441, 2007.
PubMed
8) Tanahashi T, et al:The association of genetic variants in Kruppel-like factor 11 and Type 2 diabetes in the Japanese population. Diabet Med 25 (1):19-26, 2008.
 
9) Ioannidis JP, et al:Replication validity of genetic association studies. Nat Genet 29 (3):306-309, 2001.
PubMed
10) Florez JC, et al:The Kruppel-like factor 11 (KLF11) Q62R polymorphism is not associated with type 2 diabetes in 8,676 people. Diabetes 55 (12):3620-3624, 2006.
 
P.198 掲載の参考文献
1) Palmer JP, et al:C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function:report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264, 2004.
PubMed
2) Eisenbarth G:Type l diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314:1360-1368, 1986.
 
3) Sherry NA, et al:Natural history of β-cell function in type 1 diabetes. Diabetes 54 (Suppl 2):S32-S39, 2005.
 
4) Srikanta S, et al:Type 1 diabetes mellitus in monozygotic twins:Chronic progressive beta cell dysfunction. Ann Intern Med 99:320-326, 1983.
 
5) Srikanta S, et al:Pre-type 1 diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes 33:717-720, 1984.
PubMed
6) Greenbaum CJ, et al:Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 50:470-476, 2001.
PubMed
7) Steele C, et al:Insulin secretion in type 1 diabetes. Diabetes 53:426-433, 2004.
PubMed
8) Snorgaard O, et al:Homogeniety in pattern of decline of beta-cell function in IDDM. Prospective study of 204 consecutive cases followed for 7.4 yr. Diabetes Care 15:1009-1013, 1992.
 
9) Wallensteen M, et al:Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31:664-669, 1988.
PubMed
10) Madsbad S, et al:Eiifect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia 20:530-534, 1981.
PubMed
11) Bresson D, von Herrath M:Moving towards efficient therapies in type 1 diabetes:to combine or not to combine? Autoimmun Rev 6 (5):315-322, 2007. 198
PubMed
12) Imagawa A, et al:A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301-307, 2000.
 
13) Murase Y, et al:Fulminant type 1 diabetes as a high risk group for diabetic microangiopathyanationwide 5-year-study in Japan. Diabetologia 50:531-537, 2007.
 
14) Kobayashi T, et al:Immunopathological and genetic features in slowly progressive insulin-dependent diabetes mellitus and latent autoimmune diabetes in adults. Ann N Y Acad Sci 1079:60-66, 2006.
PubMed
15) Steffes MW, et al:β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 26:832-836, 2003.
 
16) Raju B, Cryer PE:Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes:documentation of the intraislet insulin hypothesis in humans. Diabetes 54:757-764, 2005.
PubMed
P.204 掲載の参考文献
1) Sato Y,:Diminution of early insulin response to glucose in subjects with normal but minimally elevated fasting plasma glucose. Evidence for early β cell dysfunction. Diabet Med 19:566-571, 2002.
 
2) UK Prospective Diabetes Study Group:U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes:a progressive disease. Diabetes 44:1249-1258, 1995.
 
3) Weyer C, et al:The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999.
PubMed
P.214 掲載の参考文献
1) Altszuler N, et al:Glucose turnover values in the dog obtained with various species of labeled glucose. Am J Physiol 229:1662-1667, 1975.
PubMed
2) Radziuk J, et al:Experimental validation of measurements of glucose turnover in no steady state. Am J Physiol 234:E84-E93, 1978.
PubMed
3) Ishida T, et al:Comparison of hepatic extraction of insulin and glucagon in conscious and anesthetized dogs. Endocrinology 112:1098-1109, 1983.
PubMed
4) Rojdmark S, et al:Hepatic insulin and glucagon extraction after their augmented secretion in dogs. Am J Physiol 235:E88-E96, 1978.
PubMed
5) Ishida T, et al:Differential effects of oral, peripheral intravenous and intraportal glucose on hepatic glucose uptake and insulin and glucagon extraction in conscious dogs. J Clin Invest 72:590-601, 1983.
 
6) Ishida T, et al:The effect of ingestion of meat on hepatic extraction of insulin and glucagon and hepatic glucose output in conscious dogs. Metabolism 32:558-567, 1983.
PubMed
7) Ishida T, et al:Hepatic extraction of exogenous insulin in depancreatized conscious dogs. Am J Physiol 246:E369-E379, 1984.
PubMed
8) Ishida T, et al:Effects of portal and peripheral venous insulin infusion on glucose production and utilization in depancreatized conscious dogs. Diabetes 33:984-990, 1984.
PubMed
9) Botz CK, et al:Compariosn of peripheral and portal routes of insulin infusion by a computer-controlled insulin infusion system (artificial endocrine pancreas). Diabetes 25:691-700, 1976.
 
10) Brown J, et al:Importance of hepatic portal circulation for insulin action in streptozotocin-diabetic rats transplanted with fetal pancreas. J Clin Invest 64:1688-1694, 1979.
PubMed
11) Rizza RA, et al:Effect of peripheral versus portal venous administration of insulin on postprandial hyperglycemias and glucose turnover in alloxan-diabetic dogs. Mayo Clin Proc 56:434-438, 1981.
PubMed
12) Stevenson RW, et al:Effects of intraportal and peripheral insulin on glucose turnover and recycling in diabetic dogs. Am J Physiol 244:E190-E195, 1983.
PubMed
13) Chap Z, et al:First-pass hepatic extraction and metabolic effects of insulin and insulin analogues. Am J Physiol 252:E209-E217, 1987.
PubMed
14) Chap Z, et al:Effect of metabolic clearance rate and hepatic extraction of insulin on hepatic and peripheral contributions to hypoglycemia. J Clin Invest 76:2222-2234, 1985.
PubMed
15) Nomura M, et al:Intravenous infusion of sulfated insulin normalized plasma glucose levels in pancreatectomized dogs. Diabetes 32:788-792, 1983.
PubMed
16) Zeuzem S, et al:Differential bindings of sulphated insulin to adipocytes and hepatocytes. Diabetologia 27:184-188, 1984.
PubMed
17) Brandenburg D, et al:Preparation of NA, NE B29 adipoylinsulin, and intramolecularly cross-linked derivative of beef insulin. Hoppe Sealers Z Physiol Chem 353:869-873, 1972.
 
P.219 掲載の参考文献
1) White MF, et al:Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318:183-186, 1985.
 
2) Sun XJ, et al:Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73-77, 1991.
PubMed
3) Araki E, et al:Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190, 1994.
PubMed
4) Tamemoto H, et al:Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186, 1994.
PubMed
5) Bluher M, et al:Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3:25-38, 2002.
PubMed
6) Bluher M, et al:Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299:572-574, 2003.
PubMed
7) Michael MD, et al:Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6:87-97, 2000.
PubMed
8) Bruning JC, et al:A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2:559-569, 1998.
PubMed
9) Kulkarni RN, et al:Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339, 1999.
PubMed
10) Bruning JC, et al:Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122-2125, 2000.
PubMed
11) Withers DJ, et al:Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-904, 1998.
PubMed
12) Kubota N, et al:Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49:1880-1889, 2000.
PubMed
13) Kubota N, et al:Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 114:917-927, 2004.
 
14) Taguchi A, et al:Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317:369-372, 2007.
PubMed
15) Liu SC, et al:Insulin receptor substrate 3 is not essential for growth or glucose homeostasis. J Biol Chem 274:18093-18099, 1999.
 
16) Fantin VR, et al:Mice lackmg insulm receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. Am J Physiol Endocrinol Metab 278:E127-133, 2000.
PubMed
P.227 掲載の参考文献
1) Taniguchi CM, et al:Critical nodes in signalling pathways:insights into insulin action. Nat Rev Mol Cell Biol 7:85-96, 2006.
PubMed
2) Goodge KA, Hutton JC:Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic beta-cell. Semin Cell Dev Biol 11:235-242, 2000.
PubMed
3) Pullen RA, et al:Receptor-binding region of insulin. Nature 259:369-373, 1976.
PubMed
4) Bentley G, et al:Structure of insulin in 4-zinc insulin. Nature 261:166-168, 1976.
PubMed
5) Ellis L, et al:A membrane-anchored cytoplasmic domain of the human insulin receptor mediates a constitutively elevated insulin-independent uptake of 2-deoxyglucose. Mol Endocrinol 1:15-24, 1987.
 
6) Schaffer L:A model for insulin binding to the insulin receptor. Eur J Biochem 221:1127-1132, 1994.
 
7) De Meyts P:The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37 (Suppl 2):S135-148, 1994.
 
8) De Meyts P, Shymko RM:Timing-dependent modulation of insulin mitogenic versus metabolic signalling. Novartis Found Symp 227:46-57;discussion 57-60, 2000.
 
9) McKem NM, et al:Stucture of the insulin receptor ectodomain reveals a folded-over conformation. Nature 443:218-221, 2006.
 
10) Lou M, et al:The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci USA 103:12429-12434, 2006.
PubMed
11) Pillay TS, et al:Insulin stimulates the tyrosine dephosphorylation of pp125 focal adhesion kinase. J Biol Chem 270:991-994, 1995.
PubMed
12) Hubbard SR, et al:Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372:746-754, 1994.
PubMed
13) Hubbard SR:Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16:5572-5581, 1997.
PubMed
14) 安藤祥司, 稲垣昌樹:プロテインキナーゼドメインとリン酸化特異性. 実験医学 18:7-12, 2000.
Medical*Online
15) Obata T, et al:Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 275:36108-36115, 2000.
PubMed
16) Brinkworth RI, et al:Structural basis and prediction of substrate spechicity in protein serine/threonine kinases. Proc Natl Acad Sci USA 100:74-79, 2003.
PubMed
P.234 掲載の参考文献
1) Virkamaki A, et al:Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943, 1999.
PubMed
2) Sarbassov DD, et al:Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101, 2005.
PubMed
3) Avruch J, et al:Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 25:6361-6372, 2006.
PubMed
4) Hara K, et al:Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189, 2002.
PubMed
5) Sarbassov DD, et al:Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302, 2004.
PubMed
6) Elchebly M, et al:Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544-1548, 1999.
PubMed
7) Zabolotny JM, et al:PTP1B regulates leptin signal transduction in vivo. Dev Cell 2:489-495, 2002.
PubMed
8) Salmeen A, et al:Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423:769-773, 2003.
PubMed
9) McClung Jp, et al:Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 101:8852-8857, 2004.
PubMed
10) Ueki K, et al:Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446, 2004.
PubMed
11) Yasukawa H, et al:Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18:143-164, 2000.
PubMed
12) Ueki K, et al:Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabohc syndrome in the mouse. Proc Natl Acad Sci USA 101:10422-10427, 2004.
PubMed
13) Mori H, et al:Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to dietinduced obesity. Nat Med 10:739-743, 2004.
PubMed
14) Duan C, et al:Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose intolerance. Mol Cell Biol 24:7435-7443, 2004.
PubMed
15) Hotamisligil GS, et al:IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271:665-668, 1996.
PubMed
16) Aguirre V, et al:Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537, 2002.
PubMed
17) Hirosumi J, et al:A central role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002.
PubMed
18) Yu C, et al:Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:50230-50236, 2002.
PubMed
19) Um SH, et al:Absence of S6KI protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205, 2004.
 
20) Takano A, et al:Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 21:5050-5062, 2001.
PubMed
21) Rui L, et al:SOCS-1 imd SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394-42398, 2002.
 
22) Ide T, et al:SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6:351-357, 2004.
PubMed
23) Terauchi Y, et al:Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nat Genet 21:230-235, 1999.
 
24) Ueki K, et al:Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22:965-977, 2002.
PubMed
25) Taniguchi CM, et al:Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci USA 103:12093-12097, 2006.
PubMed
26) Taniguchi CM, et al:The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. Mol Cell Biol 27:2830-2840, 2007.
PubMed
27) Bandyopadhyay GK, et al:Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54:2351-2359, 2005.
PubMed
28) Stiles B, et al:Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 101:2082-2087, 2004.
PubMed
29) Butler M, et al:Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51:1028-1034, 2002.
PubMed
30) Sleeman MW, et al:Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 11 (2):199-205, 2005.
PubMed
31) Ijuin T, Takenawa T:SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. Mol Cell Biol 23:1209-1220, 2003.
PubMed
32) Du K, et al:TRB3:a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574-1577, 2003.
PubMed
33) Koo SH, et al:PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10:530-534, 2004.
PubMed
P.240 掲載の参考文献
1) 小川渉, 春日雅人:インスリン作用機構と糖尿病. 生化学 10:1332-1344, 2003.
 
2) Denton R, et al:Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449:366-369, 2007.
 
3) Li X, et al:Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447:1012-1016, 2007.
PubMed
4) Sano H, et al:Rab10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab 5:293-303, 2007.
 
5) Gray S, et al:Regulation of gluconeogenesis by Kruppel-like factor 15. Cell Metab 5:305-312, 2007.
PubMed
6) Obici S, et al:Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376-1382, 2002.
PubMed
7) Inoue H, et al:Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267-275, 2006.
PubMed
8) Pocai A, et al:Hypothalamic K (ATP) channels control hepatic glucose production. Nature 434:1026-1031, 2005.
PubMed
9) Inoue H, et al:Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10:168-174, 2004.
PubMed
10) Konner AC, et al:Insulin Action in AgRP-Expressing Neurons Is Required for Suppression of Hepatic Glucose Production. Cell Metab 5:438-449, 2007.
PubMed
11) Ueki K, et al:Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 38:583-588, 2006.
PubMed
12) Kondo T, et al:Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 111:1835-1842, 2003.
PubMed
13) Belke DD, et al:Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109:629-639, 2002.
PubMed
14) Laustsen PG, et al:Essential role of insulin and insulin-like growth factor l receptor signaling in cardiac development and function. Mol Cell Biol 27:1649-1664, 2007.
 
15) Baumgartl J, et al:Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab 3:247-256, 2006.
PubMed
P.244 掲載の参考文献
1) Clemmons DR:Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 36:109-129, 2007.
PubMed
2) Jones JI, Clemmons DR:Insulin-like growth factors and their binding proteins:biological actions. Endocr Rev 16:3-34, 1995.
PubMed
3) Yakar S, et al:Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329, 1999.
PubMed
4) Yee D:Targeting insulin-like growth factor pathways. Br J Cancer 94:465-468, 2006.
PubMed
5) D'Ercole AJ:Insulin-like growth factors and their receptors in growtih. Endocrinol Metab Clin Nonh Am 25:573-590, 1996.
 
6) Liu JP, et al:Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72, 1993.
PubMed
7) Baxter RC:Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab 70:1347-1353, 1990.
PubMed
8) Bereket A, et al:Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus:a possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 80:2282-2288, 1995.
PubMed
9) Busby WH, et al:Radioimmunoassay of a 26, 000-dalton plasma insulin-like growth factor-binding protein:control by nutritional variables. J Clin Endocrinol Metab 67:1225-1230, 1988.
PubMed
10) Fernandez AM, et al:Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926-1934, 2001.
PubMed
11) Pennisi P, et al:Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147:2619-2630, 2006.
 
12) Quattrin T, et al:Improvement of HbAlc without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated With recombinant human insulin-like growth factor-I and insulin. rhIGF-I in IDDM Study Group. J Pediatr Endocrinol Metab 14:267-277, 2001.
 
13) RH in NIDDM study Group:Evidence from a dose ranging study that recombinant insulin-like growth factor-1 (RhIGF1) effectively and safely improves glycemic control in the non-insulin dependent diabetes mellitus. Diabetes 45 (Suppl 2):27A, 1996.
 
14) Clemmons DR, et al:Rh/IGF-1/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274, 2005.
PubMed
15) Clemmons DR:Modifying IGF1 activity:an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6:821-833, 2007.
PubMed
P.249 掲載の参考文献
1) Maruyama H, et al:Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296-2299, 1984.
PubMed
2) Olsen HL, et al:Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146:4861-4870, 2005.
PubMed
3) Zhou H, et al:Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. Diabetes 56:1107-1112, 2007.
 
4) Soerensen H, et al:Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55:3463-3469, 2006.
 
5) Unger RH, Orci L:The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16, 1975.
PubMed
6) Gerich JE, et al:Lack of glucagon response to hypoglycemia in diabetes:evidence for an intrinsic pancreatic alpha cell defect. Science 182:171-173, 1973.
PubMed
7) Hirasawa A, et al:Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90-94, 2005.
PubMed
8) Brubaker PL, Drucker DJ:Minireview:Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145:2653-2659, 2004.
PubMed
9) Komatsu R, et al:Glucagonostatic and insulinotropic action of glucagonhke peptide I- (7-36) -amide. Diabetes 38:902-905, 1989.
PubMed
10) Raufman JP, et al:Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267:21432-21437, 1992.
PubMed
11) Mari A, et al:Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients With type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894, 2005.
PubMed
12) de Heer J, et al:The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 50:2135-2142, 2007.
PubMed
13) Dube PE, et al:Frontiers in glucagon-like peptide-2:multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293:E460-E465, 2007.
PubMed
14) Sigalet DL, et al:Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293:G211-221, 2007.
PubMed
15) Jeppesen PB, et al:Teduglutide (AD (-0600), a dipeptidyl peptidase rV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54:1224-1231, 2005.
 
P.253 掲載の参考文献
1) Krulich L, et al:Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783-790, 1968.
PubMed
2) Brazeau P, et al:Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79, 1973.
PubMed
3) Pradayrol L, et al:N-terminally extended somatostatin:the primary structure of somato statin-28. FEBS Lett 109:55-58, 1980.
 
4) Krantic S, et al:Novel modalities of somatostatin actions. Eur J Endocrinol 151:643-655, 2004.
PubMed
5) Weckbecker G, et al:Opportunities in somatostatin research:biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017, 2003.
PubMed
6) Patel YC:Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198, 1999.
PubMed
7) Strowski MZ, et al:Somatostatin inhibits insulin and glucagon secretion Via tWo receptors subtypes:an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-117, 2000.
 
8) Low MJ:Clinical endocrinology and metabolism. The somatostatin neuroendocrine system:physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab 18:607-622, 2004.
PubMed
9) Boehm BO, Lustig RH:Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol 16:493-509, 2002.
PubMed
10) Vbndra K, et al:Somatostatin:beneficial effects on remission in young adult patients with newly diagnosed diabetes mellitus type 1. Physiol Res 53:115-117, 2004.
 
11) Wilson SH, et al:Modulation of retinal endothelial cell behaViour by insulin-like growth factor I and somatostatin analogues:implications for diabetic retinopathy. Growth Horm IGF Res 11:S53-59, 2001.
PubMed
P.257 掲載の参考文献
1) Creutzfeldt W:The incretin concept today. Diabetologia 16:75-85, 1979.
PubMed
2) Brown JC, Dryburgh JR:A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 49:867-872, 1971.
PubMed
3) Takeda J, et al:Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci USA 84:7005-7008, 1987.
PubMed
4) Miyawald K, et al:Glucose intolerance caused by a defect in the entero-insular axis:a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847, 1999.
 
5) Miyawaki K, et al:Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742, 2002.
PubMed
6) Yamada C, et al:Genetic inactivation of GIP signaling reverses aging-associated insulin resistance through body composition changes. Biochem Biophys Res Commun 364 (1):175-180, 2007.
PubMed
7) Tsukiyama K, et al:Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation following food ingestion. Mol Endocrinol 20:1644-1651, 2006.
 
8) Yamada Y, et al:Pancreatic and extrapancreatic effects of GIP. Diabetes 55:S86-S91, 2006.
 
9) Bell GI, et al:Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718, 1983.
PubMed
10) Hansotia T, et al:Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335, 2004.
PubMed
11) Gault VA, et al:Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50:1752-1762, 2007.
PubMed
12) Kojima M, et al:Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660, 1999.
PubMed
13) Nakazato M, et al:A role for ghrelin in the central regulation of feeding. Nature 409:194-198, 2001.
PubMed
P.262 掲載の参考文献
1) 巽圭太:転写異常による下垂体ホルモン複合欠損症. 最新医学 62:2295-2301, 2007.
 
2) Melmed S, Kleinberg D:Anterior Pituitary. In:Williams Textbook of Endocrinology, 10th ed (ed by Larsen PR, et al), p 177-279, WB Saunders, Philadelphia, 2002.
 
3) Takahashi S, et al:Diabetogenic activity of 20 kDa human growth hormone (20K-hGH) and 22K-hGH in rats. Growth Horm IGF Res 11:110-116, 2001.
PubMed
4) 高野順子, 高野幸路:GH/IGF-1の化学. 成人成長ホルモン分泌不全症の臨床 (千原和夫ほか編), p2-20, メディカルレビュー社, 2006.
 
5) Vigneri R, et al:Growth hormone levels in diabetes:correlation with the clinical control of the disease. Diabetes 25:167-172, 1976.
PubMed
6) Baumann G, et al:Regulation of plasma growth hormone-binding proteins in health and disease. Metabolism 38:683-689, 1989.
PubMed
7) Waters MJ, et al:New insights into growth hormone action. J Mol Endocrinol 36:1-7, 2006.
PubMed
8) Greenhalgh CJ, et al:SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115:397-406, 2005.
PubMed
9) Yakar S, et al:Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324-7329, 1999.
PubMed
10) Brabant G, et al:Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system:results from a multicenter study. Horm Res 60:53-60, 2003.
PubMed
11) Reiter EO, Rosenfeld RG:Normal and aberrant growth. In:Williams Textbook of Endocrinology, 10th ed (ed by Larsen PR, et al), p 177-279, WB Saunders, Philadelphia, 2002.
 
12) del Rincon JP, et al:Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue:mechanism for growth hormone-mediated insulin resistance. Diabetes 56:1638-1646, 2007.
 
13) McCowen KC, Smith RJ:Insulin-like growth factors. In:Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p 169-178, Lippincott Williams and Wilkins, Philadelphia, 2005.
 
14) Gauda OP:Secondary forms of diabetes. In:Joslin's Diabetes Mellitus, 14th ed (ed by Kahn CR, et al), p 477-492, Lippincott Williams and Wilkins, Philadelphia, 2005.
 
15) Kasayama S, et al:Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52:549-555, 2000.
 
P.266 掲載の参考文献
1) Westfall TC, Westfall DP:Neurotransmission:the autonomic and somatic motor nervous system;adrenergic agonist and antagonist. In:Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed, p 137-182 and p 237-296, McGraw-Hill, New York, 2006.
 
2) Metz SA, et al:Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic alpha-adrenergic pathways. Diabetes 27:554-562, 1978.
PubMed
3) Robertson RP, et al:A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 57:791-795, 1976.
PubMed
4) Dunning BE, Taborsky GJ Jr:Galanin-sympathetic neurotransmitter in endocrine pancreas? Diabetes 37:1157-1162, 1988.
PubMed
5) Ortiz-Alonso FJ, et al:Effect of epinephrine on pancreatic beta-cell and alpha-cell function in patients with NIDDM. Diabetes 40:1194-1202, 1991.
PubMed
6) Raz I, et al:Epinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. Am J Physiol 260:E430-435, 1991.
PubMed
7) Strickland WG, et al:The role of calcium in alpha-adrenergic inactivation of glycogen synthase in rat hepatocytes and its inhibition by insulin. Diabetes 29:617-622, 1980.
PubMed
8) Laakso M, et al:Effects of epinephrine on insulin-mediated glucose uptake in whole body and leg muscle in humans:role of blood flow. Am J Physiol 263:E199-204, 1992.
PubMed
9) Garber AI, et al:Alanine and glutamine synthesis and release from skeleta1 muscle. II. The precursor role of amino acids in alanine and glutamine synthesis. J Biol Chem 251:836-843, 1976.
 
10) La Batide-Alanore A, et al:Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 21:1703-1707, 2003.
PubMed
11) Turnbull DM, et al:Hormonal and metabolic studies in a patient with a pheochromocytoma. J Clin Endocrinol Metab 51:930-933, 1980.
 
12) Lorini R, et al:Pheochromocytoma and diabetes mellitus. Clin Endocrinol (Oxf) 19:275-276, 1983.
 
13) Wiesner TD, et al:Improvement of insulin sensitivity after adrenalectomy in patients With pheochromocytoma. J Clin Endocrinol Metab 88:3632-3636, 2003.
PubMed
14) Hamaji M:Pancreatic alpha-and beta-cell function in pheochromocytoma. J Clin Endocrinol Metab 49:322-325, 1979.
PubMed
15) Bolli G, et al:Circulating catecholamine and glucagon responses to insulin-induced blood glucose decrement in a patient with pheochromocytoma. J Clin Endocrinol Metab 54:447-449, 1982.
 
P.273 掲載の参考文献
1) Montague CT, O'Rahilly S:The perils of portliness:causes and consequences of visceral adipocity. Diabetes 49:883-888, 2000.
 
2) Wajchenberg BL:Subcutaneous and visceral adipose tissue:their relation to the metabolic syndrome. Endocr Rev 21:697-738, 2000.
 
3) Masuzaki H, Flier JS:Tissue-specific glucocorticoid reactivating enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)-a promising drug target for the treatment of the metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 3:255-262, 2003.
 
4) Lindsay RS, et al:Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 88:2738-2744, 2003.
 
5) Moller DE:New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827, 2001.
PubMed
6) Masuzaki H, et al:A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170, 2001.
PubMed
7) Masuzaki H, et al:Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112:83-90, 2003.
PubMed
8) Tanaka T, et al:Central melanocortin signaling restores skeletal muscle AMP-activated protein kinase phosphorylation in mice fed a high fat diet. Cell Metab 5:395-402, 2007.
PubMed
9) Morton NM, et al:Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type-1 deficient mice. Diabetes 53:931-938, 2004.
 
10) Morton NM, et al:Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 44:41293-41301, 2001.
 
11) Kershaw EE, et al:Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54:1023-1031, 2005.
PubMed
12) Paterson JM, et al:Metabolic syndrome without obesity:Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101:7088-7093, 2004.
 
13) Kuo LE, et al:Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13:803-811, 2007.
PubMed
14) Hermanowski-Vosatka A, et al:11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527, 2005.
 
15) Ishii T, et al:Augmentation of 11β-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages-role of 11β-HSD1 in pro-inflammatory properties in macrophages. FEBS Lett 581:349-354, 2007.
 
16) Nakano S, et al:Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 292:E1213-E1222, 2007.
 
17) Arai N, et al:Ceramide and AMP-activated protein kinase are two novel regulators of 11β-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. Endocrinology 148:5268-5277, 2007.
 
18) Grundy SM:Drug therapy of the metabolic syndrome:minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5:295-309, 2006.
PubMed
P.279 掲載の参考文献
1) The DECODA Study Group:Age-and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 26:1770-1780, 2003.
 
2) Otsuki M, et al:Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause 14:404-407, 2007.
PubMed
3) Kanaya AM, et al;Heart and Estrogen/progestin Replacement Study:Glycemic effects of postmenopausal hormone therapy:the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138:1-9, 2003.
PubMed
4) Margolis KL, et al;for the Women's Health Initiative Investigators:Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women:results from the Women's Health Initiative Hormone Trial. Diabetologia 47:1175-1187, 2004.
PubMed
5) Salpeter SR, et al:Meta-analysis:effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8:538-554, 2006.
PubMed
6) Rocca WA, et al:Survival patterns after oophorectomy in premenopausal women:a population-based cohort study. Lancet Oncol 7:821-828, 2006.
PubMed
7) Okada M, et al:Effects of postmenopausal hormone replacement therapy on HbA1, levels. Diabetes Care 26:1088-1092, 2003.
PubMed
8) Maffei L, et al:A novel compound heterozygous mutation of the aromatase gene in an adult man:reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome. Clin Endocrinol (Oxf) 67:218-224, 2007.
 
9) Bilezikian Jp, et al:Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603, 1998.
 
10) Carani C, et al:Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91-95, 1997.
 
11) Herrmann BL, et al:Effect of estrogen replacement therapy on bone and glucose metabolism in a male with congenital aromatase deficiency. Horm Metab Res 37:178-183, 2005.
 
12) Maffei L, et al:Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene:effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89:61-70, 2004.
 
13) Misso ML, et al:Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinology 144:1474-1480, 2003.
PubMed
14) Bryzgalova G, et al:Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice:insulin sensitivity in the liver. Diabetologia 49:588-597, 2006.
 
15) Naaz A, et al:Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERα):a potential role for estrogen receptor beta (ERβ). Horm Metab Res 34:758-763, 2002.
 
16) Barros RP, et al:Muscle GLUT4 regula60n by estrogen receptors ERαand ERβ. Proc Natl Acad Sci USA 103:1605-1608, 2006.
 
17) Le May C, et al:Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103:9232-9237, 2006.
PubMed
18) Lee CC, et al:Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women. J Am Geriatr Soc 51:683-688, 2003.
PubMed
P.283 掲載の参考文献
1) 柳瀬敏彦:DHEA補充療法の現状と展望. 日内会誌 94:161-165, 2005.
 
2) Roth GS, et al:Biomarkers of caloric restriction may predict longevity in humans. Science 297:811, 2002.
PubMed
3) Coleman DL, et al:Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31:830-833, 1982.
PubMed
4) Aoki K, et al:Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose 1, 6-bisphosphatase activities in C57BL/Ksj-db/db mice;comparison with troglitazone. Diabetes 48:1579-1585, 1999.
PubMed
5) Ishizuka T, et al:DHEA improves glucose uptake via activation of protein kinase C and phosphatidylinositol 3-kinase. Am J Physiol 276:E196-204, 1999.
PubMed
6) Yamada Y, et al:Changes in serum sex hormone profiles after short-term low-dose administration of dehydroepiandrosterone (DHEA) to young and elderly persons. Endocr J 54:153-162, 2007.
 
7) Villareal DT, et al:Effect of DHEA on abdominal fat and insulin action in elderly women and men. JAMA 292:2243-2248, 2004.
PubMed
8) Taniguchi S, et al:The antiobesity effect of dehydroepiandrosterone in castrated or noncastrated obese Zucker male rats. Obes Res 3:639S-643S, 1995.
PubMed
9) Kajita K, et al:Dehydroepiandrosterone down-regulates the expression of peroxisome proliferatorsactivated receptor gamma in adipocytes. Endocrinology 144:253-259, 2003.
 
10) Nair KS, et al:DHEA in elderly women and DHEA and testosterone in elderly men. N Engl J Med 355:1647-1659, 2006.
 
11) Liu PY, et al:Androgens and cardiovascular disease. Endocr Rev 24:313-340, 2003.
PubMed
12) Ding E, et al:Sex differences of endogeneous sex hormones and risk of type 2 diabetes:a systematic review and meta-analysis. JAMA 295:1288-1299, 2006.
PubMed
13) Nishizawa H, et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocytederived protein. Diabetes 51:2734-2741, 2002.
PubMed
14) Page ST, et al:Testosterone administration suppresses adiponectin levels in men. J Androl 26:85-92, 2005.
 
15) Fan W, et al:Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lypolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 54:1000-1008, 2005.
 
P.289 掲載の参考文献
1) Li X, et al:Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α, transcription coactivator. Nature 447:1012-1016, 2007.
 
2) Dentin R, et al:Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449:366-369, 2007.
PubMed
3) Inoue H, et al:Role of STAT-3 in regulation of hepatic gluconeogenesis genes and carbohydrate metabolism in vivo. Nat Med 10:168-174, 2004.
PubMed
4) Okamoto H, et al:Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest 115:1314-1322, 2005.
PubMed
5) Inoue H, et al:Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267-275, 2006.
PubMed
6) Uyeda K, Repa JJ:Carbohydrate response element binding Protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 4:107-110, 2006.
PubMed
7) Ma L, et al:ChREBP-MiX is the principal mediator of glucose induced gene expression in the liver. J Biol Chem 281:28721-28730, 2006.
 
8) Matsuhisa M, et al:Augmentation of hepatic glucose uptake by a positive glucose gradient between hepatoportal and central nervous system. Diabetes 46:1101-1105, 1997.
PubMed
9) DiCostanzo CA, et al:Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. Am J Physiol Endocrinol Metab 290:E9-16, 2006.
PubMed
10) Ogihara N, et al:Characterization of the portal signal during 24-h glucose delivery in unrestrained, conscious rats. Am J Physiol Endocrinol Metab 286:E932-940, 2004.
PubMed
11) Sakura H, et al:Glucokinase gene mutation and impaired glucose uptake by liver. Lancet 341:1532-1533, 1993.
PubMed
12) Dentin R, et al:Carbohydrate responsive element binding protein (ChREBP) and sterol reguratory element binding protein-1c (SREBP-1c):two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87:81-86, 2005.
 
13) Fernandez-Novell JM, et al:Intracellular distribution of hepatic glucokinase and glucokinase regulatory protein during the fasted to refed transition in rats. FEBS Lett 459:211-214, 1999.
PubMed
14) Meijer AJ, Dubbelhunis PF:Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun 313:397-403, 2004.
 
15) Magnusson I, et al:Liver glycogen tumover in fed and fasted humans. Am J Physiol 266 (5 Pt 1):E796-E803, 1994.
 
16) Landau BR:Methods for measuring glycogen cycling. Am J Physiol Endocrinol Metab 281:E413-E419, 2001.
PubMed
P.293 掲載の参考文献
1) Cline GW, et al:Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246, 1999.
PubMed
2) Zisman A, et al:Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6:924-928, 2000.
PubMed
3) Kanzaki M:Insulin receptor signals regulating GLUT4 translocation and actin dynamics. Endocr J 53:267-293, 2006.
PubMed
4) Goodyear IJ, Kahn BB:Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235-261, 1998.
 
5) Zierath JR, et al:Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189, 1996.
PubMed
6) Shulman RG:Nuclear magnetic resonance studies of glucose metabolism in non-insulin-dependent diabetes mellitus subjects. Mol Med 2:533-540, 1996.
PubMed
7) Roden M, Shulman GI:Applications of NMR spectroscopy to study muscle glycogen metabolism in man. Annu Rev Med 50:277-290, 1999.
 
8) Keley DE, Mandarino IJ:Fuel selection in human skeletal muscle in insuln resistance:a reexamination. Diabetes 49:677-683, 2000.
 
9) Shulman GI:Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000.
PubMed
10) Bjornholm M, et al:Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46:524-527, 1997.
PubMed
11) Kim YB, et al:Normal insulin-dependent activation of Akt/protein kinase B, With diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741, 1999.
PubMed
12) Hayashi T, et al:Evidence for 5'AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47:1369-1373, 1998.
PubMed
13) Musi N, et al:AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50:921-927, 2001.
PubMed
14) Mu J, et al:A role for AMP-activated protein kinase in contraction-and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7:1085-1094, 2001.
 
15) Nishizawa H, et al:Musclin, a novel skeletal muscle-derived secretory factor. J Biol Chem 279:19391-19395, 2004.
 
P.299 掲載の参考文献
1) Matsuzawa Y:Adipocytokines and metabolic syndrome. Semin Vasc Med 5:34-39, 2005.
PubMed
2) Kadowaki T, et al:Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228:1111-1117, 2003.
PubMed
3) Giorgino F, et al:Regional differences of insulin action in adipose tissue:insights from in vivo and in vitro studies. Acta Physiol Scand 183:13-30, 2005.
PubMed
4) Abate N, et al:Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 96:88-98, 1995.
 
5) Wajchenberg BL:Subcutaneous and Visceral adipose tissue:their relation to the metabolic syndrome. Endocr Rev 21:697-738, 2000.
 
6) Ugi S, et al:Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 24:8778-8789, 2004.
PubMed
7) Du K, et al:TRB3:a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574-1577, 2003.
PubMed
8) Yang Q, et al:Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356-362, 2005.
PubMed
9) Graham TE, et al:Retinol -binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552-2563, 2006.
PubMed
10) Yamada T, et al:Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms:neuronal involvement in food-intake regulation. Cell Metab 3:223-229, 2006.
PubMed
P.302 掲載の参考文献
1) Levin BE, et al:Neuronal glucosensing:what do we know after 50 years? Diabetes 53:2521-2528, 2004.
PubMed
2) Pocai A, et al:Central leptin acutely reverses diet-induced hepatic insulin resistance. Diabetes 51:3182-3189, 2005.
 
3) Bates SH, et al:STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 421:856-859, 2003.
 
4) Morrison CD, et al:Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 289:E1051-1057, 2005.
 
5) Obici S, et al:Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376-1382, 2002.
PubMed
6) Inoue H, et al:Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267-275, 2006.
PubMed
7) Niswender KD, et al:Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus:a key mediator of insulin-induced anorexia. Diabetes 52:227-231, 2003.
PubMed
8) Choudhury AI, et al:The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest 115:940-950, 2005.
PubMed
9) Kitamura T, et al:Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med 12:534-540, 2006.
PubMed
10) Kojima M, et al:Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660, 1999.
PubMed
11) Nakazato M, et al:A role for ghrelin in the central regulation of feeding. Nature 409:194-198, 2001.
PubMed
12) Wren AM, et al:Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992-5995, 2001.
PubMed
13) Akamizu T, Kangawa K:Translational research on the clinical applications of ghrelin. Endocr J 53:585-591, 2006.
PubMed
14) Oh-IS, et al:Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443:709-712, 2006.
 
15) 北村忠弘ほか:摂食調節ペプチドの発現調節機構-FoxO1. 実験医学増刊号:解明が進むメタボリックシンドローム (春日雅人ほか編), p 141-147, 羊土社, 2007.
 
P.308 掲載の参考文献
1) King GL, et al:Differential responsiveness to insulin of endothelial and support cells from micro-and macro-vessels. J Clin Invest 71:974-979, 1983.
 
2) Zeng G, Quon MJ:Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98:894-898, 1996.
PubMed
3) Ferri C, et al:Insulin stimulates endothelm-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 80:829-835, 1995.
PubMed
4) Nishikawa T, et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404:787-790, 2000.
PubMed
5) Du XL, et al:Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222-12226, 2000.
PubMed
6) Nishio Y, et al:Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 47:1318-1325, 1998.
PubMed
7) Brownlee M:The pathobiology of diabetic complications:a unifying mechanism. Diabetes 54:1615-1625, 2005.
PubMed
8) Ilnytska O, et al:Poly (ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 55:1686-1694, 2006.
PubMed
9) Kashiwagi A, et al:Abnormal glutathione metabolism and increased cytotoxicity caused by H2O2 in human umbilical vein endothelial cells cultured in high glucose medium. Diabetologia 37:264-269, 1994.
PubMed
10) Asahina T, et al:Impaired activation of glucose oxidation and NADPH supply in human endothelial cells exposed to H2O2 in high-glucose medium. Diabetes 44:520-526, 1995.
PubMed
11) Ting HH, et al:Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97:22-28, 1996.
PubMed
12) Due XL, et al:Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348, 2001.
 
13) Tilton RG, et al:Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 99:2192-2202, 1997.
PubMed
14) Koya D, King GL:Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998.
PubMed
15) Hink U, et al:Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88:e14-e22, 2001.
PubMed
P.313 掲載の参考文献
1) Ashy AA, et al:Glucose, glutamine, and ketone-body metabolism in human enterocytes. Metabolism 37:602-609, 1988.
PubMed
2) Hanson PJ, Parsons S:Metabolism and transport of glutamine and glucose in vascularly perfused small intestine rat. Biochem J 166:509-519, 1977.
PubMed
3) Salleh M, et al:Effect of glucocorticoid treatment on glucose and glutamine metabohsm by the small intestine of the rat. Chn Sci (Lond) 75:93-100, 1988.
 
4) Ardawi A, Khoja SM:Effects of hyperthyroidism on glucose, glutamine and ketone-body metabolism in the gut of the rat. Int J Biochem 25:619-624, 1993.
 
5) Ardawi MSI Glutamine and ketone-body metabolism in the gut of streptozotocin-diabetic rats. Biochem J 249:565-572, 1988.
 
6) Tanaka T, et al:Dietary carbohydrates enhance lactase/phlorizin hydrolase gene expression at a transcription level in rat jojunum. Biochem J 331:225-230, 1998.
 
7) Kishi K, et al:Sucrase-isomaltase and hexose transporter gene expressions are coordinately enhanced by dietary fructose in rat jejunum. J Nutr 129:953-956, 1999.
PubMed
8) Rosensweig NS:Diet and intestinal enzyme adaptation:implications for gastrointestinal disorders. Am J Clin Nutr 28:648-655, 1975.
PubMed
9) Honma K, et al:Acute induction of histone acetylation on the jejunal sucrase-isomaltase gene by dietary fructose. Br J Nutr, 2008. (in press)
 
10) Gouyon F, et al:Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption:a study in GLUT2-null mice. J Physiol 552:823-832, 2003.
PubMed
11) Kellett GL, Brot-Laroche E:Apical GLUT2:A major pathway of intestinal sugar absorption. Diabetes 54:3056-3062, 2005.
 
12) Ferraris RP, et al:Luminal glucose concentration in the gut under normal conditions. Am J physiol 259:G822-G837, 1990.
PubMed
13) Tobin V, et al:Insulin internalizes GLUT2 in the enterocytes of healthy but not insulin-resistant mice. Diabetes 57:555-562, 2008.
 
14) Mace OJ, et al:Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2. J Physiol 582:379-392, 2007.
PubMed
P.317 掲載の参考文献
1) Gerich JE, et al:Renal gluconeogenesis:its importance in human glucose homeostasis. Diabetes Care 24:382-391, 2001.
PubMed
2) Cano N:Bench-to-bedside review:glucose production from the kidney. Crit Care 6:317-321, 2002.
PubMed
3) Joseph SE, et al:Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. Diabetes 49:450-456, 2000.
PubMed
4) Cersosimo E, et al:Renal glucose production during insulin-induced hypoglycemia in humans. Diabetes 48:261-266, 1999.
PubMed
5) Cersosimo E, et al:Renal substrate metabolism and gluconeogenesis during hypoglycemia in humans. Diabetes 49:1186-1193, 2000.
PubMed
6) Clemmons DR:Involvement of insulin-like growth factor-1 in the control of glucose homeostasis. Curr Opin Pharmacol 6:620-625, 2006.
PubMed
7) Snyder RW, Berns JS:Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 17:365-370, 2004.
PubMed
8) DeFronzo RA, et al:Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensidvity to insulin. J Clin Invest 62:425-435, 1978.
PubMed
9) DeFronzo RA, et al:Insulin resistance in uremia. J Clin Invest 67:563-568, 1981.
PubMed
10) McCaleb ML, et al:Induction of ilsulin resistance in normal adipose tissue by uremic human serum. Kidney Int 25:416-421, 1984.
PubMed
11) McCaleb ML, et al:Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest 75:391-396, 1985.
PubMed
12) Kraus LM, et al:Uremia and insulin resistance:N-carbamoyl-asparagine decreases insulin-sensidve glucose uptake in rat adipocytes. Kidney Int 65:881-887, 2004.
PubMed
13) Togashi N, et al:The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18:1605-1610, 2000.
 
14) Togashi N, et al:Effect of TNF-α-converting enzyme inhibitor on insulin resistance in fructose-fed fats. Hypertension 39:578-580, 2002.
 
15) Pereira BJ, et al:Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45:890-896, 1994.
 
P.322 掲載の参考文献
1) Tominaga M, et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999.
 
2) The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999.
 
3) Weyer C, et al:The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999.
PubMed
4) Igarashi Y, et al:Characteristics of Japanese subjects who progress from normal to impaired glucose tolerance. Longitudinal study excluding changes in body weight. Endocr J 52:683-689, 2005.
PubMed
5) Hirose T, et al:The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects:Rapid insulin stimulation by nateglinide in IGT subjects. Endocr J 49:649-652, 2002.
PubMed
6) 伊藤千賀子:耐糖能異常 (IGT) ・境界型の自然史. 日本臨牀 63 (増刊号2):63-66, 2005.
Medical*Online
7) Diabetes Prevention Program Research Group:Effects of Withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977-980, 2003.
 
8) Chiasson JL, et al:A STOP-NIDDM Group:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002.
PubMed
9) Nateglinide and valsartan in impaired glucose tolerance outcomes research:rational and design of the NAVIGATOR trial. Diabetes 51 (Suppl 2):A116, 2002.
 
10) Buchanan TA, et al:Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002.
PubMed
11) Yusuf S, et al:Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000.
 
12) Tenenbaum A, et al:Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26:2032-2038, 2005.
PubMed
13) Freeman DJ, et al:Pravastatin and the development of diabetes mellitus:evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001.
PubMed
14) Nakagami T, et al:The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes Res Clin Pract 55:35-43, 2002.
PubMed
P.332 掲載の参考文献
1) The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Report of the Expert Committee on the Diagnosis and Classfication of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997.
 
2) National Diabetes Data Group:Classhication and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979.
 
3) Davidson MB, et al:Relationship between fasting plasma glucose and glycosylated hemoglobin:potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 281:1203-1210, 1999.
PubMed
4) Shaw JE, et al:Impaired fasting glucose:How low should it go? Diabetes Care 23:34-39, 2000.
 
5) The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003.
 
6) American Diabetes Association:Standards of medical care in diabetes-2008. Diabetes Care 31 (Suppl 1):S12-S54, 2008.
 
7) American Diabetes Association:Diagnosis and classification of diabetes mellitus. Diabetes Care 31 (Suppl 1):S55-S60, 2008.
 
8) Report of a WHO Consultation:Definition, diagnosis and classification of diabetes mellitus and its complications:Part 1. diagnosis and classification of diabetes mellitus. World Health Organization, Department of Noncommunicable Disease Surveillance, Geneva, 1999.
 
9) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:358-404, 1999.
 
10) Kuzuya T, et al:Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 55:65-85, 2002.
 
11) 日本糖尿病学会:科学的根拠に基づく糖尿病診療ガイドライン [改訂第2版], p11-12, 南江堂, 2007.
 
12) Kosaka K, et al:A prospective study of health check examinees for the development of non-insulin-dependent diabetes mellitus:Relationship of the incidence of diabetes with the initial insulinogenic index and degree of obesity. Diabet Med 13 (Suppl 6):S120-S126, 1996.
 
13) 厚生労働省:標準的な特定保健指導プログラム (確定版), 2007.
 
14) Nathan DM, et al:Impaired fasting glucose and impaired glucose tolerance:Implications for care. Diabetes Care 30:753-759, 2007.
PubMed
15) Larsson H, et al:Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia 41 (9):1124-1125, 1998.
PubMed
16) Lim SC, et al:Cardiovascular risk profile in individuals with borderline glycemia:the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 23:278-282, 2000.
PubMed
17) Tai ES, et al:Lowering the criterion for impaired fasting glucose:Impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 27:1728-1734, 2004.
PubMed
18) Borch-Johnsen K, et al:Creating a pandemic of prediabetes:the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402, 2004.
PubMed
19) Fukushima M, et al:Insulin secretion and insulin sensitivity at different stages of glucose tolerance:a cross-sectional study of Japanese type 2 diabetes. Diabetes Res Clin Pract 66:S37-43, 2004.
 
20) Gabir MM, et al:The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108-1112, 2000.
PubMed
21) The DECODE Study Group:Is the current definition for Diabetes relevant to mortality risk from all causes and cardiovascular and non-cardiovascular diseases? Diabetes Care 26:688-696, 2003.
 
22) 富永真琴ほか:動脈硬化性疾患死亡のリスクとしてのIGTの意義-山形県舟形町のコホート研究から. 糖尿病 41 (Suppl 2):A41-A44, 1998.
 
23) Blake DR, et al:Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors:results from the Baltimore Longitudinal Study on Aging. Diabetes 53 (8):2095-2100, 2004.
PubMed
24) Hong J, et al:Differences in insulin resistance and pancreatic B-cell function in obese subjects with isolated impaired glucose tolerance and isolated impaired fasting glucose. Diabet Med 25:73-79, 2008.
PubMed
25) Meigs JB, et al:The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52:1475-1484, 2003.
PubMed
26) Hanai K, et al:Prevalence and progression of impaired glucose homeostasis assessed by the different criteria for IFG in Japanese adults. Diabetologia 48 (4):799-800, 2005.
PubMed
27) Kim SH, Reaven GM:Isolated impaired fasting glucose and peripheral insulin sensitivity:not a simple relationship. Diabetes Care 31 (2):347-352, 2008.
 
28) Laakso M, et al:Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51 (3):502-511, 2008.
PubMed
29) Barr EL, et al:Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance:the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation ll6 (2):151-157, 2007.
 
30) Abdul-Ghani HA, et al:Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130-1139, 2006.
 
P.338 掲載の参考文献
1) 河盛隆造:第45回日本糖尿病学会総会会長講演;糖のながれのシステム生物学. 糖尿病 46:101-105, 2003.
 
2) 河盛隆造:ハーゲドーン賞受賞講演:"糖のながれ" における肝・糖取り込み率制御因子の解明. 糖尿病 49:771-773, 2006.
 
3) Guideline for the management of postmeal glucose regulation. www.idf.org
 
P.342 掲載の参考文献
1) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999.
 
2) Kawasaki E, et al:Type 1 diabetes in Japan. Diabetologia 49:828-836, 2006.
PubMed
3) Itoh N, et al:Mononuclear cell infiltration and its relation to the expression of MHC antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed IDDM patients. J Clin Invest 92:2313-2322, 1993.
 
4) Kobayashi T, et al:Time course of islet cell antibodies and b cell function in non-insulin dependent stage of type 1 diabetes. Diabetes 36:510-517, 1987.
 
5) Zimmet PZ, et al:Latent autoimmune diabetes mellitus in adults (LADA):the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11:299-303, 1994.
PubMed
6) Imagawa A, et al:A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301-307, 2000.
 
7) Hanafusa T, Imagawa A:Fulminant type 1 diabetes:anovel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 3:36-45, 2007.
 
8) Eisenbarth GS:Type l diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314:1360-1368, 1986.
 
9) Todd JA, et al:Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857-864, 2007.
PubMed
P.346 掲載の参考文献
1) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999.
 
2) The International Hap Map consortium:Ahaplotype map of the human genome. Nature 437:1299-1320, 2005.
 
3) Ikegami H, Ogihara T:Genetics of insulin-dependent diabetes mellitus. Endocr J 43:605-613, 1996.
PubMed
4) Kawabata Y, et al:Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and-DQ haplotypes to susceptibility to type 1 diabetes. Diabetes 51:545-551, 2002.
PubMed
5) Fujisawa T, et al:Class 1 HLA is associated with age-at-onset of IDDM, while class II HLA confers susceptibility to IDDM. Diabetologia 38:1493-1495, 1995.
PubMed
6) Nejentsev S, et al:Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 450:887-892, 2007.
 
7) Awata T, et al:Insulin gene/IDDM2 locus in Japanese type 1 diabetes:contribution of class I alleles and influence of class 1 subdivision in susceptibility to type 1 diabetes. J Clin Endocrinol Metab 92:1791-1795, 2007.
 
8) Ueda H, et al:Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511, 2003.
 
9) Ikegami H, et al:The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease:a multicenter collaborative study in Japan. J Clin Endocrinol Metab 91:1087-1092, 2006.
PubMed
10) Vang T, et al:Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 37:1317-1319, 2005.
PubMed
11) Kawasaki E, et al:Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22):association between a promoter polymorphism and type 1 diabetes in Asian populations. Am J Med Genet A 140:586-593, 2006.
 
12) Wellcome Trust Case Control Consortium:Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678, 2007.
 
13) Todd J, et al:Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857-864, 2007.
PubMed
P.352 掲載の参考文献
1) Kawasaki E, et al:Type I diabetes mellitus. In:Molecular Mechanisms of Endocrine and Organ Specific Autoimmunity, p 149-182, Landes, Texas, 1999.
 
2) Gagnerault MC, et al:Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med 196:369-377, 2002.
PubMed
3) Savinov AY, Strongin AY:Defining the roles of T cen membrane proteinase and CD44 in type 1 diabetes. IUBMB Life 59:6-13, 2007.
 
4) Yamamoto T, et al:Development of autoimmune diabetes in glutamic acid decarboxylase 65 (GAD65) knockout NOD mice. Diabetologia 47:221-224, 2004.
PubMed
5) Saeki K, et al:Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes 51:1842-1850, 2002.
PubMed
6) Kubosaki A, et al:Targeted disnlption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice. Diabetes 53:1684-1691, 2004.
 
7) Kubosaki A, et al:Dense core vesicle proteins IA-2 and IA-2beta:metabolic alterations in double knockout mice. Diabetes 54 (Suppl 2):S46-51, 2005.
 
8) Nakayama M, et al:Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435:220-223, 2005.
PubMed
9) Kent SC, et al:Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435 (7039):224-228, 2005.
PubMed
10) Kim S, et al:Essential role fbr signal transducer and activator of transcription-1 in pancreatic β-cell death and autoimmune type 1 diabetes of nonobese diabetic mice. Diabetes 56:2561-2568, 2007.
 
11) Kawasaki E, et al:Prevention of type 1 diabetes:from the view point of beta-cell damage. Diabetes Res Clin Pract 66 (Suppl 1):S27-32, 2004.
 
12) Loweth AC, et al:Human islets of Langerhans express Fas Ugand and undergo apoptosis in response to interleukin-1β and Fas ligation. Diabetes 47:727-732, 1998.
 
13) Stassi G, et al:Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human β-cells sorted by flow-cytometry and cultured in vitro. Transplant Proc 27:3271-3275, 1995.
 
14) Itoh N, et al:Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 186:613-618, 1997.
PubMed
15) Moriwaki M, et al:Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus. Diabetologia 42:1332-1340, 1999.
PubMed
16) Cottet S, et al:cFLIP protein prevents tumor necrosis factor-α-mediated induction of caspase-8-dependent apoptosis in insulin-secreting βTc-Tet cells. Diabetes 51:1805-1814, 2002.
 
17) Thompson C, Powrie F:Regulatory T cells. Curr Opin Pharmacol 4:408-414, 2004.
PubMed
18) Sakaguchi S, et al:Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164, 1995.
PubMed
19) Bennett CL, et al:The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20-21, 2001.
PubMed
20) Gregori S, et al:Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 171:4040-4047, 2003.
PubMed
21) Lindley S, et al:Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes. Diabetes 54:92-99, 2005.
PubMed
22) Kriegel MA, et al:Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 199:1285-1291, 2004.
PubMed
P.357 掲載の参考文献
1) Mathis D, et al:beta-Cell death during progression to diabetes. Nature 414:792-798, 2001.
PubMed
2) Anderson MS, Bluestone JA:The NOD mouse:a model of immune dysregulation. Annu Rev Immunol 23:447-485, 2005.
 
3) Kataoka S, et al:Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes 32:247-253, 1983.
PubMed
4) Bach JF:Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15:516-542, 1994.
PubMed
5) Salomon B, Bluestone JA:Complexities of CD28/B7:CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225-252, 2001.
 
6) Salomon B, et al:B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-440, 2000.
PubMed
7) Tang Q, et al:In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199:1455-1465, 2004.
PubMed
8) Lanier LL:NK cell recognition. Annu Rev Immunol 23:225-274, 2005.
PubMed
9) Ogasawara K, Lanier LL:NKG2D in NK and T cell-mediated immunity. J Clin Immunol 25:534-540, 2005.
 
10) Raulet DH:Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781-790, 2003.
PubMed
11) Ogasawara K, et al:NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20:757-767, 2004.
PubMed
12) Lieberman SM, et al:Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA 100:8384-8388, 2003.
PubMed
13) Ogasawara K, et al:Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18:41-51, 2003.
PubMed
14) Rodacki M, et al:Ntered natural killer cells in type 1 diabetic patients. Diabetes 56:177-185, 2007.
PubMed
P.362 掲載の参考文献
1) Neufeld M, et al:Autoimmune polyglandular syndromes. Pediatr Ann 9:154-162, 1980.
PubMed
2) Nagamine K, et al:Positional cloning of the APECED gene. Nat Genet 17:393-398, 1997.
PubMed
3) Eisenbarth GS, Gottlieb PA:Autoimmune polyendocrine syndromes. N Engl J Med 350:2068-2079, 2004.
PubMed
4) Kriegel MA, et al:Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 199:1285-1291, 2004.
PubMed
5) Drell DW, Notkins AL:Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:132-143, 1987.
PubMed
6) Kordonouri O, et al:Natural course of autoimmune thyroiditis in type 1 diabetes:association with gender, age, diabetes duration, and puberty. Arch Dis Child 90:411-414, 2005.
PubMed
7) Mantovani RM, et al:Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus:prevalence and risk factors. J Pediatr Endocrinol Metab 20:669-675, 2007.
PubMed
8) Golden B, et al:Genetic analysis of families with autoimmune diabetes and thyroiditis:evidence for common and unique genes. J Clin Endocrinol Metab 90:4904-4911, 2005.
 
9) Thomas DJ, et al:Evidence for association between rheumatoid arthritis and autoimmune endocrine disease. Ann Rheum Dis 42:297-300, 1983.
PubMed
10) Hakala M, et al:No association between rheumatoid arthritis and insulin dependent diabetes mellitus:an epidemiologic and immunogenetic study. J Rheumatol 19:856-858, 1992.
 
11) Guo D, et al:A functional variant of SUMO4, a new IκBα modifier, is associated with type 1 diabetes. Nat Genet 36:837-841, 2004.
 
12) Noso S, et al:Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes. Diabetes 54:3582-3586, 2005.
PubMed
13) Gibbons LJ, et al:The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis. Rheumatology 44:1390-1393, 2005.
PubMed
14) Chelala C, et al:PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits. Diabetes 56:522-526, 2007.
PubMed
15) Kaufman KM, et al:Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. Arthritis Rheum 54:2533-2540, 2006.
PubMed
16) Binder A, et al:Sjogren's syndrome:association with type 1 diabetes mellitus. Br J Rheumatol 28:518-520, 1989.
PubMed
17) Suri-Payer E, et al:CD4+ CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160:1212-1218, 1998.
 
18) Wildin RS, et al:X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27:18-20, 2001.
PubMed
19) Sakaguchi S, et al:Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164, 1995.
PubMed
20) Asano M, et al:Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184:387-396, 1996.
 
21) Salomon B, et al:B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-440, 2000.
PubMed
22) Hoffmann P, et al:Large-scale in vitro expansion of polyclonal human CD4+ CD25+ high regulatory T cells. Blood 104:895-903, 2004.
PubMed
23) Jaeckel E, et al:Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54:306-310, 2005.
PubMed
24) 田中聡, 坂口志文:制御性T細胞と自己免疫疾患. 日本臨床免疫学会会誌 28:291-299, 2005.
Medical*Online
P.367 掲載の参考文献
1) Knip M, et al:Environmental triggers and determinants of type 1 diabetes. Diabetes 54 (Suppl 2):S125-S136, 2005.
 
2) Gamble DR, Taylor KW:Seasonal incidence of diabetes mellitus. Br Med J 3:631-633, 1969.
PubMed
3) Gamble DR, et al:Viral antibodies in diabetes mellitus. Br Med J 3:627-630, 1969.
PubMed
4) Yoon JW, et al:Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300:1173-1179, 1979.
PubMed
5) Juhela S, et al:T-cell responses to enterovirus antigens in children with type 1 diabetes. Diabetes 49:1308-1313, 2000.
PubMed
6) Clements GB, et al:Coxsackie B virus infection and onset of childhood diabetes. Lancet 346:221-223, 1995.
PubMed
7) Hiltunen M, et al:Islet cell antibody seroconversion in children is temporally associated with enterovirus infections. Childhood Diabetes in Finland (DiMe) Study Group. J Infect Dis 175:554-560, 1997.
 
8) Lonnrot M, et al:Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort:the Finnish Diabetes Prediction and Prevention Study. Diabetes 49:1314-1318, 2000.
 
9) Schloot NC, et al:Molecular mimicry in type 1 diabetes mellitus revisited:T-cell clones to GAD65 peptides with sequence homology to Coxsackie or proinsulin peptides do not crossreact with homologous counterpart. Hum Immunol 62:299-309, 2001.
 
10) Akerblom HK, Knip M:Putative environmental factors in Type 1 diabetes. Diabetes Metab Rev 14:31-67, 1998.
PubMed
11) Gerstein HC:Cow's milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care 17:13-19, 1994.
PubMed
12) Kimpimaki T, et al:Short-term exclusive breastfeeding predisposes young children with increased genetic risk of Type I diabetes to progressive beta-cell autoimmunity. Diabetologia 44:63-69, 2001.
PubMed
13) Roep BO, et al:HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur J Immunol 26:1285-1289, 1996.
PubMed
14) Vaarala O, et al:Cow's milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. Diabetes 48:1389-1394, 1999.
PubMed
15) Akerblom HK, et al:Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes:a pilot shldy. Diabetologia 48:829-837, 2005.
PubMed
16) EURODIAB Substudy 2 Study Group:Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia 42:51-54, 1999.
 
17) Stene LC, et al:Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 43:1093-1098, 2000.
PubMed
18) Hypponen E, et al:Intake of vitamin D and risk of type 1 diabetes:a birth-cohort study. Lancet 358:1500-1503, 2001.
PubMed
19) Baum JD, et al:Letter:Weight gain in infancy and subsequent development of diabetes mellitus in childhood. Lancet ii:866, 1975.
 
20) Bruining GJ:Association between infant growth befOre onset of juvenile type-1 diabetes and autoantibodies to IA-2. Netherlands Kolibrie study group of childhood diabetes. Lancet 356:655-656, 2000.
 
21) Hypponen E, et al:Obesity, increased linear growth, and Hsk of type 1 diabetes in children. Diabetes Care 23:1755-1760, 2000.
 
22) Akerblom HK, et al:Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 115:18-29, 2002.
PubMed
P.373 掲載の参考文献
1) Kobayashi T, et al:Time course of islet cell antibodies and B-cell function in non-insulin-dependent stage of type 1 diabetes. Diabetes 36:510-517, 1987.
 
2) Kobayashi T, et al:Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788, 1993.
PubMed
3) Nakanishi K, et al:Association of HLA-A24 with complete B-cell destruction in insulin-dependent diabetes mellitus. Diabetes 42:1086-1093, 1993.
 
4) 小林哲郎:ゆるやかに進行するインスリン依存型糖尿病 (slowly progressive IDDM). 医学のあゆみ 156:937-941, 1991.
Medical*Online
5) Kobayashi T, et al:Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. J Clin Endocrinol Metab 88:4768-4775, 2003.
PubMed
6) Kobayashi T, et al:GAD antibodies seldom disappear in slowly progressive IDDM. Diabetes Care 19:1031, 1996.
 
7) Nakanishi K, et al:Predicitive value of insulin autoantibodies for further progression of beta cell dysfunction in non-insulin-dependent diabetics. Diabetes Res 9:105-109, 1988.
 
8) Horton V, et al:Genetic heterogeneity of autoimmune diabetes:age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 42 (5):608-616, 1999.
PubMed
9) Kobayashi T, et al:Insulin intervention to preserveβcells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 958:117-130, 2002.
 
10) Kobayashi T, et al:Histopathological changes of the pancreas in islet cell antibodies (ICA) positive subjects before and after the clinical onset of insulin-dependent diabetes mellitus (IDDM). Diabetes 37:24A, 1988.
 
11) Nakanishi K, et al:Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus. Am J Gastroenterol 89:762-766, 1994.
PubMed
12) Shimada A, et al:T-cell insulitis found in anti-GAD65+ diabetes With residual B-cell function. Diabetes Care 22:615-617, 1999.
 
13) Murao S:Histological changes of the pancreas in an elderly diabetic patient positive for GAD antibody. Intern Med 39:1079-1082, 2000.
 
14) Nakanishi K, et al:Residual β-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334-1339, 1995.
 
15) Motohashi Y, et al:Vitamin D receptor gene polymorphism affects onset pattern of type 1 diabetes. J Clin Endocrinol Metab 88 (7):3137-4012, 2003.
PubMed
16) Yamada S, et al:NeuroD/beta2 gene G→A polymorphism may affect onset pattern of type 1 diabetes in Japanese. Diabetes Care 24 (8):1438-1441, 2001.
 
17) Murao S, et al:Differences in the contribution of HLA-DR and-DQ haplotypes to susceptibility to adult- and childhood-onset type 1 diabetes in Japanese patients. Diabetes 53 (10):2684-2690, 2004.
PubMed
P.381 掲載の参考文献
1) Imagawa A, et al:A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301-307, 2000.
 
2) Imagawa A, et al:Fulminant type 1 diabetes-a nationwide survey in Japan. Diabetes Care 26:2345-2352, 2003.
PubMed
3) 花房俊昭ほか:劇症1型糖尿病調査研究委員会報告-疫学調査の解析と診断基準の策定-. 糖尿病 48 (Suppl 1):A1-A13, 2005.
 
4) Hanafusa T, Imagawa A:Fulminant type 1 diabetes:a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 3 (1):36-45, 2007.
PubMed
5) Murao S, et al:Differences in the contribution of HLA-DR and-DQ haplotypes to susceptibility to adult-and childhood-onset type 1 diabetes in Japanese patients. Diabetes 53:2684-2690, 2004.
PubMed
6) Murase Y, et al:Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy-a nationwide 5-year-study in Japan. Diabetologia 50:531-537, 2007.
 
7) Cho YM, et al:Fulminant type 1 diabetes in Korea:high prevalence among patients with adult-onset type 1 diabetes. Diabetologia 50 (11):2276-2279, 2007.
PubMed
8) Imagawa A, et al:Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48:294-300, 2005.
PubMed
9) Imagawa A, et al:High titres of lgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia 48:290-293, 2005.
 
10) Sekine N, et al:Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 285:1153-1154, 2001.
 
11) Nagaoka T, et al:Insulin-dependent diabetes mellitus following acute pancreatitis caused by herpes simplex virus;a case report. J Japan Diab Soc 44:335-340, 2001.
 
12) Hashimoto N, et al:A case of insulin-dependent diabetes mellitus with coxsackie B3 Virus infection following diaminodiphenyl sulfone (DDS) syndrome. J Japan Diab Soc 30:761-765, 1987.
 
13) Nishida W, et al:A case of fulminant type 1 diabetes associated with high titer of coxsackie B3 virus antibody. J Japan Diab Soc 48 (Suppl 1):A23-27, 2005.
 
14) Shimada A, Maruyama T:Encephalomyocarditis-virus-induced diabetes model resembles "fulminant" type 1 diabetes in humans. Diabetologia 47:1854-1855, 2004.
PubMed
15) Sano H, et al:A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Res Clin Pract 79:e8-9, 2008. [Epub]
 
16) Sayama K, et al:Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes:a morphometrical assessment. Diabetologia 48:1560-1564, 2005.
PubMed
17) Yamazaki M, Hayashi T:Rapid-onset type 1 diabetes mellitus without pancreatic exocrine dysfunction. Ann Intern Med 137:145-146, 2002.
PubMed
18) Tanaka S, et al:A novel subtype of type 1 diabetes mellitus. N Engl J Med 342:1835-1838, 2000. (correspondence)
 
19) Shibasaki S, et al:Mononuclear cell infiltration to both endocrine and exocrine pancreas in patients with fulminant type 1 diabetes just after the onset. Acta Diabetol 44 (Suppl 1):S47, 2007.
 
20) Moriwaki M, et al:Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus. Diabetologia 42 (11):1332-1340, 1999.
PubMed
21) Kotani R, et al:T lymphocyte response against pancreatic beta cell antigens in fulminant Type 1 diabetes. Diabetologia 47:1285-1291, 2004.
PubMed
22) Taniguchi T, et al:Autoantibodies against the exocrine pancreas in fulminant type 1 diabetes. Pancreas 30 (2):191-192, 2005.
PubMed
23) Shimizu I, et al:Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91:471-476, 2006.
PubMed
P.386 掲載の参考文献
1) Fukushima M, et al:Insulin secretion and insuln sensitivity at different stages of glucose tolerance:a cross-sectional study of Japanese type 2 diabetes. Metabolism 53 (7):831-835, 2004.
 
2) Rhodes CJ:Type 2 diabetes-a matter of beta-cell life and death? Science 307:380-384, 2005.
PubMed
3) Robertson RP:Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 279:42351-42354, 2004.
PubMed
4) Harding HP, Ron D:Endoplasmic reticulum stress and the development of diabetes:areview. Diabetes 51 (Suppl 3):S455-461, 2002.
 
5) Delepile M, et al:EIF2AK3, encodng translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 25:406-409, 2000.
 
6) Brewer JW, Diehl A:PERK mediates cell-Cycle exit during the mammalian unfolded protein response. Proc Natl Acad Sci USA 97 (23):12625-12630, 2000.
 
7) Ishihara H, et al:Disruption of the WFS1 gene in mice causes progressive β-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 13 (11):1159-1170, 2004.
 
8) Izumi T, et al:Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 52 (2):409-416, 2003.
PubMed
9) Ozcan U, et al:Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (5695):457-461, 2004.
PubMed
10) Ozcan U, et al:Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313 (5790):1137-1140, 2006.
 
11) Yamada T, et al:Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms:neuronal involvement in food-intake regulation. Cell Metab 3 (3):223-229, 2006.
PubMed
12) Uno K, et al:Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312 (5780):1656-1659, 2006.
PubMed
13) Butler AE, et al:Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (1):102-110, 2003.
PubMed
P.391 掲載の参考文献
1) Horikawa Y, et al:Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 26:163-175, 2000.
PubMed
2) Grant SFA, et al:Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat genet 38:320-323, 2006.
PubMed
3) Groves CJ, et al:Association analysis of 6,736 U. K. subjects provides replication and confirms 7CF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55:2640-2644, 2006.
 
4) Zhang C, et al:Variant of transcription factor 7-hke 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U. S. women and men. Diabetes 55:2645-2648, 2006.
 
5) Scott IJ, et al:Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 55:2649-2653, 2006.
 
6) Cauchi S, et al:Transcription factor TCF7L2 genetic study in the French population:expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 55:2903-2908, 2006.
PubMed
7) Triggs-Raine BL, et al:HNF-1αG319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proc Natl Acad Sci USA 99:4614-4619, 2002.
 
8) Gudmundsson J, et al:Two variants on chromosome 17 confer prostate cancer risk, and the one in 7CF7L2 protects against type 2 diabetes. Nat Genet 39:977-983, 2007.
 
9) Altshuler D, et al:The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80, 2000.
PubMed
10) Ioannidis Jp, et al:Genetic associations in large versus small studies:an empirical assessment. Lancet 361:567-571, 2003.
PubMed
11) Wellcome Trust Case Control Consortium:Genome-wide associadon study of 14, 000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678, 2007.
 
12) Wacholder S, et al:Assessing the probability that a positive report is false:An approach for molecular epidemiology studies. J Natl Cancer Inst 96:434-442, 2004.
PubMed
13) Scott IJ, et al:A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341-1345, 2007.
 
14) Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research:Genome-wide association analysis identifies loci fbr type 2 diabetes and triglyceride levels. Science 316:1331-1336, 2007.
 
15) Sladek R, et al:A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885, 2007.
PubMed
16) Steinthorsdottir V, et al:A variant in CDKAL1 influences hlsuhn response and risk of type 2 diabetes. Nat Genet 39:770-775, 2007.
PubMed
17) Guo T, et al:TCF7L2 is not a major susceptibility gene for type 2 diabetes in Pima Indians:analysis of 3,501 individuals. Diabetes 56:3082-3088, 2007.
 
18) Lyssenko V, et al:Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155-2163, 2007.
PubMed
19) McCarroll SA, Altshuler DA:Copy-number variation and association studies of human disease. Nat Genet 39:S37-42, 2007.
 
20) Hahn LW, et al:Multifactor dimentionality reduction software for detecting gene-gene and geneenvironment interactions. Bioinformatics 19:376-382, 2003.
 
P.397 掲載の参考文献
1) Gillies CL, et al:Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance:systematic review and meta-analysis. BMJ 334:299, 2007.
 
2) Pereira MA, et al:Fast-food habits, weight gain, and insulin resistance (the CARDIA study):15-year prospective analysis. Lancet 365:36-42, 2005.
PubMed
3) Stettler R, et al:Interaction between dietary lipids and physical inactivity on insulin sensitivity and on intramyocellular lipids in healthy men. Diabetes Care 28:1404-1409, 2005.
PubMed
4) Tamura Y, et al:Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196, 2005.
PubMed
5) Knowler WC, et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002.
 
6) Eddy DM, et al:Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143:251-264, 2005.
PubMed
7) 井上由加利, 山田信博:糖尿病予防のエビデンス (1) -生活習慣改善:JDPPを含めて. Diabetes Frontier 17:200-204, 2006.
Medical*Online
8) Boyko EJ, et al:Visceral adiposity and risk of type 2 diabetes:a prospective study among Japanese Americans. Diabetes Care 23:465-471, 2000.
PubMed
9) Hamman RF, et al:Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29:2102-2107, 2006.
PubMed
10) Sone H, et al:Effects of lifestyle modifications on patients with type 2 diabetes:the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 34:509-515, 2002.
PubMed
11) McNeely MJ, Boyko EJ:Type 2 diabetes prevalence in Asian Americans:results of a national health survey. Diabetes Care 27:66-69, 2004.
PubMed
12) Levine JA, et al:Interindividual variation in posture allocation:possible role in human obesity. Science 307:584-586, 2005.
PubMed
13) Miller ER 3rd, et al:The effects of macronutrients on blood pressure and lipids:an overview of the DASH and OmniHeart trials. Curr Atheroscler Rep 8:460-465, 2006.
PubMed
14) Waki K, et al:Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese:a population-based prospective study in the JpHC study cohort I. Diabet Med 307:323-331, 2005.
 
15) van Dam RM, Hu FB:Coffee consumption and risk of type 2 diabetes:asystematic review. JAMA 294:97-104, 2005.
 
P.402 掲載の参考文献
1) 西川武 志, 荒木栄一:酸化ストレスと糖尿病合併症. 糖尿病学の進歩2007 (日本糖尿病学会編), p69-74, 診断と治療社, 2007.
 
2) Ihara Y, et al:Hyperglycemia causes oxidative stress in pancreaticβcells of GK rats, a model of type 2 diabetes. Diabetes 48:927-932, 1999.
 
3) Dandona P, et al:Oxidative damage to DNA in diabetes mellitus. Lancet 347:444-445, 1996.
PubMed
4) Kawamori D, et al:The forkhead transcription factor Foxol bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 281:1091-1098, 2006.
 
5) Sakai K, et al:Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic β-cells. Biochem Biophys Res Commun 300:216-222, 2003.
 
6) Butler AE, et al:β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003.
 
7) 親泊政一ほか:小胞体ストレスと膵β細胞障害. 内分泌・糖尿病科 16:38-46, 2003.
 
8) Oyadomari S, et al:Nitric oxide-induced apoptosis in pancreatic β cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci USA 98:10845-10850, 2001.
 
9) Oyadomari S, et al:Targeted disruption of the Chop gene delays endoplasmic reticulum stressmediated diabetes. J Clin Invest 109:525-532, 2002.
PubMed
10) Stey J, et al:Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 104:15040-15044, 2007.
 
11) Delepine M, et al:EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 25:406-409, 2000.
 
12) Yamada T, et al:WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway spechically in pancreatic β-cells. Hum Mol Genet 15:1600-1609, 2006.
 
13) Laybutt DR, et al:Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 50:752-763, 2007.
PubMed
14) Thameem F, et al:Association of amino acid variants in the activating transcription factor 6 gene (ATF6) on 1q21-q23 with type 2 diabetes in Pima Indians. Diabetes 55:839-842, 2006.
PubMed
P.413 掲載の参考文献
1) Matschinsky FM, et al:The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55:1-12, 2006.
 
2) Iynedjian PB, et al:Mammalian glucokinase and its gene. Biochem J 293:1-13, 1993.
PubMed
3) Moates JM, et al:The pal elements in the upstream glucokinase promoter exhibit dyad symmetry and display cell-spechic enhancer activity when multimerised. Diabetologia 47:1632-1640, 2004.
PubMed
4) Kim S-Y, et al:SREBP-1c mediates the insulin-dependent hepatic glucokinase expression. J Biol Chem 279:30823-30829, 2004.
PubMed
5) Hansmannel F, et al:Insulin induction of glucokinase and fatty acid synthase in hepatocytes:a nalysis of the roles of sterol-regulatory-element-binding protein-lc and liver X receptor. Biochem J 399:275-283, 2006.
 
6) Kim S-Y, et al:Liver glucokinase can be activated by peroxisome proliferator-activated receptor-γ. Diabetes 53 (Suppl 1):S66-S70, 2004.
 
7) Farrelly D, et al:Mice mutant fbr glucokinase regulatory protein exhibit decreased liver glucokinase, a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci USA 96:14511-14516, 1999.
 
8) Vionnet N, et al:Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 356:721-722, 1992.
PubMed
9) Gloyn AL:Glucokinase (GCK) mutations in hyper-and hypoglycemia:maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutatat 22:353-362, 2003.
PubMed
10) Sakura H, et al:Structure of the human glucokinase gene and identification of a missense mutation in a Japanese patient with early-onset non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 75:1571-1573, 1992.
 
11) Eto K, et al:Sequence variations of the glucokinase gene in Japanese subjects with NIDDM. Diabetes 42:1133-1137, 1993.
PubMed
12) Velho G, et al:Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q. Diabetes Care 19:915-919, 1996.
 
13) Velho G, et al:Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet 340:444-456, 1992.
PubMed
14) Byme MM, et al:Insulin secretory abnomlalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 93:1120-1130, 1994.
 
15) Njolstad PR, et al:Permanent neonatal diabetes caused by glucokinase deficiency. Diabetes 52:2854-2860, 2003.
PubMed
16) Njolstad PR, et al:Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 344:1588-1592, 2001.
PubMed
17) Sakura H, et al:Glucokinase gene mutation and impaired glucose uptake by liver. Lancet 341:1532-1533, 1993.
PubMed
19) Gloyn AL, et al:Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52:2433-2440, 2003.
PubMed
20) Niswender KD, et al:Cell-specific expression and regulation of a glucokinase gene locus transgene. J Biol Chem 272:22564-22569, 1997.
PubMed
21) Niswender KD, et al:Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 272:22570-22575, 1997.
PubMed
22) Shiota M, et al:Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes 50:622-629, 2001.
 
23) Terauchi Y, et al:Pancreatic β-cell-specific targeted disruption of glucokinase gene. J Biol Chem 270:30253-30256, 1995.
 
24) Grupe A, et al:Transgenic knockouts reveal a critical requirement for pancreaticβcell glucokinase in maintaining glucose homeostasis. Cell 83:69-78, 1995.
 
25) Postic C, et al:Dual role for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using cre recombinase. J Biol Chem 274:305-315, 1999.
 
26) Terauchi Y, et al:Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 andβcell glucokinase genes, genetic reconstitution of diabetes as a polygenic disease. J Clin Invest 99:861-866, 1997.
 
27) Katagiri H, et al:Nonsense mutation of glucokinse gene in late-onset non-insulin-dependent diabetes melhtus. Lancet 340:1316-1317, 1992.
 
28) Grimsby J, et al:Allosteric activators of glucokinase:potential role in diabetes therapy. Science 301:370-373, 2003.
PubMed
29) Efanov AM, et al:A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146:3696-3701, 2005.
PubMed
30) Futamura M, et al:An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 281:37668-37674, 2006.
PubMed
31) Kang L, et al:Glucokinase is a critical regulator of vetromedial hypothalamic neuronal glucosensing. Diabetes 55:412-420, 2006.
 
32) Zelent D, et al:A glucose sensor role for glucokinase in anterior pituitary cells. Diabetes 55:1923-1929, 2006.
PubMed
Wabitsch M, et al:Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycemia of infancy. Diabet Med 24:1393-1399, 2007.
 
P.420 掲載の参考文献
1) Robertson RP:Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 271:42351-42354, 2004.
 
2) Kaneto H, et al:Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. J Mol Med 83:429-439, 2005.
PubMed
3) Tiedge M, et al:Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733-1742, 1997.
PubMed
4) Ihara Y, et al:Hyperglycemia causes oxidative stress in pancreatic β-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927-932, 1999.
 
5) Matsuoka T, et al:Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 99:144-150, 1997.
 
6) Kaneto H, et al:Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 277:30010-30018, 2002.
PubMed
7) Kajimoto Y, et al:Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells. Diabetologia 42:1417-1424, 1999.
PubMed
8) Kaneto H, et al:Beneficial effects of antioxidants in diabetes:possible protection of pancreatic β-cells against glucose toxicity. Diabetes 48:2398-2406, 1999.
 
9) Tanaka Y, et al:Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci USA 96:10857」0862, 1999.
 
10) Gorogawa S, et al:Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 57:1-10, 2002.
 
11) Gokkusu C, et al:Oxidant and antioxidant systems in NIDDM patients:influence of Vitamine E supplementation. Endocr Res 27:377-386, 2001.
PubMed
12) Kawamori D, et al:Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun N-terminal kinase. Diabetes 52:2896-2904, 2003.
PubMed
13) Nakae J, et al:Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 32:245-253, 2002.
PubMed
14) Kitamura T, et al:The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110:1839-1847, 2002.
PubMed
15) Kawamori D, et al:The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 281:1091-1098, 2006.
PubMed
P.427 掲載の参考文献
1) Smith U, et al:Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Clin Invest 9 (5):327-332, 1979.
PubMed
2) Shimabukuro M, et al:Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 94:4637-4641, 1997.
PubMed
3) Nolan CJ, et al:Fatty acid signaling in the β-cell and insulin secretion. Diabetes 55 (Suppl 2):S16-23, 2006.
 
4) Shimabukuro M, et al:Lipoapoptosis in β-cells of Obese Prediabetic fa/fa Rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 273:32487-32490, 1998.
 
5) Zhou Yr, et al:Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells. Proc Natl Acad Sci USA 95:8898-8903, 1998.
 
6) Shimabukuro M, et al:Fatty acid-induced β-cell apoptosis:A link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498-2502, 1998.
 
7) Koshkin V, et al:Limited mitochondrial permeabilization is an early manifestation of palmitate-induced lipotoxicity in pancreatic beta-cells. J Biol Chem, 2007. [Epub ahead of print]
 
8) Wang X, et al:Gene and protein kinase expression profiling of reactive oxygen species-associated lipotoxicity in the pancreatic beta-cell line MIN6. Diabetes 53 (1):129-140, 2004.
PubMed
9) Shulman GI:Unraveling the cellular mechanism of insulin resistance in humans:new insights from magnetic resonance spectroscopy. Physiology (Bethesda) 19:183-190, 2004.
 
10) Perseghin G, et al:Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans:a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48 (8):1600-1606, 1999.
PubMed
11) Weiss R, et al:Prediabetes in obese youth:a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362 (9388):951-957, 2003.
PubMed
12) Kovacs P, Stumvoll M:Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19 (4):625-635, 2005.
 
13) Morino K, et al:Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 (Suppl 2):S9-S15, 2006.
 
14) Bluher M, et al:Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3:25-38, 2002.
PubMed
15) Kasuga M:Insulin resistance and pancreatic beta cell failure. J Chn Invest 116 (7):1756-1760, 2006.
 
16) Hayashi T, et al:Visceral adiposity and the prevalence of hypertension in Japanese Americans. Circulation 108 (14):1718-1723, 2003.
PubMed
17) Shimabukuro M, et al:Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88 (7):3236-3240, 2003.
 
18) Chinen I, et al:Vascular lipotoxicity:endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 148:160-165, 2007.
PubMed
P.431 掲載の参考文献
1) Rhodes CJ:Type 2 diabetes-a matter of β-cell life and death? Science 307:380-384, 2005.
 
2) Butler AE, et al:Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003.
PubMed
3) Sakuraba H, et al:Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45:85-96, 2002.
PubMed
4) Rhodes CJ, White MF:Molecular insights into insulin action and secretion. Eur J Clin Invest 32 (Suppl 3):3-13, 2002.
 
5) White MF:IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283:413-422, 2002.
 
6) Tamemoto H, et al:Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186, 1994.
PubMed
7) Araki E, et al:Alternative pathway of insulin signalling ill mice with targeted disruption of the IRS-1 gene. Nature 372:186-190, 1994.
 
8) Withers DJ, et al:Disruption of IRS-2 causes type 2 diabetes in mice. Nature 381:900-904, 1998.
 
9) Kubota N, et al:Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49:1880-1889, 2000.
PubMed
10) Kubota N, et al:Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 114:917-927, 2004.
 
11) Terauchi Y, et al:Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246-257, 2007.
PubMed
12) Jhala US, et al:cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 17:1575-1580, 2003.
PubMed
13) Weir GC, Bonner-Weir S:A dominant role for glucose in beta cell compensation of insulin resistance. J Clin Invest 117:81-83, 2007.
PubMed
P.435 掲載の参考文献
1) Katz EB, et al:Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377:151-155, 1995.
PubMed
2) Tsao TS, et al:Prevention of insulin resistance and diabetes in mice heterozygous for GLUT4 ablation by transgenic complementation of GLUT4 in skeletal muscle. Diabetes 48:775-782, 1999.
PubMed
3) Kim JK, et al:Glucose toxicity and the development of diabetes in mice With muscle-spechic inactivation of GLUT4. J Clin Invest 108:153-160, 2001.
PubMed
4) Abel ED, et al:Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409:729-733, 2001.
PubMed
5) Graham TE, et al:Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552-2563, 2006.
PubMed
6) Kloting N, et al:Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6:79-87, 2007.
PubMed
7) Shi J, et al:The luminal Vps10p domain of sortilin plays the predominant role in targeting to insulin-responsive Glut4-containing vesicles. J Biol Chem 282:9008-9016, 2007.
PubMed
8) Liu LB, et al:The SUMO conjugating enzyme Ubc9 is a regulator of GLUT4 turnover and targeting to the insulin-responsive storage compartment in 3T3-L1 adipocytes. Diabetes 56:1977-1985, 2007.
 
9) Carvalho E, et al:GLUT4 overexpression or deficiency in adipocytes of transgenic mice alters the composition of GLUT4 vesicles and the subcellular localization of GLUT4 and insulin-responsive aminopeptidase. J Biol Chem 279:21598-21605, 2004.
 
10) Sano H, et al:Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278:14599-14602, 2003.
PubMed
11) Sano H, et al:Rab 10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab 5:293-303, 2007.
 
12) Saito T, et al:The interaction of Akt with APPL1 is required for insulin-stimulated Glut4 translocation. J Biol Chem 282:32280-32287, 2007.
PubMed
13) Kanzaki M:Insulin receptor signals regulating GLUT4 translocation and actin dynamics. Endocr J 53:267-293, 2006.
PubMed
14) Yoshizaki T, et al:Myosin 5a is an insulin-stimulated Akt2 (protein kinase Bbeta) substrate modulating GLUT4 vesicle translocation. Mol Cell Biol 27:5172-5183, 2007.
PubMed
15) Chen XW, et al:Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myolc. Dev Cell 13:391-404, 2007.
 
P.440 掲載の参考文献
1) Emorine LJ, et al:Molecular characterization of the human β3-adrenergic receptor. Science 245:1118-1121, 1989.
 
2) 斉藤昌之:褐色脂肪とメタボリックシンドローム. 実験医学 25:2291-2297, 2007.
Medical*Online
3) Walston J, et al:Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 333:343-347, 1995.
 
4) Widen E, et al:Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333:348-351, 1995.
 
5) Yo shida T, et al:Mutation of β3-adrenergic-receptor gene and response to treatment of obesity. Lancet 346:1433-1434, 1995.
 
6) Yoshioka K, et al:Association of Trp64Arg mutation in the β3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia 39:1410-1411, 1996.
 
7) Kadowaki H, et al:A mutation in the β3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 215:555-560, 1995.
 
8) Sakane N, et al:β3-Adrenergic-receptor polymorphism:a genetic marker for Visceral fat obesity and the insulin resistance syndrome. Diabetologia 40二200-204, 1997.
 
9) Kimura K, et al:Mutated human β3-adrenergic receptor (Trp64Arg) lowers the response to β3-adrenergic agonists in transfected 3T3-L1 preadipocytes. Horm Metab Res 32:91-96, 2000.
 
10) Umekawa T, et al:Trp64Arg mutation of β3-adrenoceptor gene deteriorates lipolysis induced by β3-adrenoceptor agonist in human omental adipocytes. Diabetes 48:117-120, 1999.
 
11) Sakane N, et al:β3-adrenoreceptor gene polymorphism:a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes 46:1633-1636, 1997.
 
12) Fujisawa T, et al:Meta-analysis of the association of Trp64Arg polymorphism of β3-adrenergic receptor gene with body mass index. J Clin Endocrinol Metab 83:2441-2444, 1998.
 
13) Zhan S, et al:Meta-analysis of the association of the Trp64Arg polymorphism in the β3 adrenergic receptor with insulin resistance. Obes Res 13:1709-1719, 2005.
 
14) Kogure A, et al:Synergic effect of polymorphisms in uncoupling protein l and β3-adrenergic receptor genes on weight loss in obese Japanese. Diabetologia 41:1399, 1998.
 
15) Sawa M, et al:Recent developments in the design of orally bioavailableβ3-adrenergic receptor agonists. Curr Med Chem 13:25-37, 2006.
 
P.445 掲載の参考文献
1) Zhang Y, et al:Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994.
PubMed
2) Kievit P, et al:Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 4:123-132, 2006.
PubMed
3) Kitamura T, et al:Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med 12:534-540, 2006.
PubMed
4) Ren D, et al:Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body weight in mice. Cell Metab 2:95-104, 2005.
PubMed
5) Kowalski TJ, et al:Transgenic complementation of leptin-receptor deficiency. 1. Rescue of the obesity/diabetes phenotype of LEPR-null mice expressing a LEPR-B transgene. Diabetes 50:425-435, 2001.
 
6) Ogawa Y, et al:Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48:1822-1829, 1999.
PubMed
7) Minokoshi Y, et al:Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339-343, 2002.
PubMed
8) Tanaka T, et al:Central melanocortin signaling restores skeletal muscle AMP-activated protein kinase phosphorylation in mice fed a high-fat diet. Cell Metab 5:395-402, 2007.
PubMed
9) Miyanaga F, et al:Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 46:1329-1337, 2003.
PubMed
10) Ebihara K, et al:Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440-1448, 2001.
 
11) Oral EA, et al:Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-578, 2002.
PubMed
12) Ebihara K, et al:Eficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532-541, 2007.
 
13) Masuzaki H, et al:Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation:usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 48:1615-1622, 1999.
PubMed
14) Aizawa-Abe M, et al:Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105:1243-1252, 2000.
PubMed
15) Suganami E, et al:Leptin stimulates ischemia-induced retinal neovascularization:possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 53:2443-2448, 2004.
PubMed
16) Stephenson K, et al:Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice. Arterioscler Thromb Vasc Biol 23:2027-2033, 2003.
PubMed
17) Schafer K, et al:Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24:112-117, 2004.
PubMed
18) Bodary PF, et al:Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein Edeficient mice. Arterioscler Thromb Vasc Biol 25:e119-122, 2005.
PubMed
19) Satoh N, et al:Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 27:2488-2490, 2004.
PubMed
20) Honda H, et al:Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36:12-21, 2002.
PubMed
21) Yura S, et al:Role of premature leptin surge in obesity resulting from intrauterine undernutrition. Cell Metab 1:371-378, 2005.
PubMed
22) Bouret SG, et al:Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 304:108-110, 2004.
PubMed
P.452 掲載の参考文献
1) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005.
PubMed
2) Kadowaki T, et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006.
PubMed
3) Mori Y, et al:Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51 (4):1247-1255, 2002.
PubMed
4) Hara K, et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002.
PubMed
5) Yamauchi T, et al:Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001.
 
6) Yamauchi T, et al:The fat-derived homlone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001.
PubMed
7) Kubota N, et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002.
PubMed
8) Yamauchi T, et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003.
PubMed
9) Yamauchi T, et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002.
PubMed
10) Yamauchi T, et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003.
PubMed
11) Tsuchida A, et al:Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004.
PubMed
12) Tsuchida A, et al:Peroxisome proliferator-activated receptor (PPAR) α activation increases , adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPARα, PPARγ and their combination. Diabetes 54:3358-3370, 2005.
 
13) Narasimhan ML, et al:Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17:171-180, 2005.
PubMed
14) Waki H, et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003.
PubMed
15) Hara K, et al:Measurement of the high-molecular-weight form of adiponectin in plasma is useful for the prediction of insuhn resistance and metabolic syndrome, Diabetes Care 29:1357-1362, 2006.
PubMed
16) Yamauchi T, et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007.
PubMed
P.460 掲載の参考文献
1) Hotamisligil GS, et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993.
PubMed
2) Zhang Y, et al:Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994.
PubMed
3) Scherer PE, et al:A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995.
 
4) Hu E, et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996.
 
5) Maeda K, et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996.
PubMed
6) Nakano Y, et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:803-812, 1996.
PubMed
7) Tataranni PA, Ortega E:A burning question:does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 54:917-927, 2005.
 
8) Weisberg SP, et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003.
PubMed
9) Xu H, et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003.
 
10) Barbier O, et al:Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726, 2002.
PubMed
11) Issemam I, Green S:Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650, 1990.
 
12) Hannele YJ:Thiazolidinediones. N Engl J Med 351:1106-1118, 2004.
 
13) Pascual G, et al:A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437:759-763, 2005.
PubMed
14) Kubota N, et al:PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609, 1999.
PubMed
15) Yamauchi T, et al:The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245-41254, 2001.
PubMed
16) Yamauchi T, et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002.
PubMed
17) Hara K, et al:The Pro 12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216, 2000.
 
18) Deeb SS, et al:A Pro 12Ala substitUtion in PPARgamma2 associated With decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287, 1998.
 
19) Okuno A, et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998.
PubMed
20) Kubota N, et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem 281:8748-8755, 2006.
PubMed
21) Dormandy JA, et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005.
PubMed
22) Erdmann E, et al:The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction:results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (17):1772-1780, 2007.
PubMed
23) Wilcox R, et al:Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke:results from PROactive (PRO spective pioghtAzone Clinical Trial In macrovascular Events 04). Stroke 38:865-873, 2007.
 
24) Mazzone T, et al:Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes:a randomized trial. JAMA 296:2572-2581, 2006.
PubMed
25) Nissen SE, Wolski K:Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007.
PubMed
P.464 掲載の参考文献
1) Hotamisligil GS, et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993.
PubMed
2) Kern PA, et al:The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995.
PubMed
3) Hotamisligil GS, et al:Increased adipose tissue expression of tumor necrosis facto卜alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995.
 
4) Krogh-Madsen R, et al:Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 291:E108-114, 2006.
PubMed
5) Uysal Kr, et al:Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614, 1997.
 
6) Hotamisligil GS:Inflammation and metabolic disorders. Nature 444:860-867, 2006.
PubMed
7) Plomgaard P, et al:Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. D iabetes 54:2939-2945, 2005.
 
8) Yamaguchi K, et al:The effect of tUmor necrosis factor-alpha on tissue specificity and selectivity to insulin signaling. Hypertens Res 26:389-396, 2003.
PubMed
9) Aguirre V, et al:The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem 275:9047-9054, 2000.
 
10) Bouzakri K, Zierath JR:MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 282:7783-7789, 2007.
PubMed
11) Ruan H, et al:Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-Ll adipocytes:nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 51:1319-1336, 2002.
 
12) Steinberg GR, et al:Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4:465-474, 2006.
PubMed
13) Gonzalez-Gay MA, et al:Anti-tUmor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Chn Exp Rheumatol 24:83-86, 2006.
 
14) Araujo EP, et al:Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology l48:5991-5997, 2007.
 
15) Ofei F, et al:Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885, 1996.
PubMed
P.469 掲載の参考文献
1) Bachmann OP, et al:Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 50:2579-2584, 2001.
PubMed
2) Itani SI, et al:Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51:2005-2011, 2002.
PubMed
3) McGarry JD:Banting lecture 2001:dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18, 2002.
PubMed
4) Petersen KF, et al:Mitochondrial dysfunction in the elderly:possible role in insulin resistance. Science 300:1140-1142, 2003.
PubMed
5) Petersen KF, et al:Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671, 2004.
PubMed
6) Tamura Y, et al:Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196, 2005.
PubMed
7) Tamura Y, et al:Acute effects of dietary fat on intramyocellular lipid in sprinters and endurance runners. Metabolism, 2007. (in press)
 
8) Kim JK, et al:PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823-827, 2004.
PubMed
9) Kim JK, et al:Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437-446, 2001.
PubMed
10) Yuan M, et al:Reversal of obesity-and diet-induced insulin resistance With salicylates or targeted disruption of Ikkbeta. Science 293:1673-1677, 2001.
 
11) Sinha S, et al:Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear Iocalization of NFkappa B. J Biol Chem 279:41294-41301, 2004.
 
12) Hundal RS, et al:Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326, 2002.
PubMed
13) Seppala-Lindroos A, et al:Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028, 2002.
 
14) Ryysy L, et al:Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758, 2000.
PubMed
15) Kelley DE, et al:Fatty liver in type 2 diabetes mellitus:relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285:E906-916, 2003.
PubMed
16) Nielsen S, et al:Splanchnic lipolysis in human obesity. J Clin Invest 113:1582-1588, 2004.
 
17) Lam TK, et al:Free fatty acid-induced hepatic insulin resistance:apotential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 283:E682-691, 2002.
 
18) Park E, et al:Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J EndocHnol 195:323-331, 2007.
PubMed
19) Samuel VT, et al:Inhibition of protein Idnase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 117:739-745, 2007.
 
20) Tamura Y, et al:Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice. Diabetologia 50:131-141, 2007.
PubMed
21) Cai D, et al:Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183-190, 2005.
PubMed
22) Balaj M, et al:Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes 51:3043-3048, 2002.
 
23) Sato F, et al:Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 92:3326-3329, 2007.
PubMed
24) Mayerson AB, et al:The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002.
PubMed
25) Balaj M, et al:Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370, 2003.
 
26) Tiikkainen M, et al:Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004.
PubMed
27) Rasouli N, et al:Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288:E930-934, 2005.
PubMed
28) Zhou G, et al:Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001.
PubMed
29) Tamura Y, et al:Effects of merformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab, 2007. (in press)
 
P.473 掲載の参考文献
1) Holcomb IN, et al:FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19:4046-4055, 2000.
 
2) Steppan CM, et al:The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001.
PubMed
3) Ghosh S, et al:The genomic organization of mouse resistin reveals major differences from the human resistin:functional implications. Gene 305:27-34, 2003.
PubMed
4) Weisberg SP, et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003.
PubMed
5) Silswal N, et al:Human resistin stimulates the proinflammatory cytokines TNFα and IL12 in macrophages by NFκB-dependent pathway. Biochem Biophys Res Commun 334:1092-1101, 2005.
 
6) Haugen F, et al:Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 507:105-108, 2001.
PubMed
7) Shojima N, et al:Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51:1737-1744, 2002.
PubMed
8) Nogueiras R, et al:Regulation of resistin by gonadal, thyroid hormone, and nutritional status. Obes Res 11:408-414, 2003.
PubMed
9) Shojima N, et al:Serum concentrations of resistin-like molecules beta and gamma are elevated in high-fat-fed and obese db/db mice, with increased production in the intestinal tract and bone marrow. Diabetologia 48:984-992, 2005.
PubMed
10) Moon B, et al:Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 285:E106-115, 2003.
PubMed
11) Palanivel R:Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 49:183-190, 2006.
PubMed
12) Rajala MW, et al:Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225-230, 2003.
PubMed
13) Rangwala SM, et al:Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53:1937-1941, 2004.
PubMed
14) Banerlee RR, et al:Regulation of fasted blood glucose by resistin. Science 303:1195-1198, 2004.
 
15) Kushiyama A, et al:Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. J Biol Chem 280:42016-42025, 2005.
PubMed
P.479 掲載の参考文献
1) Gerard C, Rollins BJ:Chemokines and disease. Nat Immunol 2:108-115, 2001.
PubMed
2) Ross R:Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126, 1999.
PubMed
3) Shoelson SE, et al:Inflammation and insulin resistance. J Clin Invest 116:1793-1801, 2006.
PubMed
4) Hotamisligil GS, et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesitylinked insulin resistance. Science 259:87-91, 1993.
PubMed
5) Yuan M, et al:Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677, 2001.
 
6) Hirosumi J, et al:A central role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002.
PubMed
7) Shi H, et al:TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025, 2006.
PubMed
8) Weisberg SP, et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003.
PubMed
9) Xu H, et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003.
 
10) Kanda H, et al:MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505, 2006.
 
11) Kamei N, et al:Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602-26614, 2006.
PubMed
12) Inouye KE, et al:Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56:2242-2250, 2007.
 
13) Weisberg SP, et al:CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124, 2006.
PubMed
14) Bruun JM, et al:Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT):implication of macrophages resident in the AT. J Clin Endocrinol Metab 90:2282-2289, 2005.
 
15) Simeoni E, et al:Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 47:1574-1580, 2004.
PubMed
P.483 掲載の参考文献
1) Samec S, et al:Role of UCP homologues in skeletal muscles and brown adipose tissue:mediators of thermogenesis or regulators of lipids as fuel substrate? EASEB J 12:715-724, 1998.
PubMed
2) Samec S, et al:Interorgan signaling between adipose tissue metabolism and skeletal muscle uncoupling protein homologs:is there a role for circulating free fatty acids? Diabetes 47:1693-1698, 1998.
 
3) Clapham JG, et al:Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406:415-418, 2000.
 
4) Costford SR, et al:Effects of the presence, absence and overexpression of uncoupling protein-3 on adiposity and fuel metabolism in congenic mice. Am J Physiol Endocrinol Metab 290:E1304-1312, 2006.
PubMed
5) Harper JA, et al:Artifactual uncoupling by uncoupling protein-3 in yeast mitochondria at the concentrarions found in mouse and rat skeltal-mllscle mitochondria. Biochem J 361:49-56, 2002.
 
6) Bezaire V, et al:Effects of fasting on muscle mitochondrial energetics and fatty acid metabolism in Ucp3 (-/-) and wild-type mice. Am J Physiol Endocrinol Metab 281:E975-982, 2001.
PubMed
7) Son C, et al:Reduction of diet-induce obesity in transgenic mice overexpressing uncoupling protein 3 in skeletal muscle. Diabetologia 47:47-54, 2004.
PubMed
8) Gong DW, et al:Lack of obesity and normal response to fasting and thyroid hormone in mice lacking uncoupling protein-3. J Biol Chem 275:16251-16257, 2000.
PubMed
9) Vidal-Puig AI, et al:Energy metabolism in uncoupling protein 3 gene knockout mice. J Biol Chem 275:16258-16266, 2000.
 
10) Bezaire V, et al:Constitutive UCP overexpression at physiological levels increase mouse skeletal muscle capacity for fatty acid transport and oxidation. FASEB J 19:977-979, 2005.
 
11) Hoeks J, et al:The effect of hight-fat feeding on intramuscular lipid and lipid peroxidation levels in UCP3-ablated mice. FEBS Lett 580:1371-1375, 2006.
 
12) Haluzik M, et al:Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 145:3258-3264, 2004.
PubMed
13) Rossmeisl M, et al:Variation in type 2 diabetes-related traits in mouse strains susceptible to dietinduced obesity. Diabetes 52:1958-1966, 2003.
PubMed
14) Surwit RS, et al:Low plasma leptin in response to dietary fat in diabetes-and obesity-prone mice. Diabetes 46:1516-1520, 1997.
PubMed
15) Vidal-Puig A, et al:The effect of obestiy and stable weight reduction on UCP2 and UCP3 gene expression in humans. Obes Res 7:133-140, 1999.
 
16) Schrauwen P, et al:The effect of weight reduction on skeletal muscle UCP2 and UCP3 mRNA expression and UCP3 protein content in Type II diabetic subjects. Diabetologia 43:1408-1416, 2000.
PubMed
17) Mingrone G, et al:Decreased uncoupling protein expression and intramyocytic triglyceride depletion in formerly obese subjects. Obes Res 11:632-640, 2003.
PubMed
18) Mingrone G, et al:Reversibility of insulin resistance in obese diabetic patients:role of plasma lipids. Diabetologia 40:599-605, 1997.
PubMed
19) Harper ME, et al:Decreased mitochondrial proton leak and reduced expression of uncoupling protein 3 in skeletal muscle of obese diet-resistant women. Diabetes 51:2459-2466, 2002.
PubMed
20) Schrauwen P, et al:A novel polymorphism in the proximal UCP3 promoter region:effect on skeletal muscle UCP3 mRNA expression and obesity in male non-diabetic Pima Indians. Int J Obes Relat Metab Disord 23:1242-1245, 1999.
PubMed
21) Otabe S, et al:Mutation screening and association studies of the human uncoupling protein 3 gene in normoglycemic and diabetic morbidly obese patients. Diabetes 48:206-208, 1999.
PubMed
22) Gassell PG, et al:Evidence that single nucleotide polymorphism in the uncoupling protein 3 (UCP3) gene influence fat distribution in woman of European and Asian origin. Diabetologia 43:1558-1564, 2000.
 
23) Herrmann S, et al:Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. J Mol Med 81:327-332, 2003.
PubMed
24) Gable DR, et al:Variation in the UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy middle-aged men. Diabetes 55:1504-1511, 2006.
PubMed
25) Meirhaeghe A, et al:An uncoupling protein 3 gene polymorphism associated with a lower risk of developing Type II diabetes and with atherogenic lipid profile in a French cohort. Diabetologia 43:1424-1428, 2000.
 
26) Halsall DJ, et al:Uncoupling Protein 3 genetic variants in human obesity:the c-55t promoter polymorphism is negatively correlated with body mass index in a UK Caucasian population. Int J Obes Relat Metab Disord 25:472-477, 2001.
 
27) Liu YJ, et al:Linkage and association analyses of the UCP3 gene with obesity phenotypes in Caucasian families. Physiol Genomics 22:197-203, 2005.
PubMed
28) Alonso A, et al:Association of UCP3 gene-55C > T polymorphism and obesity in a Spanish population. Ann Nutr Metab 49:183-188, 2005.
 
29) Dalgaard LT, et al:The uncoupling protein 3-55 C→T variant is not associated with Type II diabetes mellitus in Danish subjects. Diabetologia 44:1065-1067, 2001.
 
30) Berentzen T, et al:Interactions between physical activity and variants of the genes encoding uncoupling proteins-2 and-3 in relation to body weight changes during a 10-y follow-up. Int J Obes (Lond) 29:93-99, 2005.
PubMed
31) Brown AM, et al:Endogeneous mutations in human uncoupring protein 3 alter its functional properties. FEBS Lett 464:189-193, 1999.
PubMed
32) Hagen T, et al:Assessment of uncoupling activity of the human uncoupling protein gene using a yeast heterologous expression system. FEBS Lett 454:201-206, 1999.
PubMed
33) Argyropoulos G, et al:Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. J Clin Invest 102:1345-1351, 1998,
PubMed
34) Chung WK, et al:Genetic and physiologic analysis of the role of uncoupling protein 3 in human energy homeostasis. Diabetes 48:1890-1895, 1999.
PubMed
P.488 掲載の参考文献
1) Bouche C, et al:The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25:807-830, 2004.
PubMed
2) Srivastava AK, Pandey SK:Potential mechanism (s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem 182:135-141, 1998.
PubMed
3) Cohen PT:Protein phosphatase 1-targeted in many directions. J Cell Sci 115:241-256, 2002.
PubMed
4) Hanashiro I, Roach PJ:Mutations of muscle glycogen synthase that disable activation by glucose 6-phosphate. Arch Biochem Biophys 397:286-292, 2002.
PubMed
5) Cid E, et al:Determinants of the nucleocytoplasmic shuttling of muscle glycogen synthase. FEBS J 272:3197-3213, 2005.
PubMed
6) Newgard CB, et al:Organizing glucose disposal:emerging roles of the glycogen targeting subunits of protein phosphatase-1. Diabetes 49:1967-1977, 2000.
PubMed
7) Thorburn AW, et al:Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522-529, 1990.
PubMed
8) Henry RR, et al:Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. Biochemical and molecular mechanisms. J Clin Invest 98:1231-1236, 1996.
PubMed
9) Orho-Melander M, et al:A paired-sibling analysis of the Xbal polymorphism in the muscle glycogen synthase gene. Diabetologia 42:1138-1145, 1999.
 
10) Orho M, et al:Isolation and characterization of the human muscle glycogen synthase gene. Diabetes 44:1099-1105, 1995.
PubMed
11) Shimomura H, et al:A missense mutation of the muscle glycogen synthase gene (M416V) is associated with insulin resistance in the Japanese population. Diabetologia 40:947-952, 1997.
PubMed
12) Rissanen J, et al:New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland. Diabetologia 40:1313-1319, 1997.
PubMed
13) Study Group for the Identification of Type 2 Diabetes Genes in Japanese:The Met416→Val variant in the glycogen synthase gene:the prevalence and the association with diabetes in a large number of Japanese individuals. Diabetes Care 23:1709-1710, 2000.
 
14) Motoyama K, et al:Association of muscle glycogen synthase polymorphism with insulin resistance in type 2 diabetic patients. Metabolism 52:895-899, 2003.
PubMed
15) Huang X, et al:Impaired insulin-stimulated expression of the glycogen synthase gene in skeletal muscle of type 2 diabetic patients is acquired rather than inherited. J Clin Endocrinol Metab 85:1584-1590, 2000.
PubMed
16) Patel S, et al:Glycogen synthase kinase-3 in insulin and Wnt signalling:a double-edged sword? Biochem Soc Trans 32:803-808, 2004.
PubMed
17) Hojlund K, et al:Reduced plasma adiponectin concentrations may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 49:1283-1291, 2006.
PubMed
P.493 掲載の参考文献
1) Engeli S, et al:The adipose-tissue renin-angiotensin-aldosterone system:role in the metabolic syndrome? Int J Biochem Cell Biol 35:807-825, 2003.
PubMed
2) Massiera F, et al:Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15:2727-2729, 2001.
PubMed
3) Tikellis C, et al:Role of the renin-angiotensin system in the endocrine pancreas:implications for the development of diabetes. Int J Biochem Cell Biol 38:737-751, 2006.
PubMed
4) Tikellis C, et al:Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53:989-997, 2004.
PubMed
5) Hansson L, et al:Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353:611-616, 1999.
 
6) Gerstein HC, et al:Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426, 2001.
PubMed
7) Dahlof B, et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised nial against atenolol. Lancet 359:995-1003, 2002.
 
8) Lithell H, et al:The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886, 2003.
 
9) Granger CB, et al:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-conveting-enzyme inhibitors:the CHARM-Alternadve trial. Lancet 362:772-776, 2003.
 
10) Julius S, et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet 363:2022-2031, 2004.
 
11) Kumar R, et al:The intracellular renin-angiotensin system:a new paradigm. Trends Endocrinol Metab 18:208-214, 2007.
PubMed
12) Ichihara A, et al:The (pro) renin receptor and the kidney. Semin Nephrol 27:524-528, 2007.
PubMed
P.500 掲載の参考文献
1) Zabolotny JM, et al:Transgenic overexpression of protein-tyrosine phosphatase I B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279:24844-24851, 2004.
 
2) Di Paola R, et al:A variation in 3" UTR of hPTPIB increases spechic gene expression and associates with insulin resistance. Am J Hum Genet 70:806-812, 2002.
PubMed
3) Elchebly M, et al:Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283:1544-1548, 1999.
PubMed
4) Xue B, et al:Protein-tyrosine phosphatase l B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem 282:23829-23840, 2007.
 
5) Bence KK, et al:Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 12:917-924, 2006.
PubMed
6) Delibegovic M, et al:Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol 27:7727-7734, 2007.
PubMed
7) Sasaoka T, et al:Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol Ther 112:799-809, 2006.
PubMed
8) Wada T, et al:Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity. Mol Cell Biol 21:1633-1646, 2001.
PubMed
9) Sasaoka T, et al:SH2-containing inositol phosphatase 2 predominantly regulates Akt2, and not Akt1, phosphorylation at the plasma membrane in response to insulin in 3T3-L1 adipocytes. J Biol Chem 279:14835-14843, 2004.
 
10) Hori H, et al:Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 51:2387-2394, 2002.
PubMed
11) Kagawa S, et al:Impact of SRC homology 2-containing inositol 5'-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling. J Clin Endocrinol Metab 90:2911-2919, 2005.
 
12) Fukui K, et al:Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 54:1958-1967, 2005.
PubMed
13) Grempler R, et al:Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice:SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis. Diabetes 56:2235-2241, 2007.
PubMed
14) Sleeman MW, et al:Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 11:199-205, 2005.
PubMed
15) Kagawa S, et al:Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice. Endocrinology 149:642-650, 2008.
PubMed
P.506 掲載の参考文献
1) Rudich A, et al:Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47:1562-1569, 1998.
PubMed
2) Tirosh A, et al:Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 274:10595-10602, 1999.
PubMed
3) Krieger-Brauer HI, Kather H:Human fat cells possess a plasma membrane-bound H2O2-generating system that is activated by insulin via a mechanism bypassing the receptor kinase. J Clin Invest 89:1006-1013, 1992.
 
4) Brownlee M:The pathobiology of diabetic complications:a unifying mechanism. Diabetes 54:1615-1625, 2005.
PubMed
5) Furukawa S, et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004.
PubMed
6) Keaney JF Jr, et al:Obesity and systemic oxidative stress:clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23:434-439, 2003.
PubMed
7) Fujita K, et al:Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 70:1437-1442, 2006.
PubMed
8) Matsuoka T, et al:Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 99:144-150, 1997.
 
9) Maddux BA, et al:Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes 50:404-410, 2001.
PubMed
10) Nakazono K, et al:Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88:10045-10048, 1991.
PubMed
11) Ohara Y, et al:Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91:2546-2551, 1993.
PubMed
12) Weisberg SP, et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003.
PubMed
13) Houstis N, et al:Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948, 2006.
PubMed
14) Kurata A, et al:Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70:1717-1724, 2006.
PubMed
P.512 掲載の参考文献
1) wang J, et al:A mutation in the insulin 2 gene induces diabetes with severe pancreatic β-cell dysfunction in the Mody mouse. J Clin Invest 103:27-37, 1999.
 
2) Oyadomari S, et al:Targeted disruption of the Chop gene delays endoplasmic reticulum stressmediated diabetes. J Clin Invest 109:525-532, 2002.
PubMed
3) StOy J, et al:Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 104:15040-15044, 2007.
PubMed
4) Kwok SC, et al:Identification of a point mutation in the human insulin gene giving rise to a structurally abnormal insulin (Insulin Chicago). Diabetes 32:872-875, 1983.
PubMed
5) Haneda M, et al:Studies on mutant human insulin genes:identification and sequence analysis of a gene encoding [SerB24] insulin. Proc Natl Acad Sci USA 80:6366-6370, 1983.
PubMed
6) Nanjo K, et al:Diabetes due to secretion of a structurally abnormal insulin (Insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin. J Clin Invest 77:514-519, 1986.
PubMed
7) Shoelson S, et al:Three mutant insulins in man. Nature 302:540-543, 1983.
PubMed
8) Robbins D, et al:A human proinsulin variant at arginine 65. Nature 291:679-681, 1981.
 
9) Yano H, et al:A novel point mutation in the human insulin gene giving rise to hyperproinsulinemia (proinsulin Kyoto). J Clin Invest 89:1902-1907, 1992.
PubMed
10) Warren-Perry MG, et al:A novel point mutation in the insulin gene giving rise to hyperinsulinemia. J Clin Endocrinol Metab 82:1629-1631, 1997.
 
11) Gnlppuso P, et al:Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin. N Engl J Med 311:629-634, 1984.
 
12) Steiner D, et al:Lessons learned from molecular biology of insulin-gene mutations. Diabetes Care 13:600-609, 1990.
PubMed
13) Nanjo K, et al:Insulin Wakayama:familial mutant insulin syndrome in Japan. Diabetologia 30:87-92, 1987.
PubMed
14) Nanjo K, et al:Pancreatic function in subjects with the mutant insulin syndrome. Diabetes 35 (Suppl):77A, 1986.
 
15) Olansky L, et al:A variant insulin promoter in non-insulin dependent diabetes mellitus. J Clin Invest 89:1596-1602, 1992.
PubMed
P.519 掲載の参考文献
1) Yamagata K, et al:Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 384:455-458, 1996.
 
2) Yamagata K, et al:Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 384:458-460, 1996.
 
3) Horikawa Y, et al:Mutation in hepatocyte nuclear factor-1/9 gene (TCF2) associated with maturity-onset diabetes of the young. Nat Genet 17:384-385, 1997.
 
4) Ellard S, Colclough K:Mutations in the gene encoding the transcription factor hepatocyte nuclear factor 1α (HNF1A) and 4α (HNF4A) in maturity-onset diabetes of the young. Hum Mutat 27:854-869, 2006.
 
5) Yamagata K, et al:Mutation P291fsinsC in the transcription factor hepatocyte nuclear factor-1alpha is dominant negative. Diabetes 47:1231-1235, 1998.
PubMed
6) Triggs-Raine BL, et al:HNF-1α G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proc Natl Acad Sci USA 99:4614-4619, 2002.
 
7) Yoshiuchi I, et al:Three new mutations in the hepatocyte nuclear factor-1alpha gene in Japanese subjects with diabetes mellitus:clinical features and functional characterization. Diabetologia 42:621-626, 1999.
PubMed
8) Yamagata K, et al:Overexpression of dominant-negative mutant HNF-1α in pancreatic β-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced β-cell proliferation and diabetes. Diabetes 51:114-123, 2002.
 
9) Fukui K, et al:The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab 2:373-384, 2005.
PubMed
10) Ihara A, et al:Functional characterization of the HNF4alpha isoform (HNF4alpha8) expressed in pancreatic beta-cells. Biochem Biophys Res Commun 329:984-990, 2005.
PubMed
11) Love-Gregory LD, et al:A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 alpha gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an ashkenazi jewish population. Diabetes 53:1134-1140, 2004.
 
12) Silander K, et al:Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes. Diabetes 53:1141-1149, 2004.
PubMed
13) Hara K, et al:Hepatocyte nuclear factor-4α P2 promoter haplotypes are associated with type 2 diabetes in the Japanese population. Diabetes 55:1260-1264, 2006.
 
14) Gupta RK, et al:The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest 115:1006-1015, 2005.
PubMed
15) Miura A, et al:Hepatocyte nuclear factor-4α is essential for glucose-stimulated insulin secretion by pancreatic β-cells. J Biol Chem 281:5246-5257, 2006.
 
16) Nammo T, et al:Expression of HNF-4α (MODY1), HNF-1β (MODY5), and HNF-1α (MODY3) proteins in the developing mouse pancreas. Gene Expr Patterns. (in press)
 
17) Edghill EL, et al:Mutations in hepatocyte nuclear factor-1β and their related phenotypes. J Med Genet 43:84-90, 2006.
 
18) Bellanne-Chantelot C, et al:Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 140:510-517, 2004.
PubMed
19) Stoffers DA, et al:Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 17:138-139, 1997.
PubMed
20) Malecki MT, et al:Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 23:323-328, 1999.
PubMed
21) Gloyn AL:Glucokinase (GCK) mutations in hyper-and hypoglycemia:maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum Mutat 22:353-362, 2003.
PubMed
22) Njolstad PR, et al:Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 344:1588-1592, 2001.
PubMed
23) Glaser B, et al:Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338:226-230, 1998.
PubMed
P.524 掲載の参考文献
1) Ballinger SW, et al:Maternally transmitted diabetes and deafness associated with a 10.4kb mitochondrial DNA deletion. Nat Genet l:11-15, 1992.
 
2) Van den Ouweland JM, et al:Mutation in mitochondrial tRNA (Leu) (UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1:368-371, 1992.
 
3) Kadowaki H, et al:Mitochondrial gene mutation and insulin-deficient type of diabetes mellitus. Lancet 341:893-894, 1993.
PubMed
4) Kadowaki T, et al:A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330:962-968, 1994.
PubMed
5) Maassen JA, Kadowaki T:Maternally inherited diabetes and deafness, a new diabetes subtype. Diabetologia 39:375-382, 1996.
PubMed
6) Otabe S, et al:The high prevalence of the diabetic patients with a mutation in the mitochondrial gene in Japan. J Clin Endocrinol Metab 79:768-771, 1994.
PubMed
7) 鈴木進ほか:ミトコンドリアDNA異常による糖尿病調査報告. 糖尿病 47:481-487, 2004.
 
P.527 掲載の参考文献
1) Chari ST, et al:Probability of pancreatic cancer following diabetes:a population-based study. Gastroenterology 129:504-511, 2005.
PubMed
2) Basso D, et al:The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res 15:2585-2588, 1995.
PubMed
3) Basso D, et al:Pancreatic cancer-derived S-100A8 N-terminal peptide:adiabetes cause? Clin Chim Acta 372:120-128, 2006.
 
4) Chari ST, et al:Pancreatic cancer-associated diabetes mellitus:prevalence and temporal association with diagnosis of cancer. Gastroenterology 134:95-101, 2008.
PubMed
5) Jonsson J, et al:Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371:606-609, 1994.
PubMed
6) Offield MF, et al:PDX-1 is required for pancreatic outgrowth and differentiation of the rosta1 duodenum. Development 122:983-995, 1996.
 
7) Gradwohl G, et al:neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci USA 97:1607-1611, 2000.
PubMed
8) Krapp A, et al:The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. Genes Dev 12:3752-3763, 1998.
PubMed
9) Kawaguchi Y, et al:The role of the transcriptional regulator ptfl a in converting intestinal to pancreatic progenitors. Nat Genet 32:128-134, 2002.
 
10) Gu G, et al:Direct evidence for the pancreatic lineage:NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129:2447-2457, 2002.
PubMed
11) Street CN, et al:Islet graft assessment in the Edmonton Protocol:implications for predicting longterm clinical outcome. Diabetes 53:3107-3114, 2004.
PubMed
12) Dor Y, et al:Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46, 2004.
PubMed
P.532 掲載の参考文献
1) Etxabe J, et al:Morbidity and mortality in Cushing's disease:an epidemiological approach. Clin Endocrinol (Oxf) 40:479-484, 1994.
PubMed
2) Nosadini R, et al:Insulin resistance in Cushing's syndrome. J Clin Endocrinol Metab 57:529-536, 1983.
PubMed
3) Faggiano A, et al:Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and l year after disease remission. J Clin Endocrinol Metab 88:2527-2533, 2003.
 
4) 厚生省特定疾患間脳下垂体機能障害調査研究班平成元年度報告書, 平成2年.
 
5) Rajasoorya C, et al:Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102, 1994.
PubMed
6) Newman CB, et al:Safety and efficacy of long-term octreotide therapy of acromegaly:results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 80:2768-2775, 1995.
PubMed
7) Barkan AL, et al:Glucose homeostasis and safety in patients With acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691, 2005.
PubMed
8) Colao A, et al:Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 86:1874-1881, 2001.
PubMed
9) Hew F, et al:Insulin resistance in growth hormone-deficient adults:defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 81:555-564, 1996.
PubMed
10) Segerlantz M, et al:Inhibition of the rise in FFA by Acipimox panially prevents GH-induced insulin resistance in GH-deficient adults. J Clin Endocrinol Metab 86:5813-5818, 2001.
PubMed
11) Stenstrom G, et al:Diabetes mellitus in phaeochromocytoma. Fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol (Copenh) 106:511-515, 1984.
PubMed
P.536 掲載の参考文献
1) Custro N, et al:Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 27 (4 Pt 1):476-481, 2001.
 
2) Kwon SY, et al:Prognostic significance of glycaemic control in patients With HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 22 (11):1530-1535, 2005.
PubMed
3) Zein CO, et al:Chronic hepatitis C and type II diabetes mellitus:aprospective cross-sectional study. Am J Gastroenterol 100 (1):48-55, 2005.
 
4) Shintani Y, et al:Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology 126 (3):840-848, 2004.
PubMed
5) Knobler H, et al:Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis Cvirus-diabetes association. Am J Gastroentero1 98 (12):2751-2756, 2003.
 
6) El-Serag HB, et al:Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-468, 2004.
PubMed
7) Ludwig J, et al:Nonalcoholic steatohepatitis:Mayo Clinic experiences with a hitherto unnamed diseases. Mayo Clin Proc 55:434-438, 1980.
 
8) Matteoni CA, et al:Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999.
PubMed
9) Brunt EM, et al:Nonalcoholic steatohepatitis:a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474, 1999.
PubMed
10) Day CP, James OF:Steatohepatitis:a tale of two "hits"? Gastroenterology 114:842-845, 1998.
PubMed
11) NASH・NAFLDの診療ガイド (日本肝臓学会編), 文光堂, 2006.
 
P.540 掲載の参考文献
1) Gorden P:Glucose intolerance with hypokalemia. Diabetes 22:544-551, 1973.
PubMed
2) Rowe JW, et al:Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 29:498-502, 1980.
PubMed
3) Malherbe C, et al:Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med 286:339-342, 1972.
 
4) Goldberg EM, Sanbar SS:Hyperglycemic, nonketotic coma following administration of Dilantin (Diphenylhydantoin). Diabetes 18:101-106, 1969.
PubMed
5) Hofeldt FD, et al:Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes 23:192-198, 1974.
PubMed
6) Levin SR, et al:hlhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas. J Clin Endocrinol Metab 30:400-401, 1970.
PubMed
7) Nabe K, et al:Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Endocrinology 147:2717-2727, 2006.
PubMed
8) Osei K, et al:Diabetogenic effect of pentamidine:in vitro and in vivo studies in a patient with malignant insulinoma. Am J Med 77:41-48, 1984.
 
9) Jain AB, et al:Primary adult liver transplantation under tacrolimus:more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 5:144-150, 1999.
PubMed
10) 武田智美ほか:生体肝移植後のタクロリムス使用により, インスリン依存状態となった糖尿病の1例. 糖尿病 44:895-899, 2001.
 
11) 原島伸一ほか:同種骨髄移植後移植片対宿主病に対するFK506投与2例に認めた糖代謝異常. 糖尿病 41:137-142, 1998.
 
12) Lawrence MC, et al:Regulation of insulin gene transcription by a Ca2+ -responsive pathway involving calcineurin and nuclear factor of activated T cells. Mol Endocrinol 15:1758-1767, 2001.
PubMed
13) Radu RG, et al:Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab 288:E365-E371, 2005.
PubMed
14) Heit JJ, et al:Calcineurin/NFAT signaling regulates pancreatic β-cell growth and function. Nature 443:345-349, 2006.
 
15) Dtifer M, et al:Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmachol 60:873-879, 2001.
 
16) Gribble FM, et al:The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J 16:1145-1152, 1997.
 
17) Ganda OP:Secondary forms of diabetes. In:Joslin's Diabetes, 14th ed, p 477-492, Lippincott, Philadelphia, 2005.
 
18) Skouby SO, et al:Mechanism of action of oral contraceptives on carbohydrate metabolism at the cellular leveL Am J Obstet Gynecol 163:343-348, 1990.
PubMed
19) Smith MR, et al:Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305-1308, 2006.
PubMed
20) Wirshing DA, et al:Novel antipsychotics:comparison of weight gain liabilities. J Clin Psychiatry 60:358-363, 1999.
PubMed
21) Ader M, et al:Metabolic dysregulation With atypical antipsychotics occurs in the absence of underlying disease:a placebo-controlled study of olazapine and risperidone in dogs. Diabetes 54:862-871, 2005.
 
22) Sasaki N, et al:The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia 49:2930-2938, 2006.
PubMed
23) Carr A, et al:Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus:acohort study. Lancet 353:2093-2099, 1999.
 
24) Riddle TM, et al:HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 276:37514-37519, 2001.
 
25) Murata H, et al:The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275:20251-20254, 2000.
PubMed
26) Koivisto VA, et al:Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 38:641-647, 1989.
PubMed
27) Shiba T, et al:Onset of diabetes with high titer anti-GAD antibody after INF therapy for chronic hepatitis. Diabetes Res Clin Pract 30:237-241, 1995.
 
28) 岩倉敏夫ほか:発症前からの自己抗体の変動をとらえた慢性C型肝炎インターフェロン治療中に1型糖尿病および甲状腺機i能低下症を発症した1症例. 糖尿病 47:459-464, 2004.
 
29) 藤倉純二ほか:インターフェロンαの投与後1型糖尿病を急性発症したC型慢性肝炎の1例 (抄録). 糖尿病 47:169, 2004.
 
P.545 掲載の参考文献
1) Saltiel AR, Pessin JE:Insulin signaling pathways in time and space. Trends Cell Biol 12:65-71, 2002.
PubMed
2) Hotamisligil GS, et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993.
PubMed
3) Uysal Kr, et al:Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614, 1997.
 
4) Wellen KE, Hotamisligil GS:Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119, 2005. Review.
PubMed
5) Lord GM, et al:Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394 (6696):897-901, 1998.
 
6) Medzhitov R:Toll-like receptors and innate immunity. Nat Rev Immunol 1:135-145, 2001. Review.
PubMed
7) Aguirre V, et al:The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem 275:9047-9054, 2000.
 
8) Shoelson SE, et al:Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity-and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27 (Suppl 3):S49-52, 2003. Review.
 
9) Ueki K, et al:Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446, 2004.
PubMed
P.550 掲載の参考文献
1) Walters EG, et al:Hypoglycaemia due to an insulin-receptor antibody in Hodgkin's disease. Lancet i:241-243, 1987.
 
2) Khokher MA, et al:Insulin-receptor antibody and hypoglycaemia associated with Hodgkin's disease. Lancet i:693-694, 1987.
PubMed
3) Uto H, et al:A case of chronic hepatitis C developing insulin-dependent diabetes meMtus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 49:101-106, 2000.
PubMed
4) Batarseh H, et al:Insulin receptor antibodies in diabetes mellitus. Clin Exp Immunol 71:85-90, 1988.
PubMed
5) 伊藤光泰:多腺性内分泌不全症 (PGA) の病因・病態と治療. 医学のあゆみ 213:439-444, 2005.
Medical*Online
6) Powers AC, et al:Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders. Clin Exp Immunol 118:349-356, 1999.
PubMed
7) Costa M, et al:T-cell reactivity to glutamic acid decarboxylase in stiff-man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity. Clin Exp Immunol 129:471-478, 2002.
 
8) Schloot NC, et al:GAD 65-reactive T cells in a non-diabetic Stiff-man syndrome patient. J Autoimmun 12:289-296, 1999.
 
9) Hiemstra HS, et al:Cytomegalovirus in autoimmunity:T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 98:3988-3991, 2001.
PubMed
10) Solimena M, et al:GAD, diabetes, and Stiff-Man Syndrome:Some progress and more questions. J Endocrinol Invest 17:509-520, 1994.
PubMed
11) Capitani G, et al:Structural model of human GAD65:prediction and interpretation of biochemical and immunogenic features. Proteins:Structure, Function, and Bioinformatics 59:7-14, 2005.
 
12) Hirsch IB, et al:Severe insulin resistance in a patient with type 1 diabetes and stiff-man syndrome treated with insulin lispro. Diabetes Res Clin Pract 41:197-202, 1998.
 
13) Masuda A, et al:Insulin autoimmune syndrome with insulin-resistant diabetes at the incipient stage prior to hypoglycemic attacks. J Endocrinol Invest 9:507-512, 1986.
PubMed
14) Kato T, et al:Severe hypoglycaemia in a person with insulin autoimmune syndrome accompanied by insulin receptor anomaly type B. Diabet Med 24:1279-1281, 2007.
 
15) Bortolotti D, et al:Spontaneous hypoglycaemia in the presence of both anti-insulin antibody and anti-insulin receptor antibody. Diabetes Metab 32:598-603, 2006.
PubMed
P.557 掲載の参考文献
1) Agarwal AK, et al:AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet 31:21-23, 2002.
PubMed
2) Magre J, et al:Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 28:365-370, 2001.
PubMed
3) Shackleton S, et al:LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24:153-156, 2000.
PubMed
4) Agarwal AK, et al:A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411, 2002.
 
5) Agarwal AK, et al:Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 12:1995-2001, 2003.
PubMed
6) Moitra J, et al:Life without white fat:a transgenic mouse. Genes Dev 12:3168-3181, 1998.
PubMed
7) Gavrilova O, et al:Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278, 2000.
PubMed
8) Colombo C, et al:Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 51:2727-2733, 2002.
PubMed
9) Ogawa Y, et al:Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48:1822-1829, 1999.
PubMed
10) Ebihara K, et al:Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440-1448, 2001.
 
11) Oral E, et al:Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-578, 2002.
PubMed
12) Ebihara K, et al:Efficacy of long-term leptin-replacement therapy for lipoatrophic diabetes in Japan. N Engl J Med 351:615-616, 2004.
 
13) Ebihara K, et al:Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532-541, 2007.
PubMed
14) Masuzaki H, et al:Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation:usefulness of leptin for the treatment of obesity-associated diabetes. Diabetes 48:1615-1622, 1999.
PubMed
15) Miyanaga F, et al:Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 46:1329-1337, 2003.
PubMed
P.561 掲載の参考文献
1) Prader A, et al:Ein Syndrome von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach Myatonieatigem Zustand im Neugeborenenalter. Schweiz Med Wschr 86:1260-1261, 1956.
 
2) Nicholls RD, et al:Imprinting in Prader-Willi and Angelman syndromes. Trends Genet 14:194-200, 1998.
PubMed
3) Glenn CC, et al:Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene. Am J Hum Genet 58:335-346, 1996.
PubMed
4) Saitoh S, Wada T:Parent-of-origin specific histone acetylation and reactivation of a key imprinted gene locus in Prader-Willi syndrome. Am J Hum Genet 66:1958-1962, 2000.
PubMed
5) Swaab DF, et al:Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome:a study of five cases. J Clin Endocrinol Metab 80:573-579, 1995.
 
6) Swaab DF, et al:Functional neuroanatomy and neuropathology of the human hypothalamus. Anat Embryol (Berl) 187:317-330, 1993.
PubMed
7) MacDonald HR, Wevrick R:The necdin gene is deleted in Prader-Willi syndrome and is imprinted in human and mouse. Hum Mol Genet 6:1873-1878, 1997.
PubMed
8) Watrin F, et al:The mouse Necdin gene is expressed from the patemal allele only and lies in the 7C region of the mouse chromosome 7, a region of conserved synteny to the human Prader-Willi syndrome region. Eur J Hum Genet 5:324-332, 1997.
 
9) 吉川和明:ヒトニューロンの発生分化と細胞死の分子機構NecdinとAPPを中心にして. 日本神経精神薬理学雑誌 20:155-159, 2000.
 
10) Jay P, et al:The human necdin gene, NDN, is maternally impprited and located in the Prader-Willi syndrome chromosomal region. Nat Genet 17:357-361, 1997.
PubMed
11) Bressler J, et al:The SNRPN promoter is not required for genomic imprinting of the Prader-Willi/Angelman domain in mice. Nat Genet 28:232-240, 2001.
 
12) Yang T, et al:A mouse model for Prader-Willi syndrome imprinting-centre mutations. Nat Genet 19:25-31, 1998.
 
13) Gerard M, et al:Disruption of the mouse necdin gene results in early post-natal lethality. Nat Genet 23:199-202, 1999.
PubMed
14) Muscatelli F, et al:Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet 9:3101-3110, 2000.
PubMed
15) Lee S, et al:Prader-Willi syndrome transcripts are expressed in phenotypically significant regions of the developing mouse brain. Gene Expr Patterns 3:599-609, 2003.
PubMed
16) Panda S, et al:Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109:307-320, 2002.
PubMed
17) Kozlov SV, et al:The imprinted gene Magel2 regulates normal circadian output. Nat Genet 39:1266-1272, 2007.
PubMed
18) Zipf WB:Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr Suppl 88:115-117, 1999.
PubMed
19) Schuster DP, et al:Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 45:1514-1520, 1996.
PubMed
P.566 掲載の参考文献
1) Yoshida K, et al:A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 9:267-272, 1995.
 
2) Harris ZL, et al:Aceruloplasminemia:molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 92:2539-2543, 1995.
PubMed
3) Daimon M, et al:A nonsense mutation of the ceruloplasmin gene in hereditary ceruloplasmin deficiency with diabetes mellitus. Biochem Biophys Res Commun 217:89-95, 1995.
PubMed
4) 大門真ほか:遺伝性セルロプラスミン欠損症 (HCD) -糖尿病の新たなる病因-. 分子糖尿病学, 第8巻, p75-80, 医学図書出版, 1997.
 
5) Miyajima H, et al:Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 57:2205-2210, 2001.
PubMed
6) Miyajima H, et al:Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 53:617-619, 1999.
PubMed
7) Miyajima H, et al:Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 37:761-767, 1987.
PubMed
8) 川並透ほか:遺伝性セルロプラスミン (Cp) 欠損症の臨床神経病理学的研究. 臨床神経学 33:1435, 1993.
 
9) De Domenico I, et al:Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 26:2823-2831, 2007.
PubMed
10) Shiva S, et al:Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2:486-493, 2006.
PubMed
11) Kato T, et al:Islet changes in hereditary ceruloplasmin deficiency. Hum Pathol 28:499-502, 1997.
PubMed
12) Daimon M, et al:Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diabetes Care 21:1525-1528, 1998.
PubMed
13) Miyajima H, et al:Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41:404-407, 1997.
PubMed
14) Skidmore FM, et al:Aceruloplasminemia with progressive atrophy without brain iron overload:treatment with oral chelation. J Neurol Neurosurg Psychiatry, 2007. (in press)
 
15) Kuhn J, et al:Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 29:450-453, 2007.
PubMed
P.570 掲載の参考文献
1) Tumer HH:A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 23:566-574, 1938.
 
2) Ullrich O:Uber typische Kombinationbilder multipler Abartungen. Zeitschrift fUr Kinderheilk 49:271-276, 1930.
 
3) Ford CE, et al:A sex chromosome anomaly in a case of gonadal dysgenesis (Turner's syndrome). Lancet i:711-713, 1959.
 
4) Ferguson-Smith MA:Karyotype-phenotype correlation in gonadal dysgenesis and their bearing on the pathogenesis of malformations. J Med Genet 39:142-155, 1965.
 
5) Forbes AP, Engel E:The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metabolism 12:428-439, 1963.
PubMed
6) Menzinger G, et al:Gonadal dysgenesis and diabetes. Lancet i:1269, 1966.
PubMed
7) Nielsen J, et al:The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinol (Copenh) 62:251-269, 1969.
PubMed
8) Van Campenhout J, et al:Diabetes mellitus and thyroid autoimmunity in gonadal dysgenesis. Fertil Steril 24:1-9, 1973.
PubMed
9) Gravholt CH, et al:Morbidity in Turner syndrome. J Clin Epidemiol 51:147-158, 1998.
PubMed
10) Tanaka T, et al:Glucose tolerance in Turner syndrome. In:Basic and Clinical Approach to Turner Syndrome (ed by Hibi I, Takano K), p 197-201, Excerpta Medica, Amsterdam, 1993.
 
11) Jackson IM, et al:Carbohydrate metabolism and pituitary function in gonadal dysgenesis (Turner's syndrome). J Endocrinol 34:289-298, 1966.
PubMed
12) Rasio E, et al:Diabetes mellitus in gonadal dysgenesis:studies of insulin and growth hormone secretion. Eur J Clin Invest 6:59-66, 1976.
PubMed
13) Polychronakos C, et al:Carbohydrate intolerance in children and adolescents With Turner syndrome. J Pediatr 96:1009-1014, 1980.
PubMed
14) 田中敏章ほか:Turner症候群における経口ブドウ糖負荷試験-第1報年齢による耐糖能の変化-. 糖尿病 46:849-856, 2003.
 
15) Bakalov VK, et al:Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 89:3516-3520, 2004.
PubMed
16) Gravholt CH, et al:Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. Diabetes Care 21:1062-1070, 1998.
PubMed
17) Caprio S, et al:Insulin resistance:an early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 72:832-836, 1991.
PubMed
18) Salgin B, et al:Insulin resistance is an intrinsic defect independent of fat mass in women with Turner's syndrome. Horm Res 65:69-75, 2006.
PubMed
19) Sas TC, et al:Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized doseresponse study. J Clin Endocrinol Metab 85:769-775, 2000.
 
20) 田中敏章ほか:Turner症候群における経口ブドウ糖負荷試験-第2報成長ホルモン治療による耐糖能の変化-. 糖尿病 46:857-862, 2003.
 
P.574 掲載の参考文献
1) Milunsky A, Neurath PW:Diabetes mellitus in Down's syndrome. Arch Environ Health 376, 1968.
 
2) Jeremiah DE, et al:Down's syndrome and diabetes. Psychol Med 3:455-457, 1973.
PubMed
3) Van Goor JC, et al:Increased incidence and prevalence of diabetes mellitus in Down's syndrome. Arch Dis Child 77:186, 1997.
PubMed
4) Anwar N, et al:Type 1 diabetes mellitus and Down's syndrome:prevalence, management and diabetic complications. Diabet Med 15:160-163, 1998.
 
5) Bergholdt R, et al:Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark:a nationwide population-based study. Diabetologia 49:1179-1182, 2006.
 
6) Burch PR, Milunsky A:Early-onset diabetes mellitus in the general and Down's syndrome populations. Genetics, aetiology, and pathogenesis. Lancet i:554-558, 1969.
PubMed
7) Shield JP, et al:Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down's syndrome? Arch Dis Child 81:147-150, 1999.
PubMed
8) Karlsson B, et al:Thyroid dysfunction in Down's syndrome:relation to age and thyroid autoimmunity. Arch Dis Child 79:242-245, 1998.
PubMed
9) Book L, et al:Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. Am J Med Genet 98:70-74, 2001.
 
10) Gillespie KM, et al:Islet autoimmunity in children with Down's syndrome. Diabetes 55:3185-3188, 2006.
PubMed
11) Bergholdt R, et al:Fine mapping of a region on chromosome 21q21.11-q22.3 showing linkage to type 1 diabetes. J Med Genet 42:17-25, 2005.
PubMed
12) Bergholdt R, et al:Transcriptional profiling of type 1 diabetes genes on chromosome 21 in a rat beta-cell line and human pancreatic islets. Genes Immun 8:232-238, Epub 2007.
 
13) Rabinowe SL, et al:Trisomy 21 (Down's syndrome):autoimmunity, aging and monoclonal antibody-defined T-cell abnormalities. J Autoimmun 2:25-30, 1989.
PubMed
14) Roizen NJ, Patterson D:Down's syndrome. Lancet 361:1281-1289, 2003.
PubMed
15) Fonseca CT, et al:Insulin resistance in adolescents with Down syndrome:a cross-sectional study. BMC Endocr Disord 5:6, 2005.
PubMed
P.580 掲載の参考文献
1) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999.
 
2) 藤枝憲二:性腺分化の異常Klinefelter症候群. 別冊日本臨牀 内分泌症候群 (第2版) II, p 487-490, 日本臨牀社, 2006.
 
3) 中田憲一ほか:糖尿病を合併したKlinefelter症候群の1例と本邦報告例の臨床的検討. 岡山済生会総合病院雑誌 21:65-71, 1989.
 
4) 北村雅哉:男子性腺機能低下症. ホルモンと臨床 54:241-245, 2006.
 
5) 梅本多嘉子ほか:低身長を伴い, インスリン依存状態の糖尿病を契機に診断されたKlinefelter症候群の1例. 徳島赤十字病院医学雑誌 11:61-65, 2006.
 
6) Nielsen J, et al:Frequency of diabetes mellitus in patients with Klinefelter's syndrome of different chromosome constitutions and the XYY syndrome. Plasma insulin and growth hormone level after a glucose load. J Clin Endocrinol Metab 29:1062-1073, 1969.
PubMed
7) Ota K, et al:Diabetes mellitus associated with Klinefelter's syndrome:a case report and review in Japan. Intern Med 41:842-847, 2002.
PubMed
8) 岩田実, 小林正:Klinefelter症候群における糖尿病について. 内分泌・糖尿病科 15:542-547, 2002.
 
9) Jacobs PA, et al:Klinefelter's syndrome:an analysis of the origin of the additional sex chromosome using molecular probes. Ann Hum Genet 52:93-109, 1988.
PubMed
10) Schoffling K, Schade C:Diabetes mellitus and impaired glucose tolerance in diseases with chromosome aberrations. In:The Genetics of Diabetes Mellitus (ed by Creutzfeld W, et al), p 125-137, Springer Verlag, Berlin, 1976.
 
11) Pei D, et al:Insulin resistance in patients with Minefelter's syndrome and idiopathic gonadotropin deficiency. J Formos Med Assoc 97:534-540, 1998.
PubMed
12) 岩崎誠ほか:Klinefelter症候群における耐糖能異常の病態-グルコースクランプ法によるインスリン感受性の検討-. 糖尿病 38:697-702, 1995.
 
13) 田中早津紀ほか:著しいインスリン抵抗性を呈し, チアゾリジン誘導体により糖尿病が改善したと考えられるIqinefelter症候群の1例. 糖尿病 45:747-752, 2002.
 
14) Hsueh WA, et al:Endocrine features of Klinefelter's syndrome. Medicine 57:447-461, 1978.
PubMed
15) Gotoh M, et al:Multiple endocrine disorders and Rathke's cleft cyst with Klinefelter's syndrome:a case report. Endocr J 49:523-529, 2002.
PubMed
P.584 掲載の参考文献
1) 河野茂夫:筋緊張性ジストロフィーにおけるインスリン抵抗性:糖尿病基礎研究の進歩. 日本臨牀 60 (増刊号7):734-738, 2002.
 
2) 難波栄二:筋緊張性ジストロフィー症. 日本臨牀 63 (3):429-433, 2005.
Medical*Online
3) 大澤仲昭:筋強直性ジストロフィーにおけるインスリン抵抗性の成因. 内分泌・糖尿病 14:631-640, 2002.
 
4) Huff TA, et al:Abnormal insulin secretion in myotonic dystrophy. N Engl J Med 227:837-841, 1967.
 
5) 井村裕夫ほか:Myotonic dystrophyにおける内分泌異常. 厚生省神経疾患研究委託費「筋ジストロフィー症の疫学, 病態および治療開発にかんする研究」昭和60年度研究報告書, p205-208, 1986.
 
6) Savkur RS, et al:Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29:40-47, 2001.
PubMed
7) 野崎園子:Myotonic dystrophyにおける内臓脂肪. 臨床神経学 32:521-523, 1992.
 
8) Johansson A, et al:Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy. J Clin Endocrinol Metab 85:3169-3176, 2000.
PubMed
9) Johansson A, et al:Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy. J Clin Endocrinol Metab 86:4276-4283, 2001.
PubMed
10) Vlachopapadopoulou E, et al:Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy-a clinical research center study. J Clin Endocrinol Metab 80:3715-3723, 1995.
PubMed
11) Sugino M, et al:A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 51:586-589, 1998.
PubMed
12) 山本敏之ほか:Pioglitazone長期投与による筋強直性ジストロフィーの糖尿病治療. 臨床神経学 45:287-292, 2005.
 
13) Hattori S, et al:Pioglitazone treatment of insulin resistance in a patient with Werner's syndrome. Diabetes Care 27:3021-3022, 2004.
 
14) Semple RK, et al:Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 91:3219-3223, 2006.
PubMed
P.588 掲載の参考文献
1) Epstein CJ, et al:Werner's syndrome:A review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine 45:177-221, 1966.
 
2) YU CE, et al:Positional cloning of the Werner's syndrome gene. Science 272:258-262, 1996.
PubMed
3) Satoh M, et al:Prevalence of Werner's syndrome heterozygotes in Japan. Lancet 353:1766, 1999.
PubMed
4) Yamada K, et al:All patients with Werner's syndrome are insulin resistant, but only those who also have impaired insulin secretion develop overt diabetes. Diabetes Care 22:2094-2095, 1999.
PubMed
5) Kausch C, et al:Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Werner syndrome. J Clin Endocrinol Metab 85:905-918, 2000.
PubMed
6) Mori S, et al:Enhanced intra-abdominal visceral fat accumulation in patients with Werner's syndrome. Int J Obes Relat Metab Disord 25:292-295, 2001.
PubMed
7) Yokote K, et al:Dysadipocytokinemia in Werner syndrome and its recovery by treatment with pioglitazone. Diabetes Care 27:2562-2563, 2004.
PubMed
8) Lebel M, Leder P:A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc Natl Acad Sci USA 95:13097-13102, 1998.
 
9) Lombard DB, et al:Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol Cell Biol 20:3286-3291, 2000.
 
10) Wang L, et al:Cellular Werner phenotypes in mice expressing a putative dominant-negative human WRN gene. Genetics 154:357-362, 2000.
PubMed
11) Chang S, et al:Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet 36:877-882, 2004.
PubMed
12) Massip L, et al:Increased insulin, triglycerides, reactive oxygen species, and cardiac fibrosis in mice with a mutation in the helicase domain of tlie Werner syndrome gene homologue. Exp Gerontol 41:157-168, 2006.
 
13) Yokote K, et al:Metabolic improvement and abdominal fat redistribution in Werner syndrome by pioglitazone. J Am Geriatr Soc 52:1582-1583, 2004.
PubMed
14) Honjo S, et al:Early amelioration of insulin resistance and reduction of interleukin-6 in Werner syndrome using pioglitazone. J Am Geriatr Soc, 2008. (in press)
 
15) Krabbe KS, et al:Inflammatory mediators in the elderly. Exp Gerontol 39:687-699, 2004.
PubMed
P.595 掲載の参考文献
1) Wolfram DJ, Wegener HP:Diabetes mellitus and simple optic atrophy among siblings:report on four cases. Mayo Clin Proc 13:715-718, 1938.
 
2) Barrett TG, et al:Neurodegeneration and diabetes:UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346:1458-1463, 1995.
PubMed
3) Karasik A, et al:Genetically programmed selective β-cell loss in diabetic subjects with Wolfram syndrome. Diabetes Care 12:135-138, 1989.
 
4) Rando TA, et al:Wolfram syndrome:evidence of a diffuse neurodegenerative disease by magnetic resonance imaging. Neurology 42:1220-1224, 1992.
PubMed
5) Inoue H, et al:Agene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Ganet 20:143-148, 1998.
 
6) Strom TM, et al:Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 7:2021-2028, 1998.
 
7) 石原寿光, 岡芳知:WFS1. 糖尿病カレントライブラリー (4) (堀川幸男編), p64-67, 文光堂, 2005.
 
8) Cryns K, et al:Mutational spectum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat 22:275-287, 2003.
 
9) Eller P, et al:Wolfram syndrome:a chnical and molecular genetic analysis. J Med Genet 38:e37, 2001.
 
10) Amr S, et al:Ahomozygous mutation in a novel zinc-finger protein, ERIS, is responsible for wolf ram syndrome 2. Am J Hum Genet 81:673-683, 2007.
 
11) Takeda K, et al:WFS1 (Wolfram syndrome 1) gene product:predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 10:477-484, 2001.
PubMed
12) Ishihara H, et al:Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 13:1159-1170, 2004.
PubMed
13) Yamada T, et al:WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. Hum Mol Genet 15:1600-1609, 2006.
PubMed
14) Takei D, et al:WFS1 protein modulates the free Ca2+ concentration in the endoplasmic reticulum. FEBS Lett 580:5635-5640, 2006.
PubMed
15) Sandhu MS, et al:Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 39 (8):951-953, 2007.
PubMed
P.599 掲載の参考文献
1) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-404, 1999.
 
2) 佐中真由実ほか:糖代謝異常妊娠全国調査の概要-1996～2002年. 糖尿病と妊娠 5:37-41, 2005.
 
3) Kirwan JP, et al:TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 51:2207-2213, 2002.
PubMed
4) 山下洋ほか:ヒト胎盤性ラクトーゲン, tumor necrosis factor-αおよびレプチンと妊娠中のインスリン抵抗性との関連. 糖尿病と妊娠 3 (1):64-67, 2007.
 
5) 綿田裕孝:膵β細胞容積を制御するシグナル(2) -妊娠時に起こる膵β細胞容積変化の分子メカニズム-. プラクティス 22 (5):489-490, 2005.
 
6) Catalano PM, et al:carbohydrate metabolism during Pregnancy in control subjects and women with gestational diabetes. Am J Physiol 264:E60-E67, 1993.
PubMed
7) Catalano PM, et al:Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 180:903-916, 1999.
PubMed
8) 本田正志ほか:糖代謝異常妊婦の分娩後の代謝正常化に関する検討-インスリン抵抗性の検討-. 糖尿病と妊娠 2 (1):64-67, 2002.
 
9) 本田正志ほか:糖代謝異常妊婦の分娩後の代謝正常化に関する検討-第13報・分娩後のインスリン 分泌能およびインスリン抵抗性の推移-. 糖尿病と妊娠 6 (1):73-75, 2006.
 
10) 本田正志ほか:糖代謝異常妊婦の分娩後の代謝正常化に関する検討-第15報・初期インスリン分泌反応に関する検討-. 糖尿病と妊娠 7 (2):S65, 2007.
 
11) 平松祐司:妊娠糖尿病と肥満は関係あるか? 周産期医学 34 (増刊号):136-137, 2004.
 
P.604 掲載の参考文献
1) 山田研太郎ほか:ケトーシスを伴って急性発症する肥満NIDDM症例-清涼飲料水ケトーシス-. 糖尿病 36:469-474, 1993.
 
2) Nagasaka S, et al:Ketoacidosis-onset type 2 diabetes in Japanese. Association with the widespread distribution of soft drinks and vending machines. Diabetes Care 21:1376-1378, 1998.
PubMed
3) 山口康平ほか:清涼飲料水ケトーシスにおけるインスリン分泌能とインスリン感受性の検討-治療に伴う変化-. 糖尿病 39:197-203, 1996.
 
4) 松本一成ほか:清涼飲料水ケトーシスにおけるインスリン分泌とインスリン感受性の治療による変化. 糖尿病 41:891-896, 1998.
 
5) Tanaka K, et al:Analysis and a long-term follow up of ketosis-onset Japanese NIDDM patients. Diabetes Res Clin Pract 44:137-146, 1999.
 
6) 市川史ほか:小中学生の食事と間食, 特に清涼飲料摂取に関する調査-清涼飲料水ケトーシスの背景. 糖尿病 43:743, 2000.
 
7) Matsui J, et al:Clinical characteristics of Japanese youth-onset type 2 diabetes with ketonuria. Diabetes Res Clin Pract 70:235-238, 2005.
PubMed
8) 山守育雄ほか:インスリン初期分泌の正常化をみた清涼飲料水ケトーシスの1例. 糖尿病 40:563-567, 1997.
 
9) 二田哲博ほか:治療によりインスリン初期分泌正常化を認めた再発性清涼飲料水ケトーシスの1例. 糖尿病 43:393-396, 1999.
 
P.610 掲載の参考文献
1) Nakayama M, et al:Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435:220-223, 2005.
PubMed
2) Gonzalez A, et al:Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes. Nat Immunol 2:1117-1125, 2001.
PubMed
3) Turley S, et al:Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med 198:1527-1537, 2003.
 
4) O'Brien BA, et al:A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. J Autoimmun 26:104-115, 2006.
PubMed
5) Ikegami H, et al:Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J Clin Invest 96:1936-1942, 1995.
PubMed
6) Inoue K, et al:Allelic variation in class I K gene as candidate for a second component of MHC-linked susceptibility to type 1 diabetes in non-obese diabetic mice. Diabetologia 47:739-747, 2004.
 
7) Vijayakrishnan L, et al:An autoimmune disease-associated CTLA4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20:563-575, 2004.
 
8) Kissler S, et al:In Vivo RNA interference demonstrates a role for Nrampl in modifying susceptibility to type 1 diabetes. Nat Genet 38:479-483, 2006.
 
9) Yamanouchi J, et al:Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39:329-337, 2007.
PubMed
10) Hornum L, et al:The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of lddm1. Diabetes 51:1972-1979, 2002.
PubMed
11) Payne F, et al:Haplotype tag single nucleotide polymorphism analysis of the human orthologues of the rat type 1 diabetes genes Ian 4 (Lyp/Iddm1) and Cblb. Diabetes 53:505-509, 2004.
 
12) Yokoi N, et al:Cblb is a major susceptibility gene for rat type 1 diabetes mellitus. Nat Genet 31:391-394, 2002.
 
P.614 掲載の参考文献
1) 鈴木研一ほか:自然発症糖尿病GK (後藤-柿崎) ラットの現況. 糖尿病動物 1:125-132, 1987.
 
2) 鈴木進:GKラットにおける糖尿病病態の特徴. Exp Anim 47 (Suppl):98-102, 1998.
 
3) Granhall C, et al:High-resolution quantitative trait locus analysis reveals multiple diabetes susceptibility loci mapped to intervals < 800 kb in the species-conserved Niddmli of the GK rat. Genetics 174:1565-1572, 2006.
 
4) 西村正彦:WBN/Kob系ラット. 日本臨牀 56 (増刊:糖尿病3):700-703, 1998.
 
5) Tsuji A, et al:Quantitative trait locus analysis for chronic pancreatitis and diabetes mellitus in the WBN/Kob rat. Genomics 74:365-369, 2001.
PubMed
6) Yamada T, et al:Role of T cells in development of chronic pancreatitis in male Wistar Bonn/Kobori rats:effects of tacrolimus. Am J Physiol Gastrointest Liver Physiol 281:G1397-1404, 2001.
PubMed
7) Nakamura S, et al:Estradiol alleviates acinar cell apoptosis and chronic pancreatitis in male Wistar Bonn/Kobori rats. Pancreas 26:e59-66, 2003.
PubMed
8) Shinohara M, et al:A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 1 (2):89-100, 2000.
PubMed
9) Masuyama T, et al:Chronological characterization of diabetes development in male Spontaneously Diabetic Torii rats. Biochem Biophys Res Commun 314:870-877, 2004.
PubMed
10) Masuyama T, et al:Genetic analysis for diabetes in a new rat model of nonobese type 2 diabetes, Spontaneously Diabetic Torii rat. Biochem Biophys Res Commun 304:196-206, 2003.
 
11) Yoshioka M, et al:A novel locus, Mody4, distal to D7Mit1890n chromosome 7 determines earlyonset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46:887-894, 1997,
PubMed
12) 小泉昭夫:ヒトMODYのマウスモデルAkita mouse. 日本糖尿病・肥満学会ニュースレター 2:4-5, 1998.
 
13) Wang J, et al:A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest 103:27-37, 1999.
 
14) Horio F, et al:The HND mouse, a nonobese model of type 2 diabetes mellitus with impaired insulin secretion. Eur J Endocrinol 153:971-979, 2005.
 
15) 松島芳文:2型糖尿病マウスDMSの発見と展望. 日本糖尿病・肥満学会ニュースレター 11:4-5, 2007.
 
P.619 掲載の参考文献
1) Zhang Y, et al:Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994.
PubMed
2) Lindstrom P:The physiology of obese-hyperglycemic mice [ob/ob mice]. Scientific World Journal 7:666-685, 2007.
PubMed
3) Lee GH, et al:Abnormal splicing of the leptin receptor in diabetic mice. Nature 379:632-635, 1996.
PubMed
4) Nishimura M:Breeding of mice strains for diabetes mellitus. Exp Anim 18:147-157, 1969.
 
5) Suzuki W, et al:A new mouse model of spontaneous diabetes derived from ddY strain. Exp Anim 48:181-189, 1999.
 
6) Hamada Y, et al:Insulin secretion to glucose as well as nonglucose stimuli is impaired in spontane ously diabetic Nagoya-Shibata-Yasuda mice. Metabolism 50:1282-1285, 2001.
 
7) Junger E, et al:The diabetes-prone NZO/Hl strain. II. Pancreatic immunopathology. Lab Invest 82:843-853, 2002.
PubMed
8) Chua SCJ, et al:Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 45:1141-1143, 1996.
 
9) Ikeda H, et al:A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 30:1045-1050, 1981.
PubMed
10) Koletsky S:Obese spontaneously hypertensive rats-a model for study of atherosclerosis. Exp Mol Pathol 19:53-60, 1973.
 
11) 山本潤子ほか:肥満・高血圧自然発症ラットSHR/NDmcr-cp. 肥満研究 10:83-84, 2004.
 
12) Takaya K, et al:Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 14:130-131, 1996.
PubMed
13) Kawano K, et al:Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:1422-1428, 1992.
PubMed
P.626 掲載の参考文献
1) Agardh E, et al:Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr Eye Res 21:543-549, 2000.
PubMed
2) Hammes HP, et al:Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartjne. Diabetologia 40:629-634, 1997.
PubMed
3) Sima AA, et al:The BB-rat-an authentic model of human diabetic retinopathy. Curr Eye Res 4:1087-1092, 1985.
PubMed
4) Miyamura N, et al:Retinal capillary changes in Otsuka Long-Evans Tokushima fatty rats (spontaneously diabetic strain). Electron microscopy study. Ophthalmic Res 31:358-366, 1999.
PubMed
5) Matsuura T, et al:Otsuka Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int J Tissue React 27:59-62, 2005.
 
6) Shinohara M, et al:A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 1:89-100, 2000.
PubMed
7) Yamada H, et al:Retinal neovascularization without ischemia in the spontaneously diabetic Torii rat. Diabetologia 48:1663-1668, 2005.
PubMed
8) Qi Z, et al:Characterization of susceptibiUty of inbred mouse strains to diabetic nephropathy. Diabetes 54:2628-2637, 2005.
PubMed
9) Doi T, et al:Glomerular lesions in nonobese diabetic mouse:Before and after the onset of hyperglycemia. Lab Invest 63:204-212, 1990.
PubMed
10) Feld LG, et al:Resistance to glomerular injury in the diabetic biobreeding rat. Exp Physiol 80:991-1000, 1995.
PubMed
11) Sharma K, et al:Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284:F1138-F1144, 2003.
PubMed
12) Gartner K:Glomenllar hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (C57BL/6J db/db and C57BL/KsJ db/db). Diabetologia 15:59-63, 1978.
PubMed
13) Ito T, et al:Glomerular changes in the KK-Ay/Ta mouse:a possible model for human type 2 diabetic nephropathy. Nephrology 11:29-35, 2006.
 
14) Haseyama T, et al:Complications of IgA nephropathy in a non-insulin-dependent diabetes model, the Akita mouse. Tbhoku J Exp Med 198:233-244, 2002.
 
15) Phillips AO, et al:Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non-insulin-dependent diabetes mellitus. Am J Kidney Dis 37:400-410, 2001.
PubMed
16) Mori S, et al:Relationships between diet control and the development of spontaneous type II diabetes and diabetic nephropathy in OLETF rats. Diabetes Res Clin Pract 33:145-152, 1996.
PubMed
17) Zemp C, et al:Morphological and morphometric study of peripheral nerves from rats with streptozotocin-induced diabetes mellitus. Acta Neuropathol 53:99-106, 1981.
PubMed
18) Yagihashi S, et al:Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am J pathol 136:1365-1373, 1990.
PubMed
19) Wada R, et al:Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats:agenetic model for type 2 diabetes. Diabetes Metab Res Rev 15:332-337, 1990.
 
20) Murakawa Y, et al:Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab Res Rev 18:473-483, 2002.
 
P.631 掲載の参考文献
1) 金沢真雄, 米田嘉重郎:糖尿病, (疾患別) モデル動物の作成と新薬開発のための試験・実験法 (内貴正治, 浅野敏彦監), p236-256, 技術情報協会, 1993.
 
2) Brecher G, Waxler SH:Obesity in albino mice due to single injections of goldthioglucose. Proc Soc Exp Biol Med 70:498-501, 1949.
PubMed
3) Olney JW:Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164:719-721, 1969.
PubMed
4) Like AA, Rossini AA:Streptozotocin-induced pancreatic insulitis:new model of diabetes mellitus. Scinece 193:415-417, 1976.
 
5) Takatori A, et al:Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments. Diabetes Metab Res Rev 20 (3):211-218, 2004.
PubMed
6) Rakieten N, et al:Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91-98, 1963.
 
7) Dunn SJ, et al:Necrosis of the islets of Langerhans produced experimentally. Lancet 244:484-487, 1943.
 
8) Kubisch HM, et al:Transgenic copper/zinc superoxide dismutase modulates susceptibility to type I diabetes. Proc Natl Acad Sci USA 91 (21):9956-9959, 1994.
PubMed
P.636 掲載の参考文献
1) Yang Y, Santamaria P:Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice. Diabetologia 46 (11):1447-1464, 2003.
PubMed
2) Moriyama H, et al:Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci USA 100 (18):10376-10381, 2003.
PubMed
3) Nakayama M, et al:Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435 (7039):220-223, 2005.
PubMed
4) Yoon JW, et al:Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 284 (5417):1183-1187, 1999.
 
5) Kash SF, et al:Glutamate decarboxylase and GABA in pancreatic islets:lessons from knock-out mice. Horm Metab Res 31 (5):340-344, 1999.
PubMed
6) Nakayama M, et al:Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes. Diabetes 51 (5):1391-1397, 2002.
PubMed
7) Leiter EH:Mice with targeted gene disruptions or gene insertions for diabetes research:problems, pitfalls, and potential solutions. Diabetologia 45 (3):296-308, 2002.
 
8) Lee JY, et al:RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 281 (5):2649-2653, 2006.
PubMed
9) Leiter EH, et al:Unexpected functional consequences of xenogeneic transgene expression in ig cells of NOD mice. Diabetes Obes Metab 9 (Suppl 2):14-22, 2007.
 
P.642 掲載の参考文献
1) Plum L, et al:Transgenic and knockout mice in diabetes research:novel insights into pathophysiology, limitations, and perspectives. Physiology 20 (3):152-161, 2005.
 
2) Matsumoto M, et al:PKCλ in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 112 (6):935-944, 2003.
 
3) Bandyopadhyay G, et al:Protein kinase C-λ knockout in embryonic stem cells and adipocytes impairs insulin-stimulated glucose transport. Mol Endocrinol 18 (2):373-383, 2004.
 
4) Hashimoto N, et al:PKCλ regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic β cells. J Clin Invest 115 (1):138-145, 2005.
 
5) Farese RV, et al:Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 117 (8):2289-2301, 2007.
PubMed
6) Barak Y, Kim S:Genetic manipulations of PPARs:Effects on obesity and metabolic disease. PPAR Res 2007:article ID 1278112pages, 2007.
 
7) Schroeder-Gloeckler JM, et al:CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr (db/db) mice. J Biol Chem 282 (21):15717-15729, 2007.
PubMed
8) Xue B, et al:Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem 282 (33):23829-23840, 2007.
PubMed
9) Smith FM, et al:Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnata1 life. Mol Cell Biol 27 (16):5871-5886, 2007.
PubMed
10) Torisu T, et al:The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 12 (2):143-154, 2007.
PubMed
11) Johnson JD, et al:RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem 279 (23):24794-24802, 2004.
PubMed
12) Uchida T, et al:Deletion of Cdknlb ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med 11 (2):175-182, 2005.
 
13) Krishnamurthy J, et al:p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443 (7110):453-457, 2006.
PubMed
14) Brunham LR, et al:β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13 (3):340-347, 2007.
 
15) Holland WL, et al:Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5 (3):167-179, 2007.
PubMed
P.647 掲載の参考文献
1) 藤澤智巳ほか:1型糖尿病モデル. 糖尿病と遺伝子 (堀川幸雄, 安田和基編), p203-207, 文光堂, 2005.
 
2) Wong FS, et al:Transgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis. Immunol Rev 169:93-104, 1999.
PubMed
3) 藤澤智巳:遺伝子操作1型糖尿病モデルマウス. モデル動物の作製と維持 (森脇和郎ほか編), p537-545, エルアイシー, 2004.
 
4) Jasinski JM, Eisenbarth GS:Insulin as a primary autoantigen for type IA diabetes. Clin Dev Immunol 12:181-186, 2005.
PubMed
5) van der Werf N, et al:Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 23:169-183, 2007.
PubMed
6) Pugliese A:Central and peripheral autoantigen presentation in immune tolerance. Immunology 111:138-146, 2004.
PubMed
7) Ikegami H, et al:Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J Clin Invest 96:1936-1942, 1995.
PubMed
8) Fujisawa T, et al:MHC class IK-linked diabetogenic genes in NOD mice. Diabetes 49 (Suppl 1):A210, 2000.
 
9) Fujisawa T, et al:MHC-linked susceptibility to type 1 diabetes in the NOD mouse:further localization of Idd16 by subcongenic analysis. Ann N Y Acad Sci 1079:118-121, 2006.
PubMed
10) Rotondi M, et al:Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28:492-520, 2007.
PubMed
11) Hotta M, et al:Pancreatic β-cell specific expression of thioredoxin, an antioxidative and antiapop totic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 188:1445-1451, 1998.
 
12) 藤澤智巳ほか:遺伝子操作マウスの飼育・遺伝背景. Diabetes Frontier 12:525-531, 2001.
 
P.651 掲載の参考文献
1) Ogawa Y, et al:Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48:1822-1829, 1999.
PubMed
2) Fukui K, et al:The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab 2:373-384, 2005.
PubMed
3) Miki T, et al:Abnormalities of pancreatic islets by targeted expression of a dominan卜negative KATP channel. Proc Natl Acad Sci USA 94:11969-11973, 1997.
 
4) Hagenfeldt-Johansson KA, et al:Beta-cell-targeted expression of a dominant-negative hepatocyte nuclear factor-1 alpha induces a maturity-onset diabetes of the young (MODY) 3-like phenotype in transgenic mice. Endocrinology 142:5311-5320, 2001.
PubMed
5) Yamagata K, et al:Overexpression of dominant-negative mutant hepatocyte nuclear factor-1 alpha in pancreatic beta-cells causes abnormal islet architecture with decreased expression of E-cadherin, reduced beta-cell proliferation, and diabetes. Diabetes 51:114-123, 2002.
PubMed
6) Moitra J, et al:Life without white fat:a transgenic mouse. Genes Dev 12:3168-3181, 1998.
PubMed
7) Ebihara K, et al:Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440-1448, 2001.
 
8) Oyama K, et al:Spontaneous recovery from hyperglycemia by regeneration of pancreatic beta-cells in Kir6.2G132S transgenic mice. Diabetes 55:1930-1938, 2006.
PubMed
9) Seibler J, et al:Reversible gene knockdown in mice using a tight, inducible shRNA expression system. Nucleic Acids Res 35:e54, 2007.
PubMed
10) Dor Y, et al:Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429:41-46, 2004.
PubMed
11) Nir T, et al:Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117:2553-2561, 2007.
PubMed
12) Janson J, et al:Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283-7288, 1996.
PubMed
13) Chong AS, et al:Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311 (5768):1774-1775, 2006.
PubMed

書評

最近チェックした商品履歴

Loading...